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Abstract
The balance between cellular proliferation and apoptosis is a co-ordinated process. Rodent 
hepatocytes proliferate rapidly in response to non-genotoxic liver growth agents such as 
peroxisome proliferators, a result o f both increased DNA synthesis and suppression of apoptosis 
(Roberts et al, 1995). This study aimed to identify groups of genes that were co-regulated in the 
response o f rodent liver to mitogenic stimuli, and used three compounds known to induce liver 
growth via different processes: cyproterone acetate (60 mg/kg/day), dexamethasone (100 
mg/kg/day) and Wy-14,643 (50 mg/kg/day). Each compound or vehicle was administered to 
groups o f five male rats for up to four days, with animals being sacrificed at time-points between 6 
and 96 hours post-intial dose. Total RNA from liver samples was processed and analysed by DNA 
microarray (Affymetrix). The expression profile for each gene was first compared between the three 
compounds across aU time points, identifying 38 genes that could be clustered into groups showing 
similar expression profiles.
From these 38 genes, two groups were selected for further investigation and validation by 
quantitative real-time PCR analysis using a range of samples dosed with the same compounds over 
the same time-points. One group, composed of malic enzyme 1 (M^/) and rat brain acyl CoA 
hydrolase (rBACH), was found to respond only to peroxisome-proliferators, and hence was not 
investigated further. The second group, comprising seven genes, showed inhibition o f gene 
expression in response to the compounds administered. A similar response was observed during 
quantitative real-time PCR validation as in the microarray analysis, therefore this group was 
investigated further using a reporter gene assay.
Promoter sequences immediately upstream of the transcriptional start site (1 kilobase) were 
successfully cloned into a plasmid upstream of a reporter gene (SEAP) for four o f the genes, and 
were transfected into the FaO rat hepatoma cell line. Exposure of transfected cells to liver growth 
agents produced a similar profile of SEAP expression to that seen in the original m vivo analysis, 
suggesting regulation of the genes was at the transcriptional level, A deletion construct series was 
prepared for two of the genes, HCaRG and Noblp, and the transcriptional response localised to
within the first ~100 bp of the proximal promoter in each case. Exposure of the ~100 bp reporter 
gene constructs to P-naphthofiavone (100 pM), which activates both the aryl hydrocarbon receptor 
(AhR) and the NF-E2-related factor 2 (Nrf2), elicited a significant >2-fold decrease in reporter gene 
expression, similar to the decrease elicited by the liver growth agents. Dosing with the AhR ligands 
3-methylcholanthrene and benzo(a)pyrene failed to mimic the response of the promoter constructs 
to P-naphthoflavone indicating that AhR was not solely responsible for the inhibition of HCaRG 
and N oblp  expression observed. However, site-directed mutagenesis o f individual potential AhR 
and Nr£2 response elements within the HCaRG and N oblp  promoter constructs failed to ablate 
the response to p-naphthofiavone or dexamethasone. This indicated either interplay between the 
two transcription factors in the response, or that the two transcription factors were capable of 
compensation.
This study has identified and confirmed a link between two genes exhibiting co-ordinate regulation 
in their expression in response to liver growth agent administration, with the potential of co­
regulation with five other genes. It has identified the mediators of this response as being the AhR, 
Nr£2 or more likely a combination of the two transcription factors, with the potential o f supporting 
the increasing observation that Nrf2 and the AhR co-operate in the regulation of genes in response 
to xenobiotic stimuli.
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1 In t r o d u c t io n
1.1 Ge n e  E x pr e ssio n  is r e g u la t e d  a n d  c o -o r d in a t e d
In prokaryotes, genes encoding proteins required for a co-ordinated response to a signal are found 
close together in the genome and form an operon. Transcription of the operon forms a single, 
multi-gene rnRNA with internal initiation codons defining the start o f individual genes. An example 
is the lac operon that is transcribed in response to lactose. The lac operon contains genes encoding 
the enzyme P-galactosidase that is required for cleavage o f lactose, a permease enzyme to allow 
lactose uptake by the cell, and a trans-acetylase to modify the molecule. All three genes are under 
the control of the lac operator whose repressor protein is inactivated by the presence of lactose 
(reviewed in Lewis, 2005). This form of co-ordinated response is very simple and is suitable for 
single-ceUed organisms. However, in higher eukaryotic organisms that are composed o f many cells 
requiring intercellular communication to exist, this simple co-ordination does not occur. In these 
organisms individual genes are transcribed producing separate mRNAs from each gene. This allows 
greater flexibility in the regulation o f gene expression, unlike prokaryotes where the need o f one 
gene wUl result in the expression of several others. In addition, co-ordinately expressed genes in 
eukaryotes are not frequently found close together in the genome.
A mechanism for eukaryotic co-ordinate gene expression was proposed by Britten and Davidson 
(1969). They suggested that genes co-ordinately regulated in response to a signal would contain a 
common regulatory element that would cause activation of the gene. Genes could contain many 
such regulatory elements and could therefore be activated by a variety o f stimuli. It is now known 
that signals result in the expression or activation of transcription factors, which can then interact 
with DNA sequence motifs termed response elements, located within or adjacent to gene 
promoters. Binding of a transcription factor leads to activation of the gene(s) containing the 
response element, resulting in production of functional protein that can produce an effect.
1.1.1 T h e  t r a n sc r ipt io n  process
Transcription of genes involves the enzyme RNA polymerase. In eukaryotes there are three classes 
o f RNA polymerase that are involved in the formation of different types of RNA. RNA polymerase
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II (RNA pol II) is responsible for the transcription of genes capable o f encoding a protein, and 
produces an mRNA transcript. RNA pol I and III are involved in the transcription o f genes 
encoding the ribosomal and transfer RNAs.
Eukaryotic RNA polymerases do not directly bind to DNA. Instead they require transcription 
factors that recognise specific DNA sequences and target the polymerase to the site of 
transcriptional initiation. This is achieved through the formation of an initiation complex. In many 
eukaryotic genes transcribed by RNA pol II a short DNA sequence containing A and T  nucleotides 
can be found, existing around 30 bp upstream of the transcriptional start site. This is known as a 
TATA box and is important in determining the point of transcriptional initiation. The TATA box 
acts as a target sequence on which the transcription complex for RNA pol II can assemble.
The first factor to bind the TATA box is the transcription factor TFIID and this is facilitated by 
another factor TFIIA. TFIID is actually composed o f the TATA-binding protein (TBP) that is 
responsible for the binding to the TATA box, and TBP-associated factors (TAFs) that are thought 
to respond to transcriptional activators. Following formation o f the TFIID /TFIIA  complex (DA 
complex), this is recognised by TFIIB (Maldonado et al, 1990) that binds to RNA pol II via TFIIF, 
recruiting it to the pre-initiation complex (PIC). A further two factors, TFITE and TFIIH then bind 
to the complex. TFIIH has an intrinsic kinase activity that phosphorylates RNA pol II leading to 
initiation o f transcription (Woychik and Hampsey, 2002). The polymerase and its associated 
proteins then move along the DNA strand towards the termination site. However, TFIID and 
TFIIA remain at the promoter allowing further recruitment of TFIIB and RNA pol II, to allow 
repeated rounds of transcription o f the same gene.
Recently a complex termed Mediator was identified that binds RNA pol II following formation of 
the DA complex in response to an activator i.e. a DNA-binding protein that regulates genes by 
affecting the rate o f transcription (Myers and Komberg, 2000). Mediator does not interact direcdy 
with DNA, but binds the RNA pol II and also influences the kinase activity o f TFIIH. Mediator is 
a modular complex consisting of multiple proteins that serve as an interface between the RNA pol 
II machinery and gene-specific regulatory proteins for both positive and negative regulation o f the 
core transcriptional machinery (Myers and Komberg, 2000).
As well as initiation of transcription via the TATA box, additional response elements have been 
identified including the CCAAT box and the GC box, which are located upstream of the TATA 
box. These motifs bind specific factors that can enhance the rate of transcription. This may be 
through increasing the stability or the activity of the basal transcription complex. The transcription 
factors Spl and Sp3 bind GC boxes and are widely expressed with Spl being able to directly 
interact with TBP and influence the basal transcription machinery (Bouwman and Phdipsen, 2002). 
The CCAAT binding factor (CBF) also termed nuclear factor Y (Coustry et al, 1995) is one 
transcription factor that can bind the CCAAT box and is believed to be important for the 
expression of genes that are specific to differentiated cells (Marziali et al, 1999).
1.1.2 Re g u l a t io n  o f  t r a n sc r ipt io n
Promotion o f gene transcription can involve a number o f different sequences. Promoters are 
composed of an array of sequence motifs, many of which are binding sites for transcription factors 
(reviewed in Muller et al, 1988). The core promoter is the site where the initiation complex is 
assembled and is composed of the transcription start site and in the majority of cases an upstream 
TATA box. Further control can be exerted from a greater distance by enhancer and silencer 
elements, which can bind many factors and may be important in the co-ordination o f gene 
expression. Locus control regions (LCRs) also influence the rate of transcription from a great 
distance.
1.1.2.1 R esponse elem ents
Response elements are usually short sequences of around 10 to 30 bp in length. As mentioned these 
sequences can either be within the promoter itself or located near to the promoter. Response 
elements within the promoter can be either palindromic or direct repeat sequences. For example, 
the estrogen response element is a 20 bp palindrome whereby the sequence is the same in either the 
5’ to 3’ or the 3’ to 5’ direction. The presence of three random bases located in the centre of the 
palindrome confers specificity for oestrogen, since the thyroid hormone response element is 
identical except for these three bases (Hirst et al, 1992). Direct repeat elements consist o f two 
repeats of a short sequence and as with the estrogen response element, the spacing between the 
repeats regulates which hormone can bind.
1.1.2.2 Transcription factors
Transcription factors bind to specific response elements leading to activation o f transcription of 
specific genes. They contain structual binding motifs for binding to DNA such as zinc fingers, and 
for binding to associated proteins via leucine zippers. Nuclear receptors are a class o f ligand- 
activated transcription factors that can be cytosolic or nuclear in localisation, and are classified 
according to their sequence homology. Nuclear receptors contain several structural domains 
including DNA and ligand binding domains, and a flexible hinged region that contains a nuclear 
localisation signal (NLS) (Robinson-Rechavi et al, 2003). The classical mechanism involves a ligand 
entering the cell and binding its respective nuclear receptor, inducing the dissociation o f heat shock 
proteins, homodimerisation and translocation to the nucleus where the receptor can bind specific 
response elements within the DNA. This allows recruitment of the transcription machinery and 
associated proteins. It is now accepted that many nuclear receptors remain in the nucleus bound to 
DNA where they serve as repressors prior to ligand binding (Giguère, 1999).
1.1.2.3 Enhancers
Enhancer elements may facilitate gene activation by the same mechanisms as response elements. 
Enhancers are regulatory DNA sequences often similar to response elements but which are located 
at a distance from the transcriptional start site. They are often necessary for high-level transcription 
of a gene, and are frequently specific to tissues in which their particular gene is normally active. An 
enhancer can activate a promoter when several thousand bp distant and from either orientation 
relative to the promoter. Furthermore, enhancers have been shown to activate a promoter whether 
positioned upstream, downstream or within a region of the transcription unit that is later removed 
by splicing. Several models exist to explain the mechanism of action of enhancers on transcription. 
The most probable is the looping model whereby the enhancer and promoter for a particular gene 
interact via DNA binding proteins forming a loop of intervening DNA (Studitsky, 1991). This 
allows interactions between regulatory proteins that are usually distant from each other.
1.1.2.4 Silencers
As well as enhancers, certain negative regulators o f gene activation termed silencer elements have 
been identified. These elements are similar in characteristics to enhancers, except that their effect is
inhibitory to gene expression. Silencers may act by causing further condensation o f the chromatin 
to prevent the transcription complex binding the DNA, or by binding a factor that inhibits 
promoter activity.
1.1.2.5 Locus control regions (LCRs)
A further element important in regulation of gene expression is the LCR, which is thought to affect 
chromatin structure allowing transcription o f surrounding genes (Felsenfeld, 1992). LCRs confer 
high-level gene expression that is position independent, and can function from many kilobases 
away. It is possible that LCRs are responsible for tissue-specific expression of genes, altering the 
chromatin structure over a large region of DNA, and allowing binding of specific transcription 
factors to the promoter and enhancer regions of individual genes by preventing the inhibitory effect 
of histones on transcription (Felsenfeld, 1992).
1.1.3 E xam ples o f  co-o r d in a t e  g e n e  r e g u l a t io n
Co-ordination of the response to a stimulus involves interplay between different pathways involved 
in homeostatic control, with the purpose of increasing the efficiency of that response. In order to 
understand the molecular mechanisms behind co-ordinate responses the individual interactions 
must first be identified. This information can then be compiled to determine the network of 
interactions. Several examples exist where co-ordinate regulation has been investigated, including 
control o f gene expression and cellular differentiation, and will be discussed below.
Gene expression in eukaryotes involves a coupled network that co-ordinates the many pathways 
involved. Formation of mRNA is a stepwise process involving 5’ capping, polyadenylation o f the 3’ 
end, and intron removal by splicing. The mRNA is then exported to the cytoplasm where it is 
translated into a protein. Alongside this process an RNA surveillance system ensures removal of 
any mutant pre-mRNA and mRNA prior to translation. However, this stepwise system is not as 
simple as first thought, with the different steps in the expression pathway interconnecting to form a 
complex network. This can be either through the tethering of components in close proximity to 
each other, or through functional interactions, both facilitating the production of mRNA. A model 
has been proposed consisting of gene expression factories whereby the proteins involved in 
transcription, capping, polyadenylation and splicing are anchored together in the nuclear
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substructure (Maniatis and Reed, 2002). This solves several logistical problems associated with 
processing of pre-mRNA. For example, tight coupling o f the 5’ capping and transcription 
machinery allows rapid capping of the pre-mRNA as it is extended by RNA pol II, therefore 
protecting the pre-mRNA from degradation. Similarly, coupling of the splicing factors close to the 
pre-mRNA as it is formed allows for efficient recognition o f intron-exon junctions. It is thought 
that these processes are coupled via distinct domains o f the carboxy-terminal domain (CTD) of the 
RNA pol II large subunit. Deletions o f this region do not affect transcription, but have significant 
implications on the efficiency o f capping, polyadenylation and splicing.
In addition to coupling via the CTD of RNA pol II, coupling has also been observed between the 
different processing steps (Maniatis and Reed, 2002). Proteins that bind to the 5’ cap o f pre-mRNA 
have been shown to interact with splicing factors, facilitating recognition of the first 5’ splice site. 
Similarly, the splicing machinery at the terminal 3’ intron is in turn coupled to polyadenylation 
factors and promotes 3’ end cleavage and polyadenylation. These interactions increase the efficiency 
and accuracy of the individual processes. In addition, co-ordination has been shown between the 
RNA surveillance system, the splicing machinery and export of the mRNA from the nucleus, 
ensuring that mRNA containing mutations is detected and degraded prior to translation.
In a study by Lam et al (2001) a link was made between gene function and mRNA half-life. Using 
the anti-cancer drug flavopiridol to broadly inhibit transcription, genomic-scale mRNA turnover 
was assessed. Flavopiridol is a cyclin-dependent kinases (Cdk) inhibitor that arrests cells in vitro at 
the Gap 1 (Gi) to Synthetic (S), and Gap 2 (Gz) to Mitosis (M) transitions, as well as slowing the 
progression through S phase. Flavopiridol also inhibits the activity o f the transcription elongation 
factor P-TEFb that phosphorylates the CTD of the RNA pol II complex, facilitating transcriptional 
elongation of cellular genes. Lam et al (2001) showed that the action of flavopiridol was mediated 
largely through inhibition of P-TEFb, and that P-TEFb regulates the transcriptional elongation o f 
the majority of cellular genes. DNA microarray analysis was used to assess cellular mRNA turnover 
rates in response to a range of stimuli, as compared with results from cells pre-treated with 
flavopiridol. Interestingly, genes with labile mRNAs included transcription factors firom the NF-kB 
family, members of the inhibitor of apoptosis (LAP) family and ceU cycle regulators such as c-Myc.
Transcriptionally inducible genes appear to preferentially encode mRNAs that are rapidly degraded. 
Adenylate-uridylate-rich elements (AREs) that are one type o f element involved in mediating rapid 
turnover of mRNA were found in the majority of unstable mRNAs, with decreasing frequency in 
the more stable mRNAs. Lam and colleagues categorised genes by the function of their proteins 
and found certain classes were enriched for unstable mRNAs. These included cytokine-encoding 
genes, immediate early transcription factor genes, regulators of apoptosis and regulators of M phase 
of the cell cycle. This indicates that levels o f mRNA can be rapidly decreased following termination 
of transcriptional activation, representing a co-ordinated strategy to rapidly modulate the mRNA 
levels o f transcriptionally inducible genes. This would be particularly important in such functions as 
cell cycle control and apoptosis.
1.2 O r g a n  size  is m a in t a in e d  by  a  b a la n c e  b e t w e e n
PROLIFERATION AND APOPTOSIS
Organ size is controlled by cellular proliferation and cell death and represents a closely regulated 
process. A high level of control is required to ensure that cells are accurately replicated and that any 
cells containing potentially deleterious mutations in their DNA are not allowed to progress through 
the cell cycle. Cells containing incorrectly replicated DNA can be detected at one o f numerous 
checkpoints throughout the cell cycle, leading to removal o f the cell by the process o f programmed 
cell death (apoptosis).
1.2.1 T h e  cell  cycle
The cell cycle is composed o f the Gi, S, Gz and M phases, with the majority o f cells being quiescent 
in the Go phase where they are not dividing. Together the Gi, S and Gz phases are termed 
interphase and represent around 95-percent of the total cell cycle time. Mitosis is the most dramatic 
phase involving separation o f the cell into two daughter cells, however this process only takes a 
short time in comparison to the other phases. The majority of cell cycle research has been 
conducted in the unicellular eukaryote Schit^ psaccharomjces pomhe with the selection o f mutants with 
altered cell division that define cell division cycle (CDC) genes. It was this type o f analysis that led 
to the discovery of Cdks, from identification of the yeast cdc2 gene that was crucial in promoting 
cell cycle progression (Nurse and Thariaux, 1980). A second gene termed was also identified as a
negative regulator of mitosis and later identified in numerous species including vertebrates where it 
was termed Weel. Cdks are composed of a 34 kDa catalytic subunit, complexed with a cycUn 
component and are regulated at three levels (Nurse, 1997). These are (Î) complex between cyclin 
and Cdk that can be reversed by degradation o f the cyclin, (ii) protein phosphorylation of a tyrosine 
residue within the kinase ATP-binding site by enzymes such as Weel that inactivate the Cdk, and 
(iii) inhibition by specific Cdk inhibitors (CKIs) that are particularly active in Gi phase. In mammals 
these include p2 1 ciPi/WAFi and p27 that inhibit the Gi to S transition, and members of the INK4 
family that inhibit Cdk4 and Cdk6.
After a cell has been signalled to divide, either by a physiological stimulus (such as following partial 
hepatectomy) or by a mitogenic substance, it leaves the resting Go state and enters Gi. This phase 
occupies approximately half of the total cell cycle time and is the longest o f the phases. During Gi 
the main drivers of cell cycle progression, the Cdks, are expressed in a highly regulated, time- 
dependent manner. Combinations of Cdks and their regulators the cyclins operate in specific parts 
of the cell cycle and can be regulated by ubiquitination and subsequent proteolysis. Cdks not only 
require binding of cyclins, but also require subsequent phosphorylation by Cdk-activating kinases 
(CAKs). The first combination is cyclin D (cyclin D l, 2 and 3) and Cdk4 and 6 that increase in late 
Gi phase, and are joined by cyclin E  and Cdk2, aU of which drive the cell into the phase o f DNA 
replication, S phase. The Gi DNA damage checkpoint is encountered towards the end o f Gi phase 
and is where DNA damage can be detected. The tumour suppressor protein p53 is expressed at this 
point and governs expression o f downstream proteins to influence the fate o f the cell. Following 
this the cell passes through the so-called restriction point (R) after which the cell is committed to 
enter S phase. Cdk activity can be negatively regulated by inhibitory phosphorylation by W eel and 
subsequent dephosphorylation to activate the Cdk by Cdc25 phosphatases (Donzelli and Draetta, 
2003).
S phase has three checkpoints all concerned with the process of DNA replication. The cell cycle 
can arrest here if the DNA is incorrectly replicated and not suitable to proceed to Gz. At the end of 
S phase there are two duplicate copies o f the genome. The cell is then driven into Gz phase by 
cyclin A and Cdk2. Gz phase is shorter than Gi and is concerned largely with preparation for cell
division, including replication of cellular organelles. Cyclins A and B in combination with Cdkl 
drive the cell through Gz and M phase. The Gz checkpoint is the last point before the cell commits 
to division. It is responsible for monitoring that there is no unreplicated DNA and that the two sets 
of the genome are intact. Any badly damaged DNA will trigger the pathway to programmed ceU 
death (apoptosis). Cdc25 phosphatases are required for activation of cyclin B /C dkl to aUow 
progress to M phase, and the Cdc25 phosphatases can be deactivated by phosphorylation by the 
checkpoint kinase Chkl protein that aUows subsequent binding of 14-3-3 proteins (Peng et al,
1997). It is thought that binding of 14-3-3 proteins creates a nuclear export signal that removes 
Cdc25 phosphatases firom the nucleus aUowing time for repair o f damaged DNA prior to mitosis 
(Lopez-Girona et al, 1999).
M phase is composed of four phases: prophase, metaphase, anaphase and telophase, and has a 
checkpoint during metaphase that identifies misaUgned chromosomes and that the microtubules are 
attached to the kinetochores prior to the start o f anaphase. FoUowing completion o f telophase the 
process of cytokinesis occurs whereby the cytoplasm is divided, completing the cycle with the 
formation of two daughter ceUs. These ceUs can then enter Go or re-enter Gi if repeated rounds of 
repUcation are required. A signalling cascade known as the mitotic exit network (MEN) is 
responsible for driving ceUs from mitosis into the next ceU cycle, and converges on the activation o f 
Cdcl4 phosphatase (Jensen et al, 2002). Cdcl4 promotes proteolytic degradation o f mitotic cyclins, 
and dephosphorylates and activates the Cdk inhibitor Sicl that in turn lead to inactivation o f Cdk 
activity, which is a requirement for progression of the ceU through telophase and cytokinesis.
1.2.2 Co n t r o l  o f  A po pto sis
Apoptosis is the controUed deletion of ceUs to counterbalance mitotic ceU division. It is an active 
process that is controUed by ceUular components in a pre-programmed manner. Without this 
negative control there would be an overabundance o f ceUs, which would result in sub-optimal 
function o f the tissue or organ. The process of apoptosis is highly regulated and morphologicaUy 
characteristic. The nucleus and the cytoplasm first condense and the ceU forms discrete fragments 
that are each membrane-bound and termed apoptotic bodies. These are then ingested by 
phagocytic ceUs and degraded by their lysosomal proteolytic enzymes. This prevents spiUage of
cellular contents that would otherwise trigger an immune response, and also allows recycling of the 
cellular constituents.
1.2.2.1 Pathways to apoptosis
An apoptotic signal is mediated and executed via the activation of a family of cysteinyl aspartate- 
specific pro teas es termed caspases, which cleave and activate each other in a cascade, leading to the 
activation of so-called execution caspases (Thomberry and Lazebnik, 1998). Caspases are 
synthesised as inactive pro-enzymes, requiring cleavage at internal aspartic acid residues, producing 
the active form of the enzyme. This cleavage can be accomplished by other caspases upstream in 
the signalling pathway, but in some cases autoproteolytic activation can occur. Control of caspase 
activation is achieved through their presence as precursor enzymes that are largely inactive. 
Activation requires either close proximity with other caspase molecules enabling auto-activation, or 
cleavage by a caspase further upstream in the cascade. Caspase activation also involves Inhibitor of 
apoptosis proteins (lAPs) that are capable o f inhibiting caspases via occlusion o f the active site 
(Crook et al, 1993).
Apoptosis can be initiated by internal or external signals. These include DNA damage, oxidative 
stress, and growth factor removal. The pathways to activation of caspases can be mediated via 
receptors, induced by toxic chemicals, or triggered by the involvement of cytotoxic T  lymphocytes 
and N K  cells. These pathways vary between cell types in their relative use, however amplification of 
the response can be achieved by overlap between the pathways (Figure 1.1).
Cytokines are able to induce apoptosis via binding to cell surface receptors, resulting in downstream 
caspase activation. Two death receptors (DR) in particular have been researched intensively, namely 
TNFR-1 and Fas (also termed CD95 or Apo-1). Activation of either receptor via binding to their 
respective ligands. Fas ligand (FasL) and TNF-related apoptosis inducing ligand (TRAIL), results in 
apoptotic cell death within a matter of hours. Binding o f TNFa to TNFR-1 causes receptor 
trimérisation allowing recruitment of the adaptor protein TNFR-associated death domain 
(TRADD), followed by TNFR associated factor-2 (TRAF-2), receptor interactive protein (RIP) and 
the Fas-associated protein with death domain (FADD). FADD can then mediate activation of 
caspase-8. The Fas receptor responds to FasL binding in a similar way to TNFR-1. Aggregation of
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pro-caspase-8 molecules is thought to form a death inducing signalling complex (DISC), which 
causes auto-activation of caspase-8 (Ashkenazi and Dixit, 1998). Caspase-8 can then cleave and 
activate caspase-3, initiating a downstream caspase cascade.
Apoptosis can be induced without the requirement for receptor activation at the plasma membrane. 
This pathway involves proteins contained within the mitochondria, and can lead to caspase 
activation, and caspase-independent cell death via proteins such as apoptosis inducing factor (AIF). 
It is now known that the release of cytochrome c into the cytosol is a central step in the progression 
of the apoptotic pathway. Cytochrome c is contained within the inter-membrane space of 
mitochondria and serves to transfer electrons between complex III and complex IV of the electron 
transport chain (Bemardi and Azzone, 1981). Liu et al. (1996) first demonstrated that cytochrome c 
forms a component of the apoptosome complex that leads to the activation of caspase-3. Using 
cytosolic extracts from apoptotic cells in vitro, they were able to demonstrate the presence of 
cytochrome c, and that removal of the protein diminished the apoptotic activity. Li et al (1997) then 
purified a protein factor required for apoptosis, termed apoptotic protease-activating factor 3 
(Apaf-3). Analysis o f the structure of Apaf-3 showed it to be pro-caspase-9. It was found that in the 
presence of cytochrome c and deoxyadenosine triphosphate (dATP), pro-caspase-9 and the 
cytosolic protein Apaf-1 were bound to each other, forming a complex termed the mitochondrial 
apoptosome, leading to caspase-9 activation. Mitochondrial release of cytochrome c is accompanied 
by the release of other pro-apoptotic proteins, for example the second mitochondria-derived 
activator o f caspase (SMAC, also termed DIABLO). SMAC was identified by Verhagen et al (2000) 
as a mediator in the formation of the apoptosome. SMAC binds to and prevents LAP inhibition of 
caspase activation.
It is thought that agents that damage DNA such as etoposide, lead to upregulation o f the cellular 
levels of the pro-apoptotic protein p53. p53 induces cell cycle arrest by regulating Cdk activity. p53 
also translocates to mitochondria where it is thought to increase the transcription o f Bax, a pro- 
apoptotic member of the Bcl-2 family of proteins (Miyashita et al, 1994). Bax is thought to localise 
to the mitochondrial membrane and facilitate the release of cytochrome c, leading to the formation 
of the apoptosome with subsequent activation of caspase-9.
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In some cell types it has been demonstrated that caspase-8 can cause the release of cytochrome c 
from the mitochondrial inter-membrane space (Desagher et al, 1999), allowing amplification of the 
death receptor pathway. This is achieved through cleavage of the pro-apoptotic protein Bid 
forming a 15 kDa C-terminal fragment termed truncated Bid (tBid). Bid and tBid translocate to 
mitochondria and activate Bax, which inserts itself into the outer mitochondrial membrane. In a 
similar way it has been suggested that caspase-3 can activate caspase-8 (Slee et al, 1999, Tang et al, 
2000) leading to cleavage of Bid and amplification of the mitochondrial response.
Figure 1.1: Pathways to caspase activation in apoptosis
Death
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FADD/TRADD
Pro-caspase 8
^ Active 
caspase 8
Bax Cell surface 
I membrane
Mitochondrion
Bid
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DIABLO / Cytochrome c
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(A) Binding of plasma membrane death receptors such as the Fas receptor to their ligand results in 
activation of pro-caspase 8 via adaptor molecules such as FADD. Aggregation of pro-caspase-8 
molecules on the cytoplasmic region of the Fas recptor leads to autoactivation of caspase-8. This 
can then activate caspase-3 directly (black lines) or cleave Bid forming tBid, which translocates to 
mitochondria and causes release of cytochrome c and SMAC, with subsequent activation of 
caspase-9 (red lines). This provides an amplification system from the initial stimulus. (B) Cellular 
stress induced by chemicals or UV-irradiation can lead to expression of the pro-apoptotic protein 
p53. This increases expression of Bax that could mediate the release of cytochrome c and SMAC 
from the mitochondrial inter-membrane space. This results in the formation of the apoptosome 
leading to caspase-9 activation (red Hnes). Caspase-9 can then activate caspase-3, which can either 
cleave downstream caspases, or possibly activate pro-caspase-8 allowing amplification of the 
response via cleavage of Bid. (Adapted from A drain and Martin, 2001.)
12
1.2.2.2 The Bcl-2 family
The Bcl-2 family of proteins have a major role in the control of apoptosis with twenty-five 
members having been identified to date. There are three subfamilies that contain at least one of 
four a-helical domains (BHl to BH4). Anti-apoptotic members such as Bcl-2 and Bcl-xL show a 
high degree of sequence homology. Pro-apoptotic members show either sequence homology at 
B H l, BH2 and BH3 domains (for example Bax and Bak), or sequence homology at BH3 domains 
only (for example Bid). Bcl-2 family members are found in the cytosol, attached to cytoskeleton 
components and membranes. They can dimerise forming hetero- or homodimers (Figure 1.2), the 
resulting ratio deternaining pro- or anti-apoptotic effects (Hunter and Hawarth, 1979). Bcl-2 family 
members respond to a diverse range o f apoptotic stimuli, including growth factor deprivation and 
exposure to cytotoxic drugs.
A proposed major site of action of Bcl-2 family members is at the mitochondrial permeability 
transition (FT) pore to modulate cytochrome c release. This is formed from a complex o f the 
adenine nucleotide translocator (ANT), the voltage-dependent anion channel (VDAC), and 
cyclophilin D. ANT and VDAC form the relatively non-selective FT pore that allows passage of 
molecules up to 1.5 kDa (Hunter and Hawarth, 1979). There is evidence for the release of 
cytochrome c from this pore in response to apoptotic stimuli. Although the exact mechanism is not 
clear Bcl-2 family members are known to interact with this process.
Over-expression o f the anti-apoptotic proteins Bcl-2 or Bcl-xL inhibits cytochrome c release, 
possibly via FT pore modulation (Yang et al, 1997), whereas over-expression o f the pro-apoptotic 
Bax leads to enhanced cytochrome c release (Susin et al, 1996). These effects could be due to the 
dimérisation states of the two proteins (Figure 1.2), with the relative levels of pro- and anti- 
apoptotic proteins determining the outcome for the cell. Bcl-2 is thought to translocate to the outer 
mitochondrial membrane (Shimizu et al, 1999) but the exact mechanism for its anti-apoptotic 
effects is unknown. Overexpression of Bcl-2 was found to prevent staurosporine or etoposide- 
induced apoptosis via reduced translocation of pro-apoptotic Bax to mitochondria and subsequent 
caspase activation (Murphy et al, 2000). Bcl-2 may also interact with the inner mitochondrial 
membrane phospholipid cardiolipin (Lutter et al, 2000). This is found at contact sites between the
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inner and outer mitochondrial membrane, where the PT pore is believed to be located. Another 
possible mechanism for the anti-apoptotic effects of Bcl-2 and Bcl-xL is via their BH4 domain that 
is required for activity. Mutations in the BH4 region prevent function of all anti-apoptotic Bcl-2 
proteins. It is thought that via its BH4 domain, Bcl-xL can induce VDAC closure (Shimizu et al,
1999) and prevent cytochrome c release.
Pro-apoptotic Bax direcdy interacts with the VDAC to induce release o f cytochrome c and 
membrane potential loss in isolated mitochondria. This was confirmed in mitochondria from 
VDAC-deficient yeast, whereby Bax-induced cytochrome c release and loss of membrane potential 
did not occur (Shimizu et al, 1999). Overexpression of Bax in Jurkat T  cells caused apoptosis via 
induction of the PT pore (Pastorino et al, 1998). Inhibition of the PT pore by cyclosporin A 
prevented all biochemical features of apoptosis, whereas caspase inhibition prevented all except 
cytochrome c release, demonstrating that caspases are not required in this process (Pastorino et al, 
1998).
Pro-apoptotic Bid is cleaved by activated caspase-8 forming tBid that is thought to induce 
cytochrome c release from mitochondria (Li et al, 1998), and to cause perinuclear clustering of 
mitochondria in apoptosis (Li et al, 1998). Bid has been shown to induce cytochrome c release but 
not via loss of mitochondrial membrane potential, or VDAC activity (Shimizu and Tsujimoto,
2000). tBid is thought to induce lipid destabilisation at contact sites between the inner and outer 
mitochondrial membrane (Lutter et al, 2001), but cannot induce cytochrome c release alone, 
requiring dimérisation with Bax. It is therefore thought that tBid in conjunction with Bax interact 
with the PT pore (Kroemer and Reed, 2000), and mediate death receptor-induced cytochrome c 
release from mitochondria (Li et al, 1998).
In non-apoptotic cells, the pro-apoptotic Bcl-2 family member Bad is inactive due to 
phosphorylation by protein kinases such as protein kinase A (PKA) and mitogen-activated protein 
kinase (MAPK). This phosphorylation occurs at two serine residues within a 14-3-3 consensus site, 
and results in the binding of Bad to the regulatory protein 14-3-3 within the cytoplasm, preventing 
its pro-apoptotic effects (Downward, 1999). When apoptosis is stimulated. Bad is 
dephosphorylated by phosphatases such as calcineurine and can then translocate to the
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mitochondria where it binds Bcl-xL, allowing release of Bax from Bcl-xL-Bax heterodimers 
(Downward, 1999). Bax can then induce release of cytochrome c causing activation of the caspase 
cascade.
Figure 1.2: Interactions between members of the Bcl-2 family of proteins
Bcl-2/Bad heterodimer
Bcl-2 homedImer Bcl-2/Bax heterodimer Bax homodimer
Inhibitory to apoptosis Inactive Stimulatory to apoptosis
The dimérisation state of anti-apoptotic proteins such as Bcl-2 and Bcl-xL and anti-apoptotic Bax 
determines the fate of the ceU and is dependent on the relative concentrations of the proteins. The 
pro-apoptotic protein Bad can influence this equilibrium by forming heterodimers with Bcl-2, 
relieving its inhibitory effect on Bax. This allows Bax to interact with the mitochondrial membrane 
in conjunction with Bid leading to cytochrome c release and apoptosis.
1.2.3 Re g u l a t io n  o f  liver  grow th
Control of liver growth involves a balance between cellular proliferation and apoptosis, however 
the mechanism for maintenance of this balance is not fully understood at present. There is no 
better model for examining the mechanisms behind growth control than in the Hver, due to its 
remarkable regenerative capacity and the ability of the organ to rapidly terminate growth and finely 
control its size. This growth is interesting as it occurs via replication of adult hepatocytes and not 
precursor cells (Fausto, 2000). The liver appears to maintain its optimal mass by the balance of 
proliferation of healthy hepatocytes, and removal of excess or damaged cells by apoptosis. Under 
physiological conditions the turnover of hepatocytes is a slow process, with the half-life estimated 
at 6 months (Michalopoulos and DeFrances, 1997). Liver is remarkable in its ability to regenerate 
following partial hepatectomy (PH), a process that has been widely used for studying the control of
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liver growth. This compensatory regeneration is known to occur following removal of up to 70- 
percent of the liver, and within minutes the remaining hepatocytes leave the quiescent Go state and 
enter the Gi phase o f the cell cycle in preparation for cell replication, restoring the liver to its 
original mass in 10 to 14 days (Haber et al, 1993). This is accomplished by hyperplasia of the 
remaining hepatocytes, with most hepatocytes undergoing at least one round of replication, with 
some replicating twice producing a later increase in proliferation that is smaller than the first (Haber 
et al, 1993). Hepatocytes rapidly enter the cell cycle, with onset of S-phase (DNA synthesis) within 
14 and 24 hours of PH, with the peak o f DNA replication occurring at 24 hours post-PH in rats 
(Fausto, 2000). Mitosis occurs around 8 hours after DNA synthesis, although this period is 
increased in older animals. Non-parenchymal cells of the liver also replicate although this can be 
delayed for approximately 24 hours and is due to a longer Gi phase (Haber et al, 1993).
Once the original mass of the liver has been restored proliferation ceases abruptly. In addition, any 
excess cells are removed by apoptosis. This can be observed following transplantation o f an 
oversized liver, where the organ mass decreases by apoptotic cell death until it is a more suitable 
size for the recipient (Fausto, 2000). This level o f control is unlikely to be co-ordinated by a single 
factor, and is known to involve several pathways leading to different genes being up- and down- 
regulated. Since the liver can alter its growth state so rapidly, it provides a useful model in which to 
study both normal and abnormal cell growth. Haber et al (1993) identified over 70 genes that were 
induced rapidly following PH. In analysing the expression of these and other genes they defined 
three basic patterns o f gene induction. These were immediate-early, delayed-early and liver-specific 
genes. It is thought that for hepatocytes to proliferate after PH they must first be primed to 
increase their responsiveness to growth factors (Fausto, 2000). Priming is thought to involve 
expression o f immediate-early genes and represents the Go to Gi transition. The proteins encoded 
by immediate-early genes then increase the expression of the delayed-early genes. Priming allows 
hepatocytes to respond fully to growth factors such as Hepatocyte Growth Factor (HGF), 
Epidermal Growth Factor (EGF), and Transforming Growth Factor a  (TGFa). This allows 
progression of the cell through the cell cycle by allowing the Gi to S transition to occur (Fausto,
2000) (Figure 1.3).
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Figure 1.3: Model for the stages in liver regeneration
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In response to a stimulus cells can leave the resting state of Go and enter the Gi gap phase that 
prepares the cell for DNA replication (S phase). Following S phase the cell enters the G2 phase 
where it prepares for mitosis (M phase). The Gi and G2 phases allow time for cell enlargement 
prior to cell division. The Gi checkpoint is one of several control points that allow the cell cycle to 
be arrested if cell division is considered unfavourable. Priming is thought to be initiated by 
cytokines that sensitise the cell to growth factors, which are required for progression past the Gi 
checkpoint in the cell cycle. (Adapted from Fausto, 2000.)
1.2.3.1 Cell cycle priming
Priming involves the expression o f immediate-early genes, a process that occurs independently o f de 
novo protein synthesis, relying on pre-existing transcription factors within the quiescent cell (Mohn 
et al^ 1990). The immediate-early genes encode transcription factors, growth factors and regulators 
of signal transduction, which regulate the induction of the delayed-early response. Several o f these 
genes are known proto-oncogenes, and although their exact role is not known, they are important 
in the regulation o f liver growth. The levels o f c-fos and c-jun mRNA increase immediately after 
PH with the peak of expression occurring after 30 minutes, and returning to normal within 2 hours 
post-PH (Morello et al, 1990). Levels of c-myc mRNA increase more slowly with peak expression 
around 2 to 4 hours post-PH (Morello et al, 1990). Activator Protein-1 (AP-1) is a transcription 
factor composed of c-Fos and c-Jun proteins bound via a leucine zipper protein termed Liver 
Regeneration Factor-1 (LRF-l). AP-1 is thought to control delayed-early gene expression during 
the Gi phase of the cell cycle (Hsu et al, 1992) such as those associated with cell cycle progression, 
and also to increase expression of the c-myc gene. The protein product of the c-myc gene 
heterodimerises with a protein Max to form a transcription factor that can activate genes required 
for DNA synthesis and cell cycle control (Hsu et al, 1992).
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The role o f cytokines in priming cells for entry into the cell cycle has been investigated. Tumour 
Necrosis Factor a  (TNFa), a multi-functional cytokine, is thought to cause production of reactive 
oxygen species (ROS) through interaction with one of its receptors TNFR-1 (Yamada et al, 1997b), 
leading to activation o f the transcription factor Nuclear Factor-icB (NF-KB). NF-KB can then 
migrate to the nucleus and bind to genes containing NF-kB recognition sites, such as those 
involved in inflammation, stress response and cell replication. NF-kB is activated very rapidly and is 
detectable within 30 minutes following PH. The levels are transient however, and are no longer 
detectable at 4 to 5 hours post-PH (Fausto, 2000). Interleukin-6 (EL-6) is also thought to be 
involved in the immediate-early response, activating the Signal Transducer and Activator of 
Transcription, STAT-3. This protein also translocates to the nucleus where it regulates the 
expression of genes involved in inflammation and cell proliferation. Studies in IL-6 knockout mice 
showed impaired liver regeneration following PH, and this was reversed by injection o f IL-6 
(Cressman et al, 1996). Activation of STAT-3 occurs at a slower rate than that o f NF-kB, with 
STAT-3 being detectable between 1 to 2 hours post-PH (Cressman etal, 1995).
Interestingly, T N Fa can function as an anti-apoptotic or a pro-apoptotic agent, the latter effect 
being opposed to liver regeneration, occurring in the absence o f NF-kB (Fausto, 2000). Blockage of 
NF-kB expression has been shown to result in apoptosis following DNA replication (limuro et al,
1998), suggesting the presence of NF-kB in the regenerating liver alters the activity o f TN Fa. 
Furthermore, in knockout mice for the TN Fa/IL -6 inducible nitric oxide synthase (iNOS) gene, 
hepatic regeneration was severely impaired with increased apoptosis, despite the normal induction 
of T N Fa and IL-6, and activation of NF-kB and STAT-3 (Rai et al, 1998). This suggests a 
requirement for nitric oxide in the proliferation observed following PH, although further 
investigation is required.
T N Fa and IL-6 signalling through NF-kB and STAT-3 may represent the initial signal for 
proliferation following PH, activating expression of immediate-early genes. Liver-specific gene 
expression is also necessary around this time to maintain metaboHc homeostasis during 
regeneration, and an increase in glucagon with decreased insulin has been observed following PH.
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This induces glycogenolysis and gluconeogenesis in the remaining hepatocytes, counteracting the 
hypoglycaemia observable following PH, with the levels o f both hormones normalising after a few 
hours (Bucher and Swaffield, 1975). Also changes in the levels of expression of genes involved in 
glucose homeostasis have been observed, such as phosphoenolpyruvate carboxykinase (PEPCK) 
and glucose-6-phosphatase (G-6-Pase) (Rosa et al, 1992). These results have led to the suggestion 
that the increased metabolic demand following PH causes the increased TNFa and IL-6 levels, 
which in turn are thought to be responsible for cell priming (Fausto, 2000). Figure 1.4 illustrates a 
possible scheme for liver regeneration with respect to metabolic demands on the organ.
Figure 1.4: Proposed sequence o f events in liver regeneration
Cell or tissue loss
Increased metabolic load on remaining hepatocytes 
(cytokine release: TNFa, IL-6)
i
ROS generation in mitochondria
i
Activation of transcription factors including NF-kB
Activation of immediate early genes 
Cell cycle priming 
Go to Gi transition
Activation of delayed-early genes
Cell becom es responsive to growth factors 
Cell cycle progression 
Gi to 8  transition
Hepatocyte proliferation 
(com pensatory hyperplasia)
Restoration of functional capacity
i
Termination of growth
Initiation and termination of liver regeneration are possibly linked to metabolic demands on the 
liver. Loss of tissue leads to increased metabolic load on the remaining hepatocytes that could be 
the trigger for activation of NF-kB and cell cycle priming. This process is thought to sensitise cells 
to growth factors that allows cell cycle progression and proliferation to restore the original 
functional capacity of the tissue. (Adapted from Fausto, 2000.)
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1.2.3.2 Cell cycle progression
Delayed-early genes are involved in progression, and require protein synthesis for their expression 
to occur, indicating that this is secondary to that of immediate-early gene expression. Delayed-early 
genes include the anti-apoptotic gene Bcl-xL that could be involved in the control o f ROS 
generation as well as inhibiting apoptosis (Fausto, 2000). A study by Loyer et al. (1996) using 
cultured hepatocytes, characterised the changes in cyclin levels throughout the cell cycle, and 
investigated the role of growth factors in progression. They found that progression through Gi 
occurred regardless of growth factor stimulation until the R point in Gi, after which EG F was 
required for continuation through the cell cycle. Cells grown in media containing serum/growth 
factors showed elevated Cyclin D l/cdk4  levels, whereas those grown in serum-free media did not, 
indicating a requirement for growth factors to allow progression from Gi to S phase (Loyer et al, 
1996).
Although TNFa is involved in the priming of hepatocytes, it is not a complete mitogen, as shown 
by the inability of cultured hepatocytes to proliferate in serum-free medium regardless of the 
presence of TNFa (Fausto, 2000). Therefore it is clear that growth factors are required for 
progression through the cell cycle. Whether growth factors are involved in the initial priming of 
hepatocytes in response to PH is not clear, however evidence indicates that growth factors such as 
HGF, EGF and TGFa are not involved in this early stage. Direct infusion o f these growth factors 
along with the co-mitogen insulin into the mesenteric vein of rats failed to induce significant DNA 
synthesis at 24 hours as determined by pulse-labelling with bromodeoxyuridine (BrdU) (Webber et 
al, 1994a). Hepatectomy was performed on the animals whereby 30-percent of the liver was 
removed, however this alone did not induce DNA synthesis. Infusion of growth factors into these 
animals caused a significant increase in DNA synthesis (Webber et al, 1994a). This indicates that 
hepatectomy causes the transition firom the Go to Gi phase, but that growth factors are required for 
progression into S-phase.
The role of growth factors in progression can be both stimulatory and inhibitory, thus providing a 
restraint on proliferation. Stimulatory growth factors include HGF, EG F and T G Fa, with negative 
control involving TGF-(3l and activin. HGF is a heterodimeric glycoprotein and a known
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stimulator of DNA synthesis (Michalopoulos and DeFrances, 1997). HGF levels increase rapidly 
following PH, with circulating levels increasing during the initial 4 hours post-PH (Fausto, 2000). 
HGF is the most powerful mitogen known for hepatocytes, and its expression is correlated with the 
extent of liver damage (Wu et al, 2006). HGF is produced by both extra-hepatic and hepatic 
mesenchymal cells (such as Kupffer cells) and acts in an endocrine and/or paracrine fashion, 
stimulating hepatocyte replication. HGF signals through its receptor, a tyrosine kinase membrane 
receptor encoded by the proto-oncogene c-met. Inactivation of either the HG F gene or c-met in 
mice leads to embryonic lethality by day 16 (Huh et al, 2004). However, prior to this a reduction in 
liver size by up to 55-percent has been observed (Pistoi and Morello, 1996). Levels of HG F mRNA 
in non-parenchymal cells reach a maximum between 18 and 24 hours post-PH, around the time 
that onset of DNA synthesis occurs. This indicates the role o f HGF in progression o f a primed cell 
from Gi into S phase of the cell cycle (Fausto etal, 1995).
EGF functions as an endocrine factor in the mouse, and is produced largely in the salivary glands. 
Removal of salivary glands delays the peak o f DNA synthesis after PH by 24 hours (Fausto et al, 
1995). Analysis of rat hepatocytes post-PH has shown rapid synthesis of EG F mRNA and protein, 
suggesting an autocrine in addition to endocrine action of EG F (MuUhaupt et al, 1994). Binding of 
EGF to its receptor EGFR causing activation o f an intrinsic tyrosine kinase that activates 
downstream signalling leading to induction o f mitosis and differentiation o f certain cell types.
T G Fa is produced in hepatocytes and is elevated after PH, reaching a maximum just prior to the 
peak of DNA synthesis (Fausto, 2000). T G Fa appears to be a more effective stimulator of DNA 
synthesis than EGF, even though it shares 35-percent sequence homology with EG F and acts 
through the EGFR. T G Fa differs from EGF and HGF in that it acts in an autocrine manner. 
Binding of either EGF or TG F-a to the EGFR allows autocrine amplification of T G F-a synthesis 
both in vitro and in vivo (Fausto et al, 1995). Constitutive expression o f T G F-a in hepatocytes was 
studied using transgenic mice that overexpress human T G F-a (Webber et al, 1994b). This resulted 
in increased hepatic proliferation with 25- to 40-percent increases in hver size during the first 
month of hfe, even though hepatocyte differentiation was maintained as normal. After one month 
of age hver size stabihsed through increased ceh turnover, and the appearance o f tumours was not
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seen until after 12 months of age. Cultures o f hepatocytes from these transgenic animals can be 
maintained in serum-free medium for a number of rounds of replication, without the requirement 
for other growth factors. Addition of the medium from these cells to cultures o f normal 
hepatocytes stimulates DNA synthesis, which can be inhibited using anti- TG F-a antibodies 
(Fausto etal, 1995). This indicates the mitogenic potency o f TG F-a in hepatocytes.
As well as the stimulatory effects of HGF, EGF and TGF-a, negative control o f progression is 
exerted by expression o f factors such as TGF-P and activin (Ichikawa et al, 2001). Hepatocytes and 
non-parenchymal cells produce TGF-P as one of three possible isoforms, TG F-pl, TGF-P2 and 
TGF-p3. TGF-p expression is low in normal liver, but increases significantly a few hours following 
PH (Fausto et al, 1995). The elevated levels of TGF-P2 and TGF-P3 mRNA are relatively short 
lived, with TGF-Pl mRNA showing prolonged elevation with a maximum between 36 and 72 
hours post-PH. TGF-P is known to inhibit DNA synthesis in vitro and in vivo, and can prevent liver 
regeneration in response to mitogenic stimuli (Russell et al, 1988). Therefore it has been proposed 
that expression of TGF-P is low initially to allow the first round of DNA synthesis to occur, but 
then increases in order to provide finer control on proliferation as the liver approaches its original 
mass (Fausto et al, 1995). In addition, TGF-P is thought to be pro-apoptotic, preventing excess 
proliferation (Caja et al, 2007). Apoptosis is infrequent in quiescent liver, however it is observable 
following removal of growth stimuli and during liver atrophy associated with starvation. A study by 
Oberhammer et al (1992) showed expression of TGF-Pl in apoptotic hepatocytes by 
immunostaining for the epitope of the protein, and demonstrated increased incidence o f apoptosis 
in hepatocytes following treatment with TG F-pl both in vitro and then in vivo after pre-treatment 
with the mitogenic compound cyproterone acetate.
Further control may involve activin, a potent inhibitor o f proliferation that is undetectable in 
quiescent liver. Activin levels have been reported to increase dramatically in the initial hours 
following PH (Yasuda et al, 1993). Similarly, proteins involved in the control of apoptosis such as 
members o f the Bcl-2 family of proteins, may play a role in refining the extent o f proliferation.
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1.3 P e r t u r b a t io n  o f  liver  h o m eo sta sis causes o r g a n  g row th
Maintenance o f organ size is regulated by the balance between proliferation and apoptosis involving 
many of the factors identified through investigation of compensatory regeneration using the PH 
model. Compensatory regeneration involves loss o f cells as a stimulus for proliferation. However, 
liver cell proliferation can be induced by mitogenic compounds without requiring cell loss, this 
process being termed direct hyperplasia. Investigation of this chemically-induced form of growth 
has demonstrated the involvement of different signal transduction pathways and growth factors as 
compared to compensatory regeneration. Several examples of xenobiotics known to cause liver 
enlargement and hepatocardnogenesis will be discussed further, with particular emphasis on the 
peroxisome proliferator (PP) class of compounds.
1.3.1 Co m p o u n d s  c au sing  liver  grow th
The rodent liver is sensitive to the effects of a variety of xenobiotics that perturb normal liver 
homeostasis, affecting the balance between hepatocyte proliferation and apoptosis that can 
ultimately result in tumourigenesis. Compounds that cause liver enlargement can do so through 
either one or a combination o f increasing cell number (hyperplasia), or increasing cell size 
(hypertrophy). Examples of compounds causing liver growth predominantly by hyperplasia include 
the anti-androgen cyproterone acetate and the peroxisome proliferators, so named because o f their 
effects on the number and size of peroxisomes. In contrast, the glucocorticoid dexamethasone 
causes liver growth predominantly via hypertrophy. These compounds will be discussed further 
with particular emphasis on the peroxisome proliferators as they provide a good model for the 
characterisation o f abnormal growth mechanisms, and have been intensively researched due to the 
differential response of rodents and humans to these compounds. Similaly, the current 
understanding regarding the species differences in the response to PPs and the mechanisms 
postulated for the rodent response to these compounds will also be discussed.
1.3.1.1 Dexamethasone
Dexamethasone is a synthetic glucocorticoid used as an immunosuppressive agent in the field of 
clinical transplantation. Glucocorticoids bind the intracellular glucocorticoid receptor (GR) and 
suppress the expression of proinflammatory genes that can be causative in the rejection o f a
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transplant. Dexamethasone is known to induce hypertrophy of hepatocytes. Nagy and colleagues 
(2001) showed that following PH, treatment with dexamethasone led to the restoration o f rodent 
liver mass despite the finding that DNA synthesis, hepatocyte hyperplasia and stem cell activation 
were inhibited. The increase in liver mass was accomplished by hypertrophy o f the remaining 
hepatocytes, and following withdrawal of dexamethasone the cells returned to a replicative state, 
restoring the normal DNA content and structure of the liver. This inhibition was shown to be via 
suppression of the expression of T N Fa and IL-6 (Nagy et al, 1998), which resulted in reduced 
activation o f the downstream effectors NF-kB and STAT3 (Debonera et al, 2003).
In partial explanation of the effect of glucocorticoid treatment on the inflammatory response was 
the finding that dexamethasone reduced the activity of Jun N-terminal kinase (Jnk) in fetal 
hepatocytes as induced by T N Fa (Ventura et al, 1999). This would in turn prevent the downstream 
effects of Jnk including formation of AP-1, a transcription factor required for liver development. 
Glucocorticoids are also known to induce deposition of glycogen via both direct induction of 
glycogen synthase, and induction of the phosphatase that activates this enzyme (Vanstapel et al, 
1980). It is thought that the resultant increase in deposition o f glycogen in hepatocytes is causative 
o f the hypertrophy in response to dexamethasone treatment (Crunkhom et al, 2004).
Dexamethasone can also inhibit apoptosis in rat hepatoma cells as induced by TGF-(3l that was 
found to be via induction o f the anti-apoptotic protein Bcl-xL (Yamamoto et al, 1998), which 
occurred by increasing both the mRNA and protein levels o f Bcl-xL, and was found to be via the 
mitochondrial pathway to activation of the apoptotic cascade and not via CD95/Fas ligand 
(Scoltock et al, 2006).
1.3.1.2 Cyproterone Acetate
Cyproterone acetate (CPA) is an anti-androgenic compound developed for treatment of prostrate
cancer, which acts by preventing the binding o f dihydrotestosterone to specific receptors in
prostatic carcinoma cell. CPA induces hepatomegaly in rodents through a combination of
hyperplasia and hypertrophy, the hyperplasia being reversible following cessation o f treatment with
CPA with removal of excess cells by apoptosis (Bursch et al, 1986). CPA was found to be a
carcinogen in rodents, causing adduct formation with hepatic DNA in vitro and in vivo, leading to the
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formation of hepatic tumours following long-term treatment with the compound (Topinka et al, 
1993). The DNA adducts formed were found to be highly persistent in rats leading to accumulation 
o f adducts within the liver (Wemer et al, 1995) with binding o f CPA to DNA being higher in the 
female than the male. CPA was therefore classified as a genotoxic carcinogen in rodents since it 
could bind to DNA potentially causing gene mutations that could result in cell transformation to a 
neoplastic state. The finding that CPA was genotoxic in rat liver was also confirmed in primary 
cultures of human hepatocytes (Wemer et al, 1997) although the induction of DNA repair was 
similar between male and female in humans. Reduction and sulfonation reactions are required for 
production of the primary metabolite of CPA that is responsible for the formation o f DNA 
adducts, however this metabolite has a short half-life and can only react with DNA within the cell 
in which it is formed (Brambilla and Martelli, 2002). The International Agency for Research on 
Cancer (lARC) has catergorised the family o f progestins (of which CPA is a member) as being 
possibly carcinogenic to humans, and as carcinogenic specifically concerning the use of CPA in 
combination with estrogen as an oral contraceptive, due to an increased risk of hepatocellular 
carcinoma (Brambilla and Martelli, 2002).
1.3.1.3 Peroxisome Proliferators
Peroxisome proliferators are non-genotoxic hepatocarcinogens that cause tumour induction 
without directly binding to or damaging DNA. Peroxisome proliferation was first described in the 
1960s by Hess et al (1965) following administration of the hypolipidaemic drug clofibrate to rats 
and mice. Common features are an increase in both the number and size o f hepatocellular 
peroxisomes, hepatomegaly, and ultimately liver cancer (Reddy et al, 1980). Many other compounds 
were found to produce similar effects in rodents including plasticisers (e.g. 2-diethylhexylphthalate), 
herbicides (e.g. lactofen), solvents (e.g. trichloroethylene) and other hypolipidaemic drugs (e.g. 
nafenopin). These compounds together form a structurally diverse group with the common feature 
of causing carcinogenesis in rodents with the liver being the major target. The following describes 
the phenomenon of peroxisome proliferation and the potential mechanisms leading to 
hepatocarcinogenesis in rodents following exposure to these compounds.
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1.3.1.3.1 Peroxisomes
Peroxisomes are specialised intracellular organelles found in all eukaryotic organisms, which contain 
oxidative enzymes necessary for the breakdown of fatty acid molecules (reviewed in Wanders et al,
2001). They are single-membrane bound organelles and do not contain DNA or ribosomes, and 
hence require import o f proteins produced in the cytosol (Kunau, 1998). These include enzymes 
such as catalase and urate oxidase, which are often present at high concentrations. Peroxisomes are 
most abundant in liver and kidney. They utilise molecular oxygen to remove hydrogen atoms from 
organic substrates resulting in the formation o f a shortened acyl CoA, acetyl CoA, NADH and 
hydrogen peroxide (Figure 1.5). The hydrogen peroxide is then utilised by catalase to oxidise 
substrates including alcohol and various toxic molecules, with any excess being converted to oxygen 
and water. The major function o f the peroxisomal oxidative reactions is the breakdown of fatty acid 
molecules to acetyl CoA, which is exported from the peroxisome for reuse in biosynthetic 
reactions. Peroxisomal enzymes are also important for alcohol oxidation, cholesterol and bile acid 
synthesis, and amino acid metabolism. The importance of peroxisomal reactions is demonstrated by 
inherited disorders such as Zellweger syndrome, which results from defective protein import into 
peroxisomes (Steinberg et al, 2006). This results in severe peroxisomal deficiency and is fatal at 
birth.
1.3.1.3.2 P-oxidation in peroxisomes
P-oxidation was found to occur in peroxisomes in 1976 (Lazarow and De Duve, 1976), and 
involves enzymes distinct from those found in mitochondrial P-oxidation. In addition, peroxisomal 
p-oxidation is not coupled to ATP production. Free fatty acids must first be converted to a CoA 
derivative before oxidation can occur. This is carried out by acyl CoA synthetases located on the 
cytoplasmic side of the peroxisomal membrane. The acyl CoA derivative is then transported 
passively into the peroxisome and oxidised by the FAD-containing enzyme ACO generating 
hydrogen peroxide. The bifunctional enzyme then carries out hydration and then dehydrogenation 
reactions, followed by thiolytic cleavage to yield acetyl CoA and the shortened acyl CoA. This can 
then be repeatedly shortened or can exit the peroxisome for use elsewhere. Although mitochondria 
and peroxisomes are both capable o f P-oxidation, the mitochondrial carnitine shuttle cannot import
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very-long-chain fatty acids (>C22). Hence the function o f peroxisomal P-oxidation may be to 
shorten very-long-chain fatty acids for subsequent oxidation in mitochondria.
Figure 1.5: P-oxidation pathway in peroxisomes
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Free fatty acids are converted to a CoA derivative by acyl CoA synthetases located on the 
cytoplasmic side o f the peroxisomal membrane prior to oxidation by Acyl CoA oxidase (ACO), a 
process that generates hydrogen peroxide. Hydration and dehydrogenase reactions are performed 
by the bifiinctional enzyme, followed by thiolytic cleavage to yield acetyl CoA and the shortened 
acyl CoA. This process can then be repeated generating shorter fatty add chains, or the acyl CoA 
can exit the peroxisome for use elsewhere, for example P-oxidation in mitochondia.
1.3.1.3.3 Peroxisome Proliferator Activated Receptor-a
PPs activate the nuclear receptor PPARa, a member of the steroid hormone receptor superfamily. 
PPARa was first cloned in mouse liver by Isseman and Green (1990). A mouse liver 
complementary DNA (cDNA) library was screened with a series o f oligonucleotide probes based 
on a highly conserved region within the DNA binding domain of several nuclear receptors, and 
identified a novel nuclear receptor that responded to PPs. The PPARa cDNA encoded a 468 
amino acid polypeptide with a predicted molecular weight of 52 kDa. PPARa was identified as a
putative transcription factor activated specifically by a range of PPs tested, as determined using a
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chimaeric receptor construct of the putative ligand-binding domain of PPARa, and the N-terminal 
sequence and DNA-binding domain o f the human estrogen receptor (hER) (Issemann and Green, 
1990). In the presence of a PP, the hER-PPARa construct transcriptionally activated a reporter 
gene under the control of hER. The level of PPARa activation was shown to correlate with the 
potency of various PPs (Issemann and Green, 1990). Expression of murine PPARa was located 
principally to the hver, the kidney and the heart (Issemann and Green, 1990). PPARa was also 
identified in the rat with expression primarily in hepatocytes, cardiomyocytes and in the proximal 
tubule ceUs of the kidney (Braissant et al, 1996).
Important evidence for the role o f PPARa in peroxisome proHferation was provided by the 
generation o f a PPARa-nuU mouse (Lee et al, 1995). Homologous recombination was used to 
disrupt the hgand-binding domain of the receptor, and resulted in abohshment of the pleiotropic 
effects of PPs in the mouse. PPARa null mice on chronic exposure to potent PPs such as Wy-
14,643 and clofibrate, do not show a transcriptional response, neither is there an increase in DNA 
synthesis as normaUy seen (Lee et al, 1995). This proved that the response to PPs is mediated 
through PPARa.
The mechanism by which PPARa interacts with DNA to modulate gene expression has been 
identified. As with other members of the steroid hormone receptor family, heterodimerisation with 
the retinoid X receptor (RXR) increases the strength of interaction o f the receptor with DNA 
(Green, 1993). Three RXRs have been identified (RXRa, (3 and y) with 9-cis-retinoic acid being the 
common ligand. RXRP was found to heterodimerize with PPARa, and to cooperatively stimulate 
the ACO gene promoter (Keller et al, 1993). Studies have shown activation o f the ACO gene in 
response to either the PP clofibrate or to 9-cis-retinoic acid, with increased activation upon 
simultaneous exposure to both ligands (Kliewer et al, 1992). The PPARa-RXR heterodimers 
interact with DNA at specified sites termed peroxisome proliferator response elements (PPRE) 
(Issemann and Green, 1990), which are located upstream of the target gene and result in specific 
gene transcription. Tugwood et al (1992) proposed that PPREs should be found in the 5’ flanking 
region of genes regulated by PPs. They examined the region upstream of the rat ACO gene that is
28
up regulated in response to PP administration, and identified an element 570 base-pairs (bp) from 
the ACO gene. The response to the potent PP Wy-14,643 was abolished upon removal o f this 
region, and the specific binding of PPARa to the PPRE was also demonstrated. The element 
contains a direct repeat of two hexameric sequence motifs TGACCT and TGTCCT, spaced by a 
single nucleotide termed direct repeat 1 (DRl). The importance of the D R l element in binding 
PPARa-RXR heterodimers was demonstrated by Issemann et al. (1993), who showed reduced or 
absent binding if the spacing was altered by even 1 bp. Following on from this, PPREs were 
identified near to many other PP-induced genes that are largely involved in Hpid metabolism and 
transport (Table 1.1).
Table 1.1: PPRE sequences identified for a number of genes induced by PPs
Gene PPRE sequence Reference
Rat acyl CoA oxidase TGACCT T TGTCCT Tugwood etal, 1992
Rat CYP4A1 TCCCCT C TGACCT Aldridge etal, 1995
Rat Bifunctional enzyme TGAACT A TTACCT Zhang et al, 1992
Human fatty acyl CoA oxidase AGGTCA C TGGTCA Varanasi et al, 1996
Human apoUpoprotein A-I TGACCC C TGCCCT Vu-Dac et al, 1994
Human apoUpoprotein C-III TGACCT TTGCCCA Hertz et al, 1995
Human Upoprotein Upase TGCCCT TTCCCCC Schoonjans et al, 1996
PPRE sequences are shown with corresponding references. Sequences represent the minimum 
required for gene activation to occur.
The physiologic role of PPARa has been determined largely from the identification o f its target 
genes. PPARa is expressed primarily in tissues that perform high levels o f fatty acid catabolism, 
such as in the liver. Genes involved with the uptake and binding of fatty acids within cells, fatty acid 
oxidation and lipoprotein assembly have been identified as containing PPREs. Fasting has been 
shown to induce hepatic expression of PPARa target genes involved in fatty acid oxidation. These 
include the mitochondrial enzymes medium-chain acyl-CoA dehydrogenase and carnitine 
palmitoyltransferase I (CPTI), and the extra-mitochondrial enzymes ACO and cytochrome P450 
4A3 (Leone et al, 1999). PPARa-nuU mice show a significant increase in basal levels o f serum
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cholesterol, particularly high-density lipoprotein (HDL) cholesterol, and in hepatic apoUpoprotein 
A-I mRNA and serum apoUpoprotein A-I levels (Peters et al, 1997). Adrninistration of Wy-14,643 
to wild-type mice typicaUy results in reduced serum triglycerides, however this did not occur in the 
PPARa-nuU mice (Peters et al, 1997). This suggests that PPARa is important in the uptake and 
metaboUsm of Upids and in Upoprotein metaboUsm. In response to fasting, PPARa mRNA levels 
increase in wUd-type mice to accommodate the increased need for hepatic fatty acid oxidation 
(Kersten et al, 1999). Up-regulation of genes involved in fatty acid transport in response to PPs has 
also been attributed to PPARa (Motojima et al, 1998). Endogenous Ugands for PPARa have been 
identified, including unsaturated long-chain fatty acids (KeUer et al, 1993) and the inflammatory 
mediator and chemotactic agent leukotriene B4 (LTB4), which on binding to PPARa causes 
activation o f genes encoding enzymes involved in fatty acid cataboUsm (Devchand etal, 1996). This 
leads to breakdown and deactivation of LTB4 thus controlling inflammation.
Several receptors demonstrating a high degree of sequence homology to PPARa have also been 
identified. PPARy is highly expressed in macrophages and white and brown adipose tissue 
(Braissant et al, 1996). It is involved in the differentiation and regulation o f adipocytes, and the 
thiazoUdienediones (gUtazones) used to treat Type 2 Diabetes MeUitus target this receptor 
(Lehmann et al, 1995). PPARô was first discovered by Schmidt and coUeagues (1992) and was 
found to be expressed ubiquitously at a higher level than PPARa or PPARy with the exception of 
adipose tissue. Less is known regarding the function of PPAR6, but it is currently under 
investigation as a therapeutic target in the treatment of Type 2 Diabetes MeUitus (Takahashi et al, 
2006).
1.3.1.3.4 Species Differences in response to Peroxisome Proliferators
The relevance of peroxisome proUferator-induced carcinogenesis to humans has been investigated 
since the 1980s. Marked species differences in the response to non-genotoxic carcinogens have 
been reported, with several studies indicating that human hepatocytes are refractory to the effects 
of PPs as seen in rodents. Perrone et al (1998) compared the response of cultured human and rat 
hepatocytes to clofibrate and ciprofibrate, which are known rodent peroxisome proUferators. Rat
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hépatocytes were found to express peroxisomal AGO at a 10-fold greater level than human 
hepatocytes. Suppression of TGFa-induced apoptosis was achieved in rat hepatocytes using 
clofibrate, as determined using TUNEL. However, the same dose failed to suppress apoptosis in 
human hepatocytes. Similarly, dprofibrate caused a two-fold increase in DNA synthesis in rat 
hepatocytes, but inhibited DNA synthesis in human hepatocytes (Perrone et al, 1998). Human 
studies have been performed on patients treated with hypohpidaemic drugs such as clofibrate and 
dprofibrate. These studies have shown an absence of significant adverse effects (Ashby et al, 1994). 
Several large epidemiological studies have confirmed the lack o f carcinogenic response to PPs. 
Long-term administration of clofibrate and gemfibrozil to hypohpidaemic patients resulted in no 
significant increase in the incidence o f cancer in studies with follow-up periods of up to nine years 
(reviewed in Stott and Hawkins, 1993). Taken together, this evidence indicates that humans are 
resistant to the effects o f peroxisome prohferators. Research has now centred on discovering the 
cause of this resistance.
The possibihty of non-responsive species lacking functional PPARa was refuted by the cloning of 
fully functional receptors in both human (Sher et al, 1993) and guinea-pig (Bell et al, 1998), a 
species that shows similar resistance to PPs. Sher et al (1993) used a reporter gene assay to compare 
the response of human PPARa with mouse PPARa in réponse to the PPs Wy-14,643, clofibrate 
and nafenopin. Induction of chloramphenicol acetyltransferase (CAT) activity via the PPRE of the 
AGO gene was used to compare the functionality of human and mouse PPARa cDNAs. Human 
PPARa (hPPARa) exhibited the ability to activate the AGO gene promoter and was comparable to 
the mouse PPARa (mPPARa) in this respect, indicating that PPARa activity was not responsible 
for the species differences observed.
The quantity of PPARa mRNA was shown to be 10-fold less in human (Palmer et al, 1998) and 
guinea-pig (Tugwood et al, 1998) compared to rodents. Following on from this, the possibility of 
mutant forms of PPARa was investigated. Two such forms have been cloned firom human liver. 
The first mutant receptor to be discovered was hPPARa8/14, a truncated form of hPPARa 
produced by incorrect splicing of the PPARa mRNA at exon 6 (Roberts et al, 2000). The splice
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defect producing hPPARa8/14 results in the generation o f a premature stop codon, producing a 
174 amino acid truncated receptor instead o f the full-length 409 amino acid receptor. The truncated 
mRNA encoding this mutant receptor appears to be universally expressed in human liver, with 
incidence between 10- and 40-percent of total PPARa mRNA (Roberts et al, 2000). The second 
mutant receptor reported was hPPARa6/29, a full-length receptor with normal DNA-binding 
capacity, but which is unresponsive to PPs. hPPARa6/29 has four amino acid substitutions with 
two of these affecting the ability o f hPPA Rab/29 to respond to PPs (Myers et al, 1997). Roberts 
and colleagues (1998) used electrophoretic mobility shift assays (EMSA) to demonstrate the ability 
of hPPA Raô/29 to bind the rat AGO PPRE in the presence o f RXRa. hPPARa6/29 was found to 
be unresponsive to a number PPs, and acted as a dominant negative repressor of mPPARa activity 
(Roberts et al, 1998). This was demonstrated by adding increasing amounts of hPPARa6/29 to a 
reporter gene assay containing Wy-14,643 and a constant amount of mPPARa. hPPARa6/29 
caused inhibition of mPPARa activation of the PPRE-containing reporter gene in a concentration- 
dependent manner. This was further proved when hPPARa6/29 was introduced into rat 
hepatocytes in vitro, where it prevented the suppression o f apoptosis in response to nafenopin 
(Roberts et al, 1998). However, humans do respond to the hypohpidaemic properties o f certain 
PPs, altering expression of enzymes involved in Hpid homeostasis. One hypothesis to explain this 
selectivity in response is that the expression of hPPARa is sufficient to enable the beneficial effects 
o f therapeutic PPs, but is insufficient to affect the number o f genes required to produce the 
pleiotropic effects observed in rodents (Roberts et al, 2000).
Differences in the promoter sequences of PP-responsive genes may cause species differences. 
Activity of AGO in response to PPs is reported to be 10-fold lower in human hepatocytes than in 
rat hepatocytes (Perrone et al, 1998). Varanasi et al (1996) identified a PPRE upstream of the 
human AGO gene and showed it to be active in reporter gene assays. However, in an attempt to 
verify this observation, Woodyatt et al (1999) looked for evidence o f the AGO PPRE in 22 
unrelated individuals. They found the PPRE to be inactive in every case. Therefore it is likely that a 
combination of reduced quantity of PPARa and reduced efficacy contribute to the lack o f response 
to PPs seen in humans.
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1.3.2 M e c h a n ism s  o f  h e pa t o c a r c in o g e n e sis  - e v id e n c e  u sin g  P ero xiso m e  
Proliferato rs
Since many of the compounds displaying peroxisomal proliferative effects in rodents are frequentiy 
exposed to humans, research has focussed on defining the underlying mechanisms to their 
hepatocarcinogenicity, and the investigation o f PP effects in humans. Despite the differential 
response of humans and rodents to peroxisome proliferators, this class of compounds has been 
useful in advancing the understanding of mitogen-induced hepatocarcinogenesis. The exact 
mechanism leading to carcinogenesis is unknown, although a number have been proposed and wiU 
be discussed here. These include the generation of reactive oxygen species (ROS), tumour 
promotion, and induction of cellular proliferation through increased DNA synthesis and 
suppression of apoptosis.
1.3.2.1 Oxidative Stress
This theory describes the indirect formation of PP-induced mutations through intracellular 
hydrogen peroxide generation (Lake, 1995). Hydrogen peroxide can cause DNA damage possibly 
leading to tumour initiation. Some evidence exists in support of this theory. PPs are known to 
increase peroxisomal P-oxidation particularly the activity o f AGO, which generates hydrogen 
peroxide as a by-product. This increase in AGO activity is not mirrored by an increase in catalase, 
which is a peroxidase that allows breakdown of potentially harmful excess hydrogen peroxide 
(Yeldandi et al, 2000). Therefore through repeated cycles of P-oxidation large amounts o f hydrogen 
peroxide could be generated. Peroxide can diffuse freely out of peroxisomes where it could cause 
oxidative damage to DNA and cellular membranes, potentially leading to DNA mutations. Levels 
of the cytosolic enzyme glutathione peroxidase have been shown to decrease on long-term 
exposure to PPs, and hence another mechanism for removal o f hydrogen peroxide is reduced 
(Gonway et al, 1989). In common with this, peroxide-modified lipids have been described in 
hepatocytes of rats treated with PPs (Gonway et al, 1989), and increased levels of 8- 
hydroxydeoxyguanosine (8-OHdG), a marker of oxidative DNA damage, have been observed in 
hepatic DNA following chronic exposure to PPs (Kasai et al, 1989).
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However, a weight of evidence exists against the theory of PP-induced hepatic oxidative damage. 
The measurement o f 8-OHdG in response to PP exposure by Kasai and colleagues (1989) was 
performed using total cellular DNA. This experiment was repeated using hepatic nuclei only, and 
found no significant increase in 8-OHdG levels (Cattley and Glover, 1993). This difference can be 
explained since total cellular DNA includes both nuclear and mitochondrial DNA, however 
mitochondrial DNA is known to be more susceptible to oxidative damage (Richter et al, 1988). 
Soliman et al (1997) used measurement of hepatic F2-Isoprostanes, a sensitive indicator of 
oxidative stress in vivo, to determine the response to PPs. They found Wy-14,643 caused a 16-fold 
increase in peroxisomal P-oxidation, with minimal effects on catalase activity. However, the hepatic 
levels o f esterified F2-Isoprostanes were unaltered, indicating that oxidative stress does not occur in 
response to PP administration. This was further substantiated by Conway and Popp (1995) who 
found no increase in ethane exhalation or hepatic conjugated diene levels (both indicators of 
oxidative stress) using a higher dose o f Wy-14,643 in a longer study. Perhaps the most crucial 
evidence disproving the oxidative stress theory was found using ACO-nuU mice, whereby 
peroxisome proliferation and hepatocarcinogenesis in response to PP administration were unaltered 
(Fan et al, 1998). Also, in studies comparing the response to Wy-14,643 and less potent PPs, little 
difference in the effect on peroxide formation was found, even though Wy-14,643 is known to be 
more carcinogenic (Lake, 1995). Therefore it seems unlikely that oxidative stress is the sole cause 
for PP-induced hepatocarcinogenesis.
1.3.2.2 Control of cellular proliferation
Balancing cell proliferation and cell death by apoptosis finely controls cell number. It has been 
observed by Berman and colleagues (1983) that PPs cause cellular proliferation in the liver in 
common with the liver growth agent phénobarbital. Rodent hepatocytes proliferate rapidly in 
response to PPs, an effect of both increased DNA synthesis and suppression o f apoptosis (Roberts 
et al, 1995). In response to most PPs there is induction of DNA synthesis, but this frequendy 
returns to basal levels (Ashby et al, 1994), however some more potent carcinogenic PPs such as 
Wy-14,643 can cause sustained elevation of hepatocyte proliferation (Marsman et al, 1988). 
Therefore it appears that the degree of hepatocarcinogenicity of a compound is more related to its
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ability to induce a persistent increase in DNA synthesis rather than inducing an acute phase of 
growth that quickly returns to basal levels.
As well as stimulating proliferation, there is evidence that PPs suppress apoptosis. Apoptosis can be 
triggered by TGF(3l, genotoxic agents such as the anti-cancer drug etoposide, and by activation of 
the CD95 death receptor. Gill et al. (1998) showed that the effects of the afore-mentioned apoptotic 
stimuli could be suppressed in vitro by the PP nafenopin using cultured rodent hepatocytes. This 
suppression has been shown to be reversible, with withdrawal of non-genotoxic agents causing 
increased apoptosis and regression o f hepatic hyperplasia in vivo (Bursch et al, 1984).
The mechanism for PP-induced DNA synthesis and suppression o f apoptosis is not fully 
understood, though it is likely to involve the combination of several pathways. Recent interest has 
centred on the role o f hepatic non-parenchymal cells, particularly Kupffer cells. Nafenopin and Wy-
14,643 caused increased phagocytic activity of Kupffer cells in vivo (Bojes and Thurman, 1996), a 
marker of Kupffer cell activation. Kupffer cells are hepatic macrophages that represent 
approximately 10-percent o f the liver cell population. They secrete a range of cytokines including 
TN Fa. A role for T N Fa has been proposed following the observation of reduced hepatic 
regeneration in TNFRl-nuU mice following partial hepatectomy (Yamada et al, 1997b). Rolfe and 
colleagues (1997) investigated whether treatment of cultured rodent hepatocytes with T N F a gave 
analogous results to treatment with PPs. They stimulated apoptosis using T G F a and found 
significant suppression of apoptosis and stimulation of DNA synthesis following T N F a treatment. 
The suppression of apoptosis was significantly reduced following addition of anti-TNFa antibodies 
to the medium (Rolfe et al, 1997). Decreased DNA synthesis following administration o f anti- 
T N Fa antibodies has been observed in vivo (Bojes and Thurman, 1996), and inactivation o f Kupffer 
cell T N Fa production using glycine prevented Wy-14,643-induced hepatocyte proliferation (Rose et 
aZ, 1997).
Further experiments by Hasmall et al (2000) showed the dependency o f PP-induced hepatocyte 
changes on non-parenchymal cells. Addition o f non-parenchymal cells or medium from non- 
parenchymal cell cultures increased hepatocyte DNA synthesis and suppressed TG Fal-induced
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apoptosis. Without these cells the response o f hepatocytes to nafenopin was prevented, and was 
restored by re-addition of non-parenchymal cells to the hepatocyte culture. This evidence indicates 
a role for non-parenchymal cells and TNFa in mediating PP effects on the hver. However, TNFa 
alone cannot be responsible for the effects o f PPs, since levels o f TNFa produced by cultured non- 
parenchymal cells (NPCs) in response to nafenopin treatment were not high enough to elicit an 
effect on cultured hepatocytes (Hasmall et al, 2000). Peters et al (2000) demonstrated that PPARa 
is not expressed in Kupffer cells, suggesting that Kupffer cells either respond generally to toxic 
stimuli by secreting TNFa, or that this is somehow dependent on PPARa in hepatocytes.
The proliferative effects of TNFa are possibly mediated by activation o f NF-kB. This is usually 
bound to and inactivated by the inhibitory proteins I-KBa or I-icBp. The most efficient activators 
o f NF-KB are TNFa and JL-1, which rapidly stimulate I-kB kinase (IKK) that phosphorylates I-kB 
inhibitory proteins (DiDonato et al, 1997). Phosphorylation of these proteins leads to their rapid 
degradation, allowing nuclear translocation o f NF-kB, where it is involved in the production of 
cytokines for control of cell growth and differentiation (Baldwin, 1996). This includes IL-6 that is 
essential for liver regeneration following partial hepatectomy (Cressman et al, 1996). Rusyn and 
colleagues (1998) showed that the PP Wy-14,643 activated NF-kB in rat liver and that early 
activation occurred predominantly in Kupffer cells by as much as 25-times greater than in 
hepatocytes. This suggests that PP-induced hepatocyte activation o f NF-kB occurs following early 
activation o f NF-KB in Kupffer cells. Rusyn et al (1998) hypothesised that activation o f NF-kB in 
Kupffer cells leads to induction of TNFa and other cytokines, which then cause activation of NF- 
kB in hepatocytes leading to hepatocyte proliferation (Rose et al, 1999b). The importance o f NF- 
kB activation in suppressing apoptosis has also been demonstrated by the inhibition o f NF-kB 
using a dominant mutant o f I-KB, which resulted in hepatocyte cell death by apoptosis (Hellerbrand 
etal, 1998). This effect could contribute to hepatocyte proliferation in response to PP treatment.
The mechanism for activation of NF-kB in Kupffer cells remains unclear. There is evidence for a 
mechanism involving reactive oxygen species. Xanthine oxidase is present at a significant level in 
Kupffer cells, and is activated rapidly in response to cellular stress. It is possible that PPs directly
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increase the activity of this enzyme leading to the generation of ROS (Rose et al, 1999a). Pre­
treatment of rats with the free radical scavenger and xanthine oxidase inhibitor allopurinol, 
prevented the rapid activation o f NF-kB in non-parenchymal cells (Rusyn et al, 1998).
Protein kinase C (PKC) may be involved in NF-kB activation, either through direct 
phosphorylation and removal of I-KB (Diaz-Meco et al, 1994), or through increasing oxidant levels 
in the Kupffer cell that indirectly modulate NF-kB activity (Flohe et al, 1997). PKC is activated by 
free fatty acids (Nishizuka, 1988) and these could accumulate in the cell due to inhibition o f acyl 
CoA synthetase, which has been demonstrated in vitro using the PP Wy-14,643 (Bojes and 
Thurman, 1994). Rose and colleagues (1999a) assessed in vitro superoxide production from direct 
exposure of Kupffer cells to Wy-14,643. They found a dose-dependent 7-fold increase in 
superoxide production compared with controls. This could be inhibited using glycine, which has 
been shown to inhibit intracellular calcium signalling (Ikejima et al, 1997), on which PKC activity is 
dependent. Similarly, the PKC inhibitor staurosporine inhibited superoxide production in a dose- 
dependent manner, indicating the production of oxidants involves PKC. In support of PKC 
involvement, Bojes and Thurman (1994) demonstrated that PKC activity increased 3-fold in 
response to long-term administration of Wy-14,643, and that the levels o f PKC elevated in 
proportion to the hepatocarcinogenic potency of a number of PPs tested.
It has been shown that PKC activity up-regulates expression o f PPARa in response to 
administration of certain PPs in vitro (Yaacob et al, 2001). However, PKC was not found to be 
involved in the transcriptional activity o f PPARa. This su^ests that PPs activate responsive genes 
in hepatocytes via PPARa, but also lead to increased PPARa expression and possibly other effects 
via PKC.
Cosulich and colleagues (2000) demonstrated a role for mitogen-activated kinases (MAP kinases) in 
the induction of cell proliferation by PPs. Using inhibitors to p38 MAP kinase and MAP kinase 
kinase (MKIQ they found the nafenopin-induced induction o f DNA synthesis and suppression of 
TGFP-induced apoptosis were prevented. However peroxisome proliferation was unaffected as 
shown by induction of palmitoyl CoA oxidation, a measure o f peroxisome proliferation. The p38
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and extracellular signal regulated kinase (ERK) families of MAP kinases are known to be involved 
in NF-kB activation (Vanden-Berghe et al, 1998) and IL-6 release (Beyaert et al, 1996). Based on 
this evidence, Roberts and colleagues (2002) proposed that cross talk between MAP kinases and 
PPARa could lead to regulation of hepatocyte growth (Figure 1.6).
Figure 1.6: Scheme depicting the possible relationship between PPARa and p38 MAP 
kinase in the control o f hepatocyte growth
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In response to peroxisome proliferators there may be cross-talk between MAP kinases as induced 
by the response of non-parenchymal cells via T N Fa and IL-6, and PPARa in hepatocytes. The 
interplay between MAP kinases and PPARa could lead to deregulation of hepatocyte proliferation, 
peroxisome proliferation and potentially carcinogenesis. (Adapted fcom Roberts et al, 2002.)
Therefore evidence suggests that PPs act through PPARa that is expressed in hepatocytes but not 
in non-parenchymal cells. Cytokines such as T N Fa produced by non-parenchymal cells are 
involved in the proliferative response to PPs, most probably through activation of NF-KB either 
through generation of ROS by xanthine oxidase and PKC, or through PKC-mediated removal o f I- 
kB proteins. Proliferation may also involve signalling through MAP kinases, although the exact 
mechanisms are not fully understood.
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1.3.2.3 Role in tumour promotion
Promotion describes the acceleration of pre-initiated cells to form tumours. PPs have a mitogenic 
effect particularly early in administration (Eldridge et al, 1990), and could cause increased 
replication of pre-initiated cells. Older animals have a higher frequency of hepatic pre-neoplastic 
lesions, which probably arise through accumulation during the life of the animal. Studies using Wy-
14.643 (Cattley et al, 1991) and nafenopin (Kraupp-Grasl et al, 1991) showed higher incidence of 
hepatic carcinomas and adenomas in older animals, suggesting a requirement for initiated cells to be 
present for PP-induced heaptocarcinogenesis. It has been demonstrated that Wy-14,643 
administration following prior initiation with a genotoxic carcinogen such as diethylnitrosamine 
(DEN) results in significantly increased numbers of hepatic tumours compared to controls (without 
PP administration), su^esting a role for PPs in tumour promotion (Cattley and Popp, 1989).
Intercellular communication is essential for the normal functioning of cells, and may be affected by 
the action of PPs at gap junctions. It is known that neoplastic cells show reduced or absent 
intercellular signalling, losing contact inhibition and proliferating despite this restraint. Loss of 
connexin (Cx) molecules that form gap junctions has been associated with the cancer process. Mally 
and colleagues (2002) showed significant reduction in expression of Cx32 in liver following Wy-
14.643 treatment. This correlated with induction of hepatocyte proliferation and suppression of 
apoptosis. It has been suggested that this loss of intercellular signalling involves PKC (Elcock et al, 
2000). Therefore it is possible that reduced intercellular communication plays an important part in 
PP-induced hepatocarcinogenesis.
1.3.3 E pig e n e t ic  m ec h a n ism s  a ff e c t in g  c a r c in o g e n e sis
As well as the effects of carcinogens on the process of transcription already described, recent 
advances have highlighted the role of epigenetic mechanisms in carcinogenesis. Epigenetics refers 
to the study of changes in gene function occurring without a change in the actual sequence o f the 
DNA. Numerous mechanisms have been implicated as causative in carcinogenesis and the 
following describes the known influence of two such mechanisms.
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1.3.3.1 DNA méthylation
Examples of epigenetic phenomena are chromatin remodelling and DNA méthylation that both 
contribute to the regulation o f gene expression. Chromatin remodelling involves the 
posttranslational acétylation of histones that make up the nucleosomes of chromatin by histone 
acetyltransferases (HATs), and the subsequent deacetylation by histone deacetylases (HDACs). 
Chromatin is usually restrictive to transcription and as such does not allow binding o f the 
transcriptional machinery (TFIID and RNA pol II). It requires a conformational change via 
acétylation of key lysine residues in the histone N-terminal tad domains that weakens the histone- 
DNA interactions and allows transcription to occur (Hassig and Schreiber, 1997). HDACs reverse 
this acétylation and hence restrict access to the DNA, preventing transactivation o f gene 
promoters.
DNA méthylation facilitates the process of histone deacetylation, resulting in transcriptional 
silencing of genes via méthylation of CpG islands in gene promoters. CpG islands are regions of 
DNA composed of dinucleotides of cytosine and guanine, and are so-called as a single site is 
composed of a cytosine linked to a guanine by a phosphodiester bond. Méthylation of CpG islands 
by DNA methyltransferases occurs on the cytosine producing 5-methylcytosine, and is a critical 
event in determining the expression of a gene (Pradhan and Esteve, 2003). Following méthylation 
of the CpG island by a methyltransferase enzyme such as the DNA(cytosine-5)-methyltransferase 1 
(Dnmtl), the most abundant methyltransferase in mammals, methyl-CpG binding proteins 
(MeCPs) are recruited that can bind either naked DNA or within chromatin (Nan et al, 1997). 
Trancriptional repression is then allowed by recruitment of a HDAC by MeCPs such as MeCP2 
(Nan et al, 1998). The HDAC then removes acetyl groups firom the N-terminal tails o f histones, 
resulting in gene silencing. It has been postulated that méthylation of CpG islands by the 
methyltransferase D nm tl causes repression of gene expression not only by binding o f MeCP2, 
which in turn binds to a histone deacetylase such as HDACl, but also by direct binding o f D nm tl 
to HDACl via its transcriptional repression domain (Fuks et al, 2000). MeCP2 has also been linked 
to histone méthylation, another epigenetic modification that regulates chromatin organisation and 
subsequently gene expression (Fuks et al, 2003).
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The relevance of DNA méthylation and chromatin remodelling to carcinogenesis has been 
implicated in numerous studies and is the focus of much research as a target for chemotherapeutic 
intervention (Worm and Guldberg, 2002). Abnormal DNA méthylation has been observed for over 
50 genes in various cancers (Bombail et al, 2004), including the k-ras oncogene for which 
hypermethylation has been implicated in the development o f colon tumours (Esteller, 2002). 
Cancer cells commonly present with global hypomethylation with regions o f hypermethylation 
when compared to normal cells, and this has been most intensively researched with respect to 
hypermethylation of tumour suppressor and tumour-related genes. In the normal cell the Rb 
tumour suppressor protein (pRb) is known to physically interact with HDACl and is recruited by 
the transcription factor E2F1 to target promoters where it masks the E2F1 transactivation domain, 
suppressing expression of genes that could promote progression through the cell cycle (Magnaghi- 
Jaulin et al, 1998). Robertson and colleagues (2000) showed that D nm tl also interacts with pRb, 
E2F1 and HDACl to repress transcription from gene promoters containing E2F1 binding sites, 
indicating that in the normal cell the process of DNA méthylation was co-operating with pRb 
repression of downstream transactivation to regulate progression through the cell cycle. McCabe 
and colleagues (2005) found that the mouse and human Dnmtl gene promoters contained E2F 
binding sites, and that in the absence o f pRb the cellular levels of D nm tl increase, which correlates 
with inactivation o f a tumour suppressor gene by DNA hypermethylation. This suggests that 
disruption o f the pRB/E2F pathway that is a common finding in human cancer can lead to 
hypermethylation and gene silencing of important cell cycle regulators.
The effect of DNA méthylation on gene expression has also provided a potential mechanism for 
the action of non-genotoxic carcinogens (Goodman and Counts, 1993) since these compounds do 
not directly damage the DNA. Pereira and colleagues (2004) evaluated the ability o f certain bile 
acids known to be non-genotoxic carcinogens in rats to induce hypomethylation in colon DNA, 
measured as the 5-methylcytosine content. They observed a correlation between the carcinogenicity 
of the bile acid and the degree of hypomethylation observed, with no evidence o f hypomethylation 
found in response to administration o f the anti-carcinogenic bile acid ursodeoxycholic acid. Watson 
and Goodman (2002) compared the response of liver tumour-sensitive and a relatively resistant 
strain o f mice to treatment with the non-gentoxic rodent carcinogen phénobarbital. They observed
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more méthylation changes, particularly hypermethylation, in the tumour-sensitive animals 
compared to the resistant animals, indicating that the ability to maintain normal méthylation 
patterns is inversely related to tumour susceptibility. Similarly the effect of the PP Wy-14,643 on 
DNA méthylation has been determined in mouse liver where it was proposed that hypomethylation 
of key regulators o f proliferation such as c-myc were involved in the increased proliferation in 
response to the compound (Ge et al, 2001).
1.3.3.2 MicroRNAs
MicroRNAs (nuRNAs) are an abundant class of small, non-coding RNAs (~22 nucleotides) that 
are thought to regulate expression of protein-coding genes in animals and plants. The first o f these 
regulatory RNAs to be identified was the lin-4 RNA of Caenorhahditis elegans that controls the timing 
during larval development. It does so by pairing with sites in the 3’ untranslated region (UTR) of 
target mRNAs and negatively regulating their translation via this RNA-RNA interaction (Lee et al, 
1993). Following on from this discovery, over 300 miRNA genes have been identified in the human 
genome, and the predictions of interactions with mRNA estimates that between dozens and 
hundreds of mRNAs may be regulated by each miRNA, due to the short nature o f the sequences, 
and the fact that silencing is possible without requiring an exactly complementary sequence (Tang et 
al, 2003).
miRNAs have been implicated as possessing both tumour suppressor and oncogenic properties. 
miRNAs have been linked to numerous cancers including chronic lymphocytic leukaemia (CLL) 
that is characterised by malignant B cells overexpressing the anti-apoptotic protein Bcl-2. The 
expression of two miRNAs, m{K-15a and miR.-16-1 were found to be down-regulated or deleted in 
the majority of CLLs, and consequently it was shown that both miRNAs negatively regulate 
Bcl-2 levels at a post-transcriptional level (Cimmino et al, 2005). This suggests that the normal 
apoptotic response may be potentiated by miR.-15a and mtK-16-1 via reduction of translation of 
Bcl-2. Another ntiRNA shown to be suppressed in cancer is lethal-7 {let-7), as demonstrated in lung 
tumours when compared to normal lung tissue. The let-7 ntiRNA is expressed in C. elegans and has 
been postulated as a suppressor of cellular proliferation, since this ntiRNA targets and negatively 
regulates let-60, the C. elegans ortholog of the oncogene Ras (Johnson et al, 2005). Target sites for let-
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7 were also identified in the mammalian Ras genes allowing let-7 to negatively regulate Ras 
expression.
The majority o f miRNA genes are down-regulated in cancer, however several exceptions have been 
investigated, including those of the miK-17-92 cluster. The expression of these nuRNAs was found 
to be increased in primary lymphoma and a wide range of tumour-derived cell lines (Hammond, 
2005), and a direct role in tumourigenesis has been demonstrated for these ntiRNAs in a mouse 
model for Burkitt’s lymphoma where forced expression of the miR-17-92 cluster acted with c-myc 
expression to accelerate the development of tumours (He et al, 2005).
1.3.4 Sum m ary
The mechanisms controlling the response to liver growth agents are complex, involving signalling 
through many classical mediators including cytokines, nuclear receptors and members of the MAP 
kinase family. The response to PPs has been extensively researched although the exact mechanism 
underlying this response is still unknown. PPARa is clearly a requirement in the response although 
the interplay between this and other regulators such as p38 MAP kinase requires further 
investigation. It is clear that non-parenchymal cells are involved in the response, however the 
mechanisms involved are not clear. Similarly the extent to which ROS generation is involved is 
unknown, with further investigation o f the involvement o f T N Fa and IL-6 in the initial response to 
mitogenic stimuli being required. The current challenge is therefore to elucidate how these factors 
interact both within hepatocytes and between non-parenchymal cells and hepatocytes, allowing co­
ordination of the suppression o f apoptosis and cell cycle progression as observed in response to 
liver growth agents. Similarly the involvement of epigenetic mechanisms such as alterations in 
DNA méthylation patterns, or the expression of microRNAs may play a role in the cellular 
response to carcinogens.
This project seeks to further investigate the regulation o f cellular proliferation and apoptosis using 
the rodent response to liver growth agents as a model, with the view to identifying central 
regulators in the co-regulation of these two homeostatic processes.
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1.4 A im s  o f  t h e  P r o j e c t
DNA synthesis and apoptosis are related in their regulation, as evidenced by the response of rodent 
liver to peroxisome proliferators (section 1.3.2.2), however the molecular mechanisms underlying 
this regulation are not fully understood. The main hypothesis of this project is that genes exhibiting 
similar expression profiles in response to mitogenic compounds will share common pathways to 
their activation. Therefore the aims of this project were to identify genes involved in cellular 
proliferation and apoptosis that show evidence of co-ordinate regulation, and to characterise the 
central regulators in the expression of these genes. This in turn will improve the understanding of 
the mechanisms involved in liver growth, and potentially provide molecular markers for future use 
in analysis of the effects of xenobiotics on hver growth.
The research objectives necessary to achieve these aims were as follows:
1. To identify co-ordinately regulated gene pairs through inspection of gene expression profiles 
produced by DNA microarray analysis o f a number of genes foUowing exposure to xenobiotics 
known to cause Hver growth such as the peroxisome proHferator Wy-14,643.
2. To verify initial data using (i) Real-Time Polymerase Chain Reaction (RT-PCR) and (ii) reporter 
gene assay of upstream promoter sequences.
3. To identify common regulatory pathways in response to different xenobiotics by analysing the 
promoters o f gene pairs to identify common transcription factor binding sites.
4. To prove expetimentahy the co-ordinate regulation using site-directed mutagenesis (SDM) to 
disrupt these binding sites and determine their effect on the co-ordinate regulation.
5. To build an interaction network to aUow identification of genes central to the regulation o f Hver 
homeostasis and the response to xenobiotic exposure. The central regulators may then be used 
as molecular markers of Hver growth and would be useful in the assessment of the xenobiotic 
effect of compounds under development.
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2 M a t e r ia l s  AND M e t h o d s
2.1 M a t e r ia l s
Table 2.1 shows the list of reagents and materials used in the course o f the project, and the 
suppliers used in each case. All other chemicals were purchased fcom Sigma-Aldrich (Gillingham, 
UIQ and were of molecular biology standard.
Table 2.1: List o f suppliers o f reagents and materials used in the project
Applied Biosystems (Foster City, 
USA)
TaqMan® Universal PCR Master Mix (4364340) 
Ambion® siRNAs
Canberra Packard (Schwadorf, 
Austria)
96-weU Optiplates
Invitrogen Ltd (Paisley, UK) polymerase (11708-013) 
dNTPs (10297-018)
TA cloning kit (K4500-01) 
cDNA synthesis reagents
Dulbecco’s Modified Eagle Medium: with L-glutamine 
(41965-039)
Gentamicin (10 mg/mL) (15710-049)
Foetal Bovine Serum (10108-165)
MEM Non-essential amino acids (11140-035)
Trypsin-EDTA (15400-054)
MP Biomedicals (lUkirch, France) Aurora Chemiluminescent Reporter gene assay kit
MWG (Milton Keynes, UK) PCR primers 
TaqMan probes
Novagen (Nottingham, UK) Rat genomic DNA (69238)
Oxoid (Basingstoke,UK) Tryptone 
Yeast Extract 
Bacterial Agar
Phosphate buffered saline (PBS) tablets
Promega UK (Southampton, UK) DNA modifying enzymes 
Taq polymerase (M1861)
1 kb DNA step ladder (G6941) 
Transfast transfection reagent (E2431)
Qiagen Ltd (Crawley, UK) MinElute Gel Extraction Kit (28604) 
QIAprep Spin Miniprep Kit (27106) 
EndoFree Plasmid Maxi Kit (12362)
Roche (Welwyn Garden City, UK) Agarose
Cytotoxicity Detection Kit (4744926001)
2.2 BIOINFORMATIC ANALYSIS
For the microarray analysis, all steps up to, and including the raw data production from DNA 
Microarrays was performed prior to the commencement o f the project at GlaxoSmithKline
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(Welwyn, UK). Methods for these steps are included for reference only. All stages of Bioinformatic 
analysis following from this were carried out at the University of Surrey by Elizabeth Anderson.
2.2.1 An im a l  t r e a t m e n t  a n d  d o sin g
Three compounds known to induce liver enlargement in rodents were administered to groups of 
male Sprague-Dawley (SD) rats (n=5). The compounds (and doses) were cyproterone acetate (60 
mg/kg/day), dexamethasone (100 mg/kg/day) and Wy-14,643 (50 mg/kg/day). AH compounds 
were administered in com oil. Three doses of each compound (or com oil as vehicle control) were 
administered at 9am in the morning at 0, 24 and 48 hrs from the start of the study. Groups of 
animals were sacrificed at 6, 12, 24, 48, 72 and 96 hrs post-initial dose, the livers were excised, 
minced and stored at -80°C until analysis.
2.2.2 M icroarray  ANALYSIS
Collected liver samples were analysed using Rat Genome U34 GeneChip® microarray chips 
(Affymetrix), containing probe sets for over 24,000 mRNA transcripts and ESTs across three 
arrays. Total RNA was extracted from the tissue samples using the QIAGEN RNeasy kit, and RNA 
integrity checked by gel electrophoresis. RNA was quantified to determine RNA concentration and 
protein contamination using absorbance spectroscopy (A260/A 280 ratio between 1.9 and 2.1 
required). First Strand Synthesis was performed using the T7 primer (Figure 2.1) to hybridise to 
mRNA strands and prime the first strand synthesis by Superscript RT II (Invitrogen). The T7 
primer incorporates an oligo(dT) region that allows binding to the poly(A) tail of mRNA.
Figure 2.1: T7 primer for First strand cDN A synthesis from mRNA
5’ - GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(dT)24 - 3’
Extra bases 
T7 promoter sequence 
Transcription Initiation Sequence
OUgo(dT) for mRNA poly-A tail (or gene specific sequence if required)
The transcription initiation sequence is necessary for the in vitro transcription stage to synthesise 
biotin-labeUed cRNA prior to fragmentation and hybridisation to the array.
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A second cDNA strand was then synthesised by RNA replacement (Nick translation) using the 
cDNA produced in the first reaction. The double-stranded cDNA was cleaned prior to in vitro 
transcription (TVT). The IVT reaction allows high yield biotin-labelling o f transcripts. T7 RNA 
polymerase catalyses IVT in the presence of biotin-labelled UTP, using the transcription initiation 
sequence incorporated in the T7 primer. RNA polymerase binds its double-stranded DNA 
promoter and separates the two strands. It then uses the 3’ to 5’ (antisense) strand as a template for 
synthesis of a complementary 5’ to 3’ RNA strand (cRNA). The biotin-labelled cRNA was cleaned 
in order to remove RNA firom the sample, and quantitated so that the same amount could be 
applied to each array. The cRNA yield from the IVT reaction was then adjusted in order to reflect 
carryover of unlabelled RNA (minimum concentration for cRNA fragmentation was 0.6 pg/mL).
The cRNA was then fragmented prior to hybridisation onto the array, using metal-induced 
hydrolysis/”Hammerhead cleavage” to produce 35 - 200 base-pair fragments. A hybridisation 
cocktail containing fragmented cRNA, synthetic control oligonucleotide and hybridisation controls 
was then applied to a primed array, and incubated overnight at 45°C in a rotating oven. Arrays were 
washed and stained using a three-stage system using a Genechip® fluidics station 400 operated by 
Affymetrix Microarray Suite version 5.0:
• streptavidin phycoerythrin (SAPE) conjugate was applied to the array - biotin-labelled 
fragments bind the SAPE conjugate
• an anti-streptavidin biotinylated antibody then binds the streptavidin
• further SAPE was added that binds the biotinylated antibody
Each array was then read twice at 3pm resolution with an emission of 578 nm by an Agilent 
GeneArray® confocal scanner (excitation at 488 nm). The signal was converted to an electrical 
current and hence to a numerical value using Affymetrix Microarray Suite version 5.0.
2.2.2.1 Pre-processing of Microarray data
The data generated from the microarray analysis was normalised using an Affymetrix algorithm that 
allows reliable comparison o f multiple arrays, minimising differences o f both biological and 
technical origin. Biological variation can be due to differences for example in age, weight, genetic
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background of test subjects. Technical variations could be due to for example, handling error, or 
differences in the quality or quantity of the target hybridised or the reagents used. The 
normalisation step is necessary to correct for such variations between any two arrays, allowing 
comparison of the results between multiple arrays. The normalisation factor is shown in equation 1. 
Each 25-mer oligonucleotide probe on the array has a corresponding mismatch probe (MM) that 
contains a single mismatch at position 13, providing a specificity control when compared to the 
corresponding perfect match (PM) probe. Hence if there are no mismatches on either array, the 
normalisation factor is 1. Any difference between the two chips provides a scaling factor that can 
be applied to normalise chip2 to chipi.
V  chipl{PM -  m m )
Nômialisation factor = Equation 1
2.2.2.2 Identification of co-otdinately regulated genes
Following normalisation, it was necessary to mine the data, identifying those genes that showed co­
ordinate regulation in response to drug exposure: The general schema for this analysis is shown in 
Figure 2.2, and described in detail below. Initially, only gene fragments showing a minimum three­
fold change in expression (in either direction, at least one time point for any compound) were 
further considered. This cut-off was chosen to increase the likelihood that the genes included 
would reflect expression changes of biological importance. Once gene fragments had been filtered 
by their maximal change (>3-fold), data was sorted to identify those fragments that showed similar 
patterns of expression across the six time-points measured.
Firstly, the data was sorted by accession number using Microsoft® Excel 2000 thus grouping all 
gene profiles together. The direction of change o f gene expression for each gene fragment was 
labelled for each time point (up, down or unchanged). The CONCATENATE function was then 
used to link fragment accession number and direction o f change together producing a single 
description for each profile i.e. D88890_at(ll)upupupupupup where D88890_at(ll) is the 
fragment accession number and the repeated up represents the direction o f change for aU six time 
points. The IF function was then used to identify whether one description was the same as for the 
following row i.e. same accession number and same direction of change for aU time points: If
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descriptions were identical the statement KEEP was entered in the subsequent column, and if non 
identical then DISCARD was entered. Wherever three KEEP statements were found adjacent (i.e. 
all three compounds producing the same description) the fragment accession number was noted.
Secondly, fragments with similar profiles across multiple compounds were clustered manually into 
groups showing potential co-ordinate regulation. Clustering was verified using the Multi-Variate 
Statistical Package (MVSP 3.13b© Kovach Computing Services). Clustering was by Pearson 
Correlation Coefficient (unweighted pair group average linkage technique with randomised input 
order).
Figure 2.2: Scheme outlining data mining process following Microarray analysis o f SD rat 
liver transcript levels in response to liver growth agents
Data Mining Process Number of genes
Total number of genes on Microarray 20,000 genes
Screened for genes showing >3 fold 
change in transcript level in response to 
compounds (in either direction and at 
any time point permitted)
CPA
DEX -> 
WY
2420 genes 
3072 genes 
1992 genes
Screened for genes showing similar 
profile across all three compounds used 38 genes
Genes with similar profiles clustered 
together to form potentially co-regulated 
groups
10 groups
The number of gene fragments showing response to all three liver growth agents was determined 
by expression profile comparison, the profiles for these 38 genes were then clustered.
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2.2.2.3 Investigation of common response elements
Promoter regions immediately adjacent to the putative transcriptional start site (TSS) for each gene 
showing co-ordinate regulation were obtained from the NCBI website (www.ncbi.nlm.nih.gov) as 
follows. The gene related to each gene fragment under investigation was obtained using both the 
NCBI BLAST tool to probe the blastn database (www.ncbi.nlm.nih.gov/BLAST, Altschul et al, 
1990), and the NetAffix analysis database (www.affymetrix.com). The mRNA sequence for each 
gene was then used to probe the rat genome using the NCBI BLAST tool. The one kilobase region 
adjacent to the first exon was then entered into the Match tool 
(http://transfac.gbf.de/TRANSFAC) and Matlnspector (available at http://www.genomatix.de) 
that interrogate the TRANSFAC database of transcription factor binding sites (Quandt et al, 1995). 
The output from these searches is in the form of matrix numbers that define a single transcription 
factor binding site, or that of a group o f related transcription factors. In both cases the core 
similarity and matrix similarity were both set at 0.7 (a low stringency search to minimise false 
negatives) and the analysis performed. The matrix similarity describes the similarity between a 
matrix and a part o f the input sequence, with the core similarity representing the similarity between 
only the five most conserved nucleotides in the matrix and the input sequence. From the results 
for each individual gene, a list of the matrix numbers common between the genes was compiled 
and the corresponding response elements identified using the Genecards website 
(http://bioinfo.wei2 mann.ac.il/cards) to provide information on the known function o f the 
transcription factors.
2.3 Ge n e r ic  M olecular  B io lo g y  T e c h n iq u e s
2.3.1 A g a r o s e  G e l  E l e c t r o p h o r e s i s
All electrophoresis was performed on 1% agarose gels prepared by dissolving 1 g agarose 
(Promega) in 100 mL IxTAE (0.04 M Tris Acetate, 0.01 M EDTA, pH 8.3) plus ethidium bromide 
(0.5 pg/mL). Once set, gels were placed in RunOne™ electrophoresis tanks filled with IxTAE 
buffer. Samples were mixed with loading buffer (0.25% Orange G, 50% glycerol) and were loaded 
(maximum 20 pL per well) along with 5 pL 1 kb DNA ladder (100 pg/mL, Promega) as size 
marker. Electrophoresis was performed at 5 V /cm  until the loading dye had moved three-quarters
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of the gel length. Bands were visualised using a 302 nm medium wavelength ultra-violet 
transHluminator (Syngene Gene Genius Biolmaging System) at 0.04 second exposure, and 
GeneSnap 4.01 (Synoptics) software.
2.3.2 N u cleic  a cid  c o n c e n t r a t io n  d e t e r m in a t io n
DNA concentration was determined by spectrophotometry using a GeneQuant II RNA/DNA 
calculator (Pharmacia Biotech). One absorbance unit at 260 nm correlates to 50 pg/m L of double 
stranded DNA. The A260/A 280 ratio was determined to estimate DNA purity with respect to protein 
contamination. Pure DNA has a ratio of between 1.7 and 1.9 in 10 mM Tris (pH 7.5).
2.3.3 Gr o w th  o f  Bacterial  Cu ltu r es
Plasmid-containing bacteria from recent transformations (less than 1 week old) or a glycerol stock 
were spread across the surface of an antibiotic-containing agar plate (100 pg/m L ampicHlin or 50 
pg/m L kanamycin as required) and incubated overnight at 37°C. A single colony was picked using 
a sterile toothpick and inoculated into 5 mL LB medium containing the appropriate antibiotic. This 
culture was incubated overnight at 37°C on a rotary incubator at 225 rpm. For subsequent maxi­
preparation 100 pL of mini-culture was added to 250 mL antibiotic-containing LB medium and 
grown overnight at 37°C with shaking.
2.3.4 Pr epa r a tio n  o f  glycerol  stocks
From mini-cultures (section 2.3.3) glycerol stocks were prepared for long-term storage, whereby 
150 pL o f sterile glycerol was added to 850 pL of bacterial culture in a sterile 1.5 mL tube. The tube 
was vortexed briefly and stored at -20°C.
51
2.3.5 P olym erase  Ch a in  Re a c t io n  (PCR)
2.3.5.1 Template DNA
For cloning of target genes/promoters polymerase chain reaction (PCR) was performed using 
either rat genomic DNA (Novagen) as template. If  no suitable PCR product was amplified, 
bacterial artificial chromosome (BAC) clone DNA was used as an alternative (Children’s Hospital 
Oakland Research Institute, CHORI) (Table 2.2). These are rat genomic DNA clones containing 
approximately 200 kilobase-pairs (kbp) each. The exact clones required were selected using the 
clone-finder available at the Human Genome Sequencing Center (HGSC) firom Baylor College of 
Medicine (www.hgsc.bcm.tmc.edu/projects/rat). BAC clone DNA was prepared as described in 
section 2.3.6.4.I.
Table 2.2; Bacterial Artificial Chromosome clones (CHORI) used as PCR templates
Gene Project Clone Accession N o.
HCaRG kaxx CH230-335N13 AC124883
N oblp gjld CH230-110021 AC106171
Mel gbwr CH230-6H6 AC124868
RBACH gtso CH230-229D4 AC118359
BAC clones ordered for genes were PCR was unsuccessful using rat genomic DNA as template. 
The reduced size o f template improved the specificity o f the PCR.
2.3.B.2 Primer Design
The published sequence for the 5’ flanking regions of HCaRG, LRCH4, Ces2 and rBACH, and the 
3’ flanking regions of N oblp, Sp3, Mel and rCOUPg were obtained as in section 2.2.2.3 and 
imported into Vector NTI 4.0 (InforMax Inc.). PCR primers were then designed using this program 
with the following parameters; Product length 900 to llOObp, % GC to between 40 and 60% and 
primer length 17 to 23 bp. Derived primer sequences with the expected amplicon sizes are shown 
in Table 2.3.
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Table 2.3: Primer sequences for PCR o f genes o f interest
Gene Size
(t>p)
Sense/
Antisense Primer Name Sequence (5’ to 3)
HCaRG
1006
Sense HCaRG-949s 5’- TAAGCAGCTGGGCAGCTCTTC-3’
HCaRG Antisense HCaRG+57a 5’- CAAGCCTTTACCGCCCTCTG-3’
N oblp
1087
Sense Noblp-26s 5’- AGCCACAACGTGCTCCACAG-3’
N oblp Antisense Noblp+1061a 5’- T rrrG G G lA T A lG C C C A G G A G A G -3’
LRCH4
1138
Sense LRCH4-986S 5’- GTCTTAGCTGGGCGGTGATG-3’
LRCH4 Antisense LRCH4+152a 5’- ACGGAGACTGAAGCTGCAGC-3’
Sp3
1049
Sense Sp3-61s 5’- TGTTGGGCAGCGGTATTCTG-3’
Sp3 Antisense Sp3+988a 5’- TGGGCAGTATGTCCTTCCCC-3’
rBACH
970
Sense rBACH-800s 5’- TTCTGTGGCCTGAAACTTGG-3’
rBACH Antisense rBACH+170a 5’- CATCCTTGTGAGCCTATAGCATC-3’
Upon receipt, lyophilised primers (MWG) were resuspended in Ix TE (10 mM Tris-HCl, 1 mM 
EDTA, pH 7.0) to a stock concentration of 100 mM. The stock primers were diluted with nuclease- 
free water to 10 mM. Stock and working concentrations were both stored at -20°C.
2.3.S.3 PCR Protocol
PCR reactions were performed using 200 ng o f BAC plasmid DNA as template (section 2.3.5.1) or 
250 ng of rat genomic DNA (Novagen). Reactions were performed in duplicate using thin-walled 
GeneAmp reaction tubes (Perkin Elmer). Tables 2.4 (Taq polymerase) and 2.5 {Pfx polymerase) 
show the volumes used for PCR reactions with low fidelity and high fidelity polymerase 
respectively. Table 2.6 shows the temperature cycles used for each primer pair, and Table 2.7 shows 
the optimised annealing temperatures.
PCR products were visualised by separation in a 1% agarose gel containing ethidium bromide 
(section 2.3.1) and size estimated by comparison to a 10 kb step ladder (Promega).
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Table 2.4: Volumes used in PCR reactions (Taq polymerase)
Reagent Volume (pL) Working concentration
lOx PCR Buffer 5 Ix
MgClz (25 mM) 3 1.5 mM
Primers (20 mM) 1.5 (1:1 combined mixture) 30 pm ol/ pL
dNTPs (10 mM) 1.5 300 pM
Betaine (5x) 10 Ix
Taq Polymerase (5 U/pL) 0.5 2.5 U
DNA 200 ng 4 n g /p L
Nuclease-ffee water Volume up to 50 pL
Table 2.5: Volumes used in PCR reactions (7%r polymerase)
Reagent Volume (pL) Working concentration
lOx PCR Buffer 5 Ix
MgS0 4  (50 mM) 1 1 mM
Primers (20 mM) 1.5 (1: 1 combined mixture) 30 pm ol/ pL
dNTPs (10 mM) 1.5 300 pM
Enhancer (lOx) 5 Ix
Pfx Polymerase (2.5 U/pL) 0.5 1.25 U
DNA 200 ng 4 n g /p L
Nuclease-free water Volume up to 50 pL
Table 2.6: Example temperature program for PCR amplifications
Stage Temperature (°C) Time (minutes) Number o f cycles
1 94 5 1
2
94 0.5
3055 1
72 2
3 72 5 1
Table 2.7: Optimised annealing temperatures and enzymes for genes cloned
Gene Enzyme for PCR Annealing Temperature (°C)
HCaRG Taq polymerase 50
N oblp Taq polymerase 50
LRCH4 Taq polymerase 57
Sp3 Taq polymerase 57
rBACH Pfx polymerase 47
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2.3.6 Cl o n in g
2.3.6.1 DNA extraction from agarose gels
PCR reactions (50 pL) were separated using a 1% agarose gel containing 100 pg/m L crystal violet 
DNA stain. Gels were run as section 2.3.1 in 1 x TAE buffer. Bands o f expected size 
(approximately 1000 bp) were excised from the gel using a scalpel and the DNA extracted using the 
MinElute Gel Extraction Kit (Qiagen). The columns contain a silica membrane for binding of 
DNA in high-salt buffer, and elution with low salt buffer or water. This allows removal o f agarose, 
primers, enzymes and other impurities from DNA. The manufacturer’s protocol was followed, with 
a final elution volume of 10 pL.
2.3.6.2 Ligation and One Shot Ttansfomiation
Taq amplified flanking sequences were ligated into the pCR®2.1-TOPO vector (Invitrogen). 
Reactions were set up as shown in Table 2.8 and allowed to proceed overnight at 14°C before 
transformation into bacteria. Alternatively, PCR products fcom Pjx polymerase were cloned into 
the pCR Blunt cloning vector (Invitrogen) using the same protocol, but with ligation at 16°C for 1 
hour.
Table 2.8: pCR®2.1-TOPO ligation reaction
Reagent Volume (pL)
Linear vector (25ng/pL) 1
PCR product 5
lOx ligation buffer 1
T4D NAligase(4U/pL) 1
Nuclease-free water 2
Resultant ligation mixtures were transformed into competent TOPIC D.coli cells using the One Shot 
Transformation kit (Invitrogen). Bacterial cells were stored at -80°C until required, then thawed on 
ice for 10 minutes. 5 pL of each ligation reaction was added to a vial of cells and incubated on ice 
for 30 minutes. Cells were subjected to a brief heat shock (42°C for 45 seconds) and recovered on 
ice for 2 minutes. 200 pL LB broth was added to each vial, followed by incubation at 37°C for 1 
hour with shaking (200 rpm). The pCR 2.1-transformed cells were plated on agar containing 50
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fXg/mL ampiciUin, 0.012 mg/mL 5-bfomo-4-chloro-3-indolyl-|3-D-galactopyranoside (X-Gal) and 
10 mM isopropyl-P-D-thiogalactopyranoside (IPTG) to allow blue/white selection. The pCR 
Blunt-transformed cells were plated on agar containing 50 pg/m L kanamycin. These cells did not 
require blue/white screening due to an integral ccd& lethality gene. AH plates were incubated 
overnight at 37°C. For each vector ten white colonies were picked and inoculated in 5 mL LB 
containing the appropriate antibiotic. For pCR 2.1-transformed cells, one blue colony was picked to 
provide a vector only control. Cultures were grown overnight at 37°C with shaking (200 rpm) and 
then stored at 4°C.
2.3.6.3 Phenol/chlorofotm check for inserts
To rapidly assess for the presence o f inserts, 60 pL of overnight LB culture was mixed with 60 pL 
phenol/chloroform (1:1, pH 7.9) and 10 pL 5 x Orange G loading dye (0.25 % Orange G, 50 % 
Glycerol). Samples were vortexed and centrifuged for 1 minute at 10,000 rpm. 20 pL of the top 
phase was analysed by agarose gel electrophoresis (section 2.3.1) along with 10 pL of starting 
plasmid (5 ng/pL). The presence of an insert was confirmed by comparison with the original 
plasmid.
2.3.6.4 Preparation of plasmid DNA
2.3.6.4.1 Preparation of BAG clone DNA
BAG clones were cultured on agar containing 25 pg/m L chloramphenicol. Individual colonies were 
picked and incubated overnight at 37°C in 5 mL LB broth containing 25 pg/m L chloramphenicol. 
The BAG vector was isolated using a modified alkaline lysis method and QIAGEN mini-prep 
solutions (1 to 3). Briefly, 1 mL of culture was centrifuged at 3,000 rpm for 10 minutes. 
Supernatants were discarded and pellets resuspended in 300 pL solution 1 and vortexed briefly. 300 
pL solution 2 was added to each sample and mixed gently. Samples were incubated at room 
temperature for up to 5 minutes. 300 pL solution 3 was added and mixed gently. Samples were 
placed on ice for 5 minutes and centrifuged at 10,000 rpm for 10 minutes at 4°G. Supernatants were 
transferred to fresh microcentrifuge tubes containing 800 pL ice-cold isopropanol and incubated
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on ice for 5 minutes. Samples were centrifuged at 10,000 rpm for 15 minutes at 4°C. Pellets were 
washed with 500 pL 70% ethanol and centrifuged at 10,000 rpm for 5 minutes. Pellets were then 
air-dried at room temperature and resuspended in 40 pL Ix TE solution (10 mM Tris-HCl, 1 mM 
EDTA, pH 8) by gentle tapping. Clones were verified to confirm the target sequence using real­
time quantitative PCR (TaqMan) with probe/primer sets appropriate for each target gene. Clone 
preparations were diluted 1000-fold for PCR reactions and 5 pL was used for quantitiative real-time 
PCR analysis (section 2.5.6) to confirm the correct BAC clone.
2.3 6.4.2 Alkaline lysis preparation of plasmid DNA
Plasmid DNA was extracted from cultured cells using the alkaline lysis method (personal 
communication. D r K. Plant). 1 mL of each culture was centrifuged for 1 minute at 10,000 rpm. 
Pellets were re-suspended in 100 pL solution 1 (50 mM glucose, 25 mM Tris-HCl, 10 mM EDTA, 
pH 8) and vortexed. 200 pL solution 2 (0.2M NaOH, 1% SDS) was added and mixed gently by 
inverting. Samples were incubated on ice for 2 minutes, followed by addition of 150 pL solution 3 
(3M potassium acetate, 10% glacial acetic acid). Samples were mixed gently and left on ice for 5 
minutes. Samples were centrifuged for 5 minutes at 10,000 rpm. The supernatant was transferred to 
a clean microcentrifuge tube together with an equal volume of phenol/chloroform (1:1, pH 7.9). 
Samples were vortexed and centrifuged for 5 minutes at 10,000 rpm. The aqueous phase was added 
to 800 pL ethanol and immediately centrifuged for 5 minutes at 13,000 rpm. Pellets were washed 
with 800 pL 70% ethanol solution, and centrifuged for 2 minutes at 13,000 rpm. Pellets were air- 
dried for 5 minutes and re-dissolved in 50 pL Ix TE (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). 
Preparations were stored at -20°C.
2.3.6 4.3 QIAGEN Endo-free™ preparation o f plasmid DNA
For sequencing and sub-cloning o f pCR Blunt and pCR 2.1 constructs, DNA was isolated from 
B .^coli D H 5a cells using the QIAGEN Mini-prep kit. Generation of pg quantities of DNA was 
achieved for pSEAP constructs using the QIAGEN Endofree™ Maxiprep kit to isolate plasmid 
DNA from ^.coli D H 5a cells. The manufacturer’s protocols were followed in each case with the
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DNA being re-dissolved in between 250 pL and 500 pL of endotoxin-free buffer TE. DNA 
concentrations were determined by spectrophotometry (section 2.3.2) and the integrity of the 
plasmid DNA checked by electrophoresis (section 2.3.1).
2.3.6.5 Sequence confirmation
2.3.6.5.1 Diagnostic restriction enzyme digest
Restriction enzymes suitable to produce two fragments of differing size were selected using 
restriction maps (Vector NTI). Reagent volumes are shown in Table 2.9 and represent reactions 
requiring two enzymes. Where a single enzyme was used an extra 0.5 pL water was added per 
sample. A master-mix was prepared for multiple reactions.
Table 2.9: Reagent volumes for confirmatory Restriction Enzyme digests
Reagent Volume (pL)
Enzyme 1 (10 U/pL) 0.5
Enzyme 2 (10 U/pL) 0.5
Buffer 1.5
Nuclease-free water 7.5
Plasmid mini-prep 5
The digests were incubated at 37°C for 1 to 2 hours. The results were visualised by electrophoresis 
on a 1% agarose gel containing ethidium bromide (section 2.3.1).
2.3.6.S.2 D N A  Sequencing
Sequencing was carried out using a Beckman Coulter 2000XL instrument by Mrs Victoria L e ^ e tt  
using the “termination reaction” method. Four different fluorescent dye labels were incorporated 
into extended DNA products using 3’ dye-labelled dideoxynucleotide triphosphates, products 
separated by capillary electrophoresis and detected by fluorescence emission. Plasmids were 
sequenced from 250 ng DNA per reaction, using M l3 forward and reverse primers for pGR Blunt 
and pCR 2.1 vectors, and pSEAP 5’ (CTAGCAAAATAGGCTGTCCC) and 3’ 
(CCTCGGCTGCCTCGCGGTTCC) primers. Sequence identity was then confirmed using the 
BLAST algorithm (http://www.ncbi.nlm.nih.gov/blast).
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2.3.6.6 Deletion mutant construction
For the HCaRG and N oblp  promoters, deletion constructs were produced to allow closer 
examination of the 1 kb promoter sequences that were initially cloned. Deletion constructs were 
produced using PCR primers designed to include restriction enzyme sites, allowing the production 
o f smaller daughter fragments using the initial 1 kb as target sequence. Primer names represent the 
gene name and the entire region cloned (including some vector sequence). PCR from deletion 
mutant primers was carried out using Taq polymerase (Invitrogen). Table 2.10 shows the primer 
sequences used to generate the deletion constructs. Table 2.11 shows the annealing temperatures 
for each primer pair with the corresponding restriction endonuclease sites generated. Following 
amplification by PCR, fragments were purified by gel extraction, digested with the appropriate 
restriction endonucleases and ligated into pSEAP (pre-digested with the same enzymes).
Table 2.10: Primers and restriction endonucleases used to generate deletion constructs
Primer Nam e Sense primer Antisense primer
HCaRG-158 bp gcgctcggttççgggaaccac atçtçgagcggccgccagtg
HCaRG-537 bp taaggcaggtaccacacaaatttacgaccc atçtçpgcggccgccagtg
HCaRG-765 bp gaactcacagagatctgtctgcct gcttacttagatcgcagatctcgag
Noblp-144 bp gttcctçtçgagtccgggaggagtg atçtçgagcggccgccagtg
Noblp-382 bp atcgaaggtaccttactgatttatatgatag gcttacttagatcgcagatctcgag
Noblp-797 bp tagctcggtaccccattttttaatagg gcttacttagatcgcagatctcgag
Restriction endonuclease recognition sequences are underlined, with mutated nucleotides shown in 
bold. Constructs were verified using restriction digests and by direct sequencing.
Table 2.11: Primer annealing temperatures (Tm) for HCaRG and N ob lp  deletion mutants
Primer Pair Tm (°C) Restriction Endonucleases
HCaRG-158 bp 61 Acc65 I/X ho I
HCaRG-537 bp 50 Acc65 I/X ho I
HCaRG-765 bp 50 B glll
Noblp-144 bp 61 X h o l
Noblp-382 bp 50 B glll
Noblp-797 bp 50 Acc65 I/Bgl II
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2.3.6.7 Site-directed mutagenesis (SDM)
SDM was used to introduce point mutations into the HCaRG-158 bp and Noblp-144 bp 
constructs to knock-out the effects of potential transcription factor binding sites. In each case two 
sets of PCR primers were produced. One set amplified a large region upstream of the putative 
binding site, while the second set amplified the dovmstream region. In each case a minimum of 
four bases were mutated to convert the sequence to the required restriction endonuclease 
recognition sequence (Table 2.12). PCR from SDM primers was carried out using Taq polymerase 
(Invitrogen). Primer annealing temperatures and the restriction endonucleases appropriate to each 
primer pair are shown in Table 2.13.
Table 2.12: Primer sequences for HCaRG and N ob lp  SDM mutants
G ene/ 
D istance 
from TSS
Fragm ent
ID Sense prim er Antisense prim er
HCaRG/ 
Nrf2-28 bp
Upstream cgccattcaggctgcgcaac cgggtccggagaagtggacca
Downstream cacttctccggacccgccaac tggctgtggctccactgtctgg
N o b lp / 
Nr£2+27 bp
Upstream gcagcgtgaccgctacacttgcca agctccggtgatcaccacaacgtgct
Downstream ttgtggtgatcaccggagctttct acaggtaggccgtggctgt^ctcca
N o b lp / 
Nrf2-281 bp
Upstream tggagtccacgttctttaatagtggact tgaaagggcccagctagaaagag
Downstream ctagctgggccctttcaacca acaggtaggccgtggctgtg
N o b lp / 
AhR+17 bp
Upstream gcagcgtgaccgctacacttgcca agccacactagtctccacaggcgccatgt
Downstream tgt^agactagtgt^ctgac tggctgtggctccactgtctggc
N o b lp / 
AhR-66 bp
Upstream aggctgcgcaactgttgggaagggcgatc ccacagggccctccacaggcgccat
Downstream gtggagggccctgtggctgac %gctgtggctccactgtc%g
Potential transcription factor binding site and the distance o f the site from the TSS (upstream and 
downstream) are shown. Mutated bases are shown in bold corresponding to restriction 
endonuclease recognition sequences.
PCR amplification of the primers sets produced two overlapping products per binding site. PCR 
products were gel extracted (section 2.3.6.1) and digested with the appropriate enzyme (Table 2.13). 
The two corresponding products were then ligated to form a single section with the binding site 
mutated to the restriction endonuclease recognition sequence. The ligated product was then diluted 
1 in 100 prior to PCR amplification using either HCaRG-158 or Noblp-144 primers (Table 2.10) in 
order to generate sufficient quantities of the mutated region to allow ligation into pSEAP and 
subsequent transformation of E.Co/iDH5(X cells as described in section 23.6.6.
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Table 2.13: Primer annealing temperatures (Tm) and enzymes for SDM mutants
Gene/Distance from TSS Primer Fair Tm (°C)
Restriction
Endonuclease
HCaRG/Nrf2-28 bp
Upstream fragment 64 Acc III
Downstream fragment 66 Acc III
N oblp/N rf2+27 bp
Upstream fragment 71 B ell
Downstream fragment 65 B ell
Noblp/Nrf2-281 bp
Upstream fragment 63 Apa I
Downstream fragment 63 Apa I
Noblp/A hR+17 bp
Upstream fragment 70 Spe I
Downstream fragment 57 S pel
Noblp/AhR-66 bp
Upstream fragment 68 Apa I
Downstream fragment 68 Apa I
2.4 Cell  ba sed  t e c h n iq u e s
2.4.1 R e c o v e r y  FROM LIQUID NITROGEN
FaO hepatoma cells (Moore and Weiss, 1982; ECAGG number 89042701) were stored frozen (in 
liquid nitrogen) in 90% foetal bovine serum (FBS) and 10% dimethylsulfoxide (DMSO). A vial 
containing approximately 1x10^ cells was thawed at 37°C for 10 minutes, and mixed gendy with 10 
mL of Dulbecco’s modified eagle medium [with phenol red and L-glutamine, supplemented with 
10% FBS, Ix non-essential amino acids (NEAA) and 10 pg/m L gentamycin (Gibco BRL)]. Cells 
were centrifuged at 150 x g for 5 minutes, and resuspended in 10 mL fresh medium. The cell 
suspension was transferred to a 25 cm^ vented culture flask (Nunclon™, Nunc Brand Products), 
and incubated at 37°C in 4% CO2.
2.4.2 M a in t e n a n c e  c ultur e
Cells were passaged every five days in the ratio of 1:4. When confluent cells were washed with 10 
mL Ix phosphate-buffered saline (PBS), and incubated with 2 mL Trypsin-EDTA solution (Ix) for 
approximately 5 minutes (until the monolayer had detached). The TE was neutralised with 2 mL of 
medium, and the cells resuspended with a pipette. Then 1 mL of cell suspension was transferred to 
each o f four fresh 75 cm^ vented culture flask (Nunclon™, Nunc Brand Products) containing 14 
mL of complete medium (section 2.4.1), and incubated at 37°C in 4% CO2.
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2.4.3 D o s in g  f o r  In  vitro  e x p e r im e n ts
FaO cells were seeded onto plates (Nunclon™, Nunc Brand Products) at a density o f 5 x 10  ^ cells 
per mL. Cells were passaged to a maximum of 12 times following which fresh cells were recovered 
(section 2.4.1) and cultured. For 6-well plates 2.5 mL of cell suspension was transferred to each 
well, and for 96-well plates this volume was 100 pL. Plates were incubated for 48 hours to allow the 
cells to attach and reach approximately 70% confluence. Stock solutions o f xenobiodcs were 
prepared in DMSO (0.5 mL) at lOOOx concentration with all drug stocks being prepared daily to 
prevent degradation during storage. Working solutions were prepared by 1000-fold dilution in 
complete medium, resulting in a working DMSO concentration o f 0.1 %. The xenobiotics used 
were cyproterone acetate (Sigma C3412), clofibric acid (ICN Biochemicals no.l50701), 
dexamethasone (Sigma D-1756), Wy-14,643 (Sigma C7081), p-naphthoflavone (Sigma N3633), 3- 
methylcholanthrene (Sigma 213942) and benzo(a)pyrene (Sigma 48564). Medium (with or without 
compound/DMSO) was replaced every 48 hours.
2.4.4 T r a n sie n t  t r a n sf e c t io n  o f  t h e  FaO  cell  l in e
Transfast (Promega) was chosen as the transfection reagent for FaO cells as it was used previously 
in this laboratory (Swales et a/, 2003). The method was optimised for the amount o f DNA 
transfected, using 0.05 pg, 0.1 pg and 0.25 pg with a reagentrDNA ratio of 3:1. Cells were seeded 
into clear 96-well plates (Nunclon™, Nunc Brand Products) at a density o f 5 x 10  ^ cells/mL (100 
pL per well). Cells were incubated overnight and were hence 50 to 70 % confluent at the time of 
transfection. DNA (0.25 pg per well) was added to serum-free medium (for a total volume o f 40 pL 
per well) and vortexed briefly. Transfast (9 pL per pg DNA) was then added to the DNA/medium  
mixture and vortexed immediately. The transfection mixture was incubated at room temperature 
for 15 minutes. The medium was then removed from the cells, and 40 pL of transfection mixture 
was added to each well. Cells were incubated for 1 hour at 37°C. The transfection mixture was then 
directly overlaid with 80 pL of complete medium, and the cells were mixed gently by swirling the 
plate. Cells were incubated overnight at 37°C (section 2.4.2) prior to assay for basal activity o f the 
promoter, or dosing with liver growth agents in growth medium for the required incubation time.
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2.4.5 P r o to c o l  f o r  c h e m il u m in e sc e n t  d e t e c t io n  o f  SEAP p r o t e in
Luminescence o f secreted alkaline phosphatase was measured using the Aurora™ AP 
chemiluminescent assay kit (MP Biochemicals). For each well, 100 pL of medium was removed and 
transferred to a fresh 96-well plate and stored at -20°C until analysis. The assay was performed 
using the following adaptation of the manufacturer’s protocol. Medium to be analysed (10 pL) was 
transferred to a 96-well Optiplate containing 18 pL of Ix dilution buffer and incubated at 65°C for 
1 hour to destroy endogenous alkaline phosphatase activity (pSEAP produces placental alkaline 
phosphatase that is stable at this temperature). The plate was cooled on ice for 2 minutes and left to 
equilibrate to room temperature for 15 minutes. 24 pL of assay buffer was added and left for 5 
minutes at room temperature. Then 24 pL of reaction buffer (containing the substrate disodium 
3-(4-methoxyspiro [l,2-dioxetane-3,2’-(5’-chloro)tricyclo(3.3.1.1)decan—4-yl)phenyl phosphate]) 
(CSPD) was added and left for 10 minutes at room temperature. Dephosphorylation o f the 
substrate by alkaline phosphatase yields luminescence, which was read using a Packard 
LumiCount^^ (Packard Bioscience) luminometer with PlateReader version 2.10 (Packard 
Instrument Co. Inc.) software. Results were expressed as relative luminescence units (RLU) for 
direct comparison between reporter constructs.
2.5 Q u a n t it a t iv e  Real-T im e  PCR Analysis (Ta qM a n ®)
Quantitative real-time PCR is a technique that uses the kinetics of the early amplification phase of a 
PCR reaction to quantify the level of mRNA transcript in a sample. Samples are compared to 
genomic DNA standards of known copy number to provide a final quantitation. Therefore, in 
order for successful quantitation the primers must be designed within exons, and DNA 
contamination must be avoided.
The method used in this experiment used fluorescent-labelled target specific probes termed 
TaqMan probes (Heid et al, 1996). The probe is dual-labelled with a reporter dye (FAM) covalently 
linked to the 5’ end of the probe, and a quencher molecule (TAMRA) linked to the 3’ end. The 
probe and its specific primer pair hybridise to the target sequence, allowing priming of Taq DNA 
polymerase. The 5’ to 3’ exonuclease activity of Taq DNA polymerase allows the enzyme to cleave
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the terminal nucleotides of double-stranded DNA. Therefore during the extension cycle of the 
PCR, the reporter dye is cleaved from the probe. The quencher molecule and the fluorescent dye 
are then distanced and hence the peak fluorescence emission increases. The fluorescence is 
measured by an ABI Prism 7900 sequence detection system (SDS) that uses a charge-coupled 
device (CCD). The fluorescence is then normalised to a reference dye by the SDS software to 
obtain a ratio for each sample at the end of each thermal cycle. A baseline value is produced by 
measuring the fluorescence between cycles 3 and 15, unless there is an increase in the amplification 
curve prior to cycle 15. A threshold (Th) is set above the baseline so that it falls within the 
exponential phase o f amplification. The threshold cycle (Ct) for any sample is the fractional cycle 
number at which the normalised ratio crosses the Th. The copy number (Cn) for a given target gene 
is calculated by comparison of sample Ct values with those o f standards with known copy number. 
A lower Ct value corresponds to a higher Cn value, since the higher the level of starting material in 
the sample, the sooner the amplification would reach exponential phase.
2.5.1 T otal  R N A  E x t r a c t io n
Following incubation cells were washed with 2.5 mL Ix PBS, and lysed on the plate using 350 pL 
Buffer RLT (QIAGEN RNeasy® extraction kit) containing 1% p-mercaptoethanol (Sigma). Cell 
lysates were homogenised by passing through a 21-gauge needle ten times. Samples were then 
stored at -80°C until required. Samples were then thawed at in a water-bath at 37°C for 15 minutes, 
and added to 350 pL isopropanol. The mixture was transferred directly to an RNeasy® column and 
centrifuged according to the manufacturer’s protocol. Lysates were passed through the column 
twice, and the RNA was eluted from the column using 50 pL RNase-ffee water that was re-eluted a 
second time to increase the RNA yield. All centrifugation steps were performed at 13,000 rpm, and 
the extracted RNA was stored at -20°C until required.
2.5.2 R N A  QUANTITATION AND INTEGRITY DETERMINATION
RNA quality was assessed by agarose gel electrophoresis (section 2.3.1). 5 pL extract was separated 
on a 1% agarose gel and visualised by UV. The RNA was considered of sufficient integrity if the
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ribosomal RNA (rRNA) bands were sharp, and the 28S rRNA band was roughly twice as intense as 
the 18S rRNA band.
RNA quantitation was performed using the Ribogreen™ RNA Quantitation Assay kit (Molecular 
Probes, R-11490). The Ribogreen™ reagent is a fluorescent nucleic acid stain for quantitation of 
RNA in solution with a 1000-fold greater sensitivity than UV spectrophotometry (Molecular Probes 
datasheet MPI 1490). The low range assay was used in each case. Briefly, a IxTE working solution 
was prepared from the provided 20xTE stock solution. This was used to dilute the provided 100 
Pg/mL rRNA standard producing a 1000 ng/m L RNA solution. A standard curve was prepared 
using this 1000 ng/m L RNA solution. 100 pL was added to two neighbouring wells on the 96-well 
plate. 100 pL IxTE was added to well 2 and to six other wells. Double dilutions were made by 
transferring 100 pL of well 2 into well 3, mixing by pipetting, and so on until the seventh well. The 
final well was a blank containing only IxTE. The excess 100 pL in well 7 was discarded. This 
provided a standard curve firom 1000 ng/mL to 15.62 ng/mL. Samples were diluted 20-fold using 
IxTE and 5 pL of each diluted sample was transferred to a well o f black 96-well plate containing 95 
pL IxTE. This provided concentrations within the range of the standard curve (approximately 125 
ng/m L from spectrophotometric assessment). The Ribogreen™ RNA quantitation reagent was 
warmed to room temperature and protected from light to avoid photo-degradation. It was diluted 
200-fold with IxTE, and 100 pL was added to each well. The plate was incubated at room 
temperature for 5 minutes, and the fluorescence was measured using a fluorescent plate reader 
(Molecular Devices SpectraMax Gemini XS) and Softmax® Pro 4.0 software at 485 nm excitation 
and 530 nm emission. Sample concentrations were calculated using the standard curve after 
subtraction of the background fluorescence.
2.5.3 D N ase  t r e a t m e n t  a n d  F irst  str a n d  cD N A  sy n t h e sis
2.5.3.1 DNase treatment
The total RNA samples were treated with DNase I (Promega) to remove all genomic DNA 
contamination. For each sample, 5 pg RNA was transferred to a 0.5 mL microcentrifuge tube along 
with 2 pL lOx DNase reaction buffer, 2 pL DNase I (1 U/pL). The volume in each tube was made
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up to 20 pL with RNase-free water. Samples were incubated in a PCR machine at 37°C for 30 
minutes. The reaction was stopped by addition of 2 pL DNase stop solution (20 mM EGTA, pH 8, 
Promega) and incubation at 65°C for 10 minutes.
2.5.3.2 cDNA synthesis
To ensure DNase treatment was successful, cDNA synthesis was performed on two aliquots of 
each sample. One aliquot was treated with the Reverse Transcriptase (RT) enzyme and the other 
was not. Therefore any DNA remaining after DNase treatment was detectable in the RT negative 
sample during subsequent quantitative real-time PCR analysis. Any samples showing evidence of 
DNA contamination were not included in analysis. For cDNA synthesis, 1 pg o f DNase treated 
RNA (equivalent to 4 pL) was transferred to each of two 0.5 mL microcentrifuge tubes. To each 
tube were added 1.5 pL RNase-free 10 mM dNTP mixture (Invitrogen) and 1.5 pL random 
hexamer primer mixture (3 pg/pL  diluted 20-fold in RNase-free water, Invitrogen) and 4 pL 
RNase-free water. Samples were incubated at 65°C for 5 minutes, and then cooled on ice for at 
least 2 minutes.
The cDNA synthesis used the Invitrogen Superscript II First-strand synthesis system for RT-PCR 
(catalogue no. 11904-018) that allows cDNA synthesis from between 1 ng and 5 pg total RNA. An 
RT-posidve reaction mixture was prepared for n+2 samples:
4 pL 5x First strand buffer 
2pL D T T (0 .1M )
1 pL RNaseOUT RNase inhibitor
0.25 pL Superscript II RNase H-RT (200 U/pL)
0.75 pL Diethylpyrocarbonate (DEPC)-treated water
An RT-negative reaction mixture was also prepared containing:
4 pL 5x First strand buffer 
2pL D T T (0 .1M )
2 pL DEPC-treated water
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To each sample 8 |LiL of the appropriate mixture was added, and samples were mixed gently and 
collected by brief centrifugation. The samples were then incubated as Table 2.14.
Table 2.14: Temperature program for cDNA synthesis
Temperature (°C) Time (minutes)
25 10
42 50
70 15
Samples were made up to 100 jilL total volume with RNase-free water giving an approximate 
concentration of 10 pg/mL. Samples were stored at -20°C until required.
2.5.4  P r im er  a n d  Pr o b e  D e sig n
Primers and probes were designed within a single exon using the ABI Primer Express software and 
following the selection criteria provided by the program (Table 2.15). The chosen primer and probe 
sequences (Table 2.16) were ordered from MWG. Primers were supplied lyophHised and were 
diluted to a stock concentration o f 100 mM with Ix TE (10 mM Tris-HCl, 1 mM EDTA, pH  7.0) 
for prolonged storage. The stock primers were diluted with nuclease-ffee water to a working 
concentration of 10 mM. Probes were similarly diluted to a stock concentration o f 100 mM with Ix 
TE, and a working concentration o f 5 mM using nuclease-free water. Stock and working 
concentrations were stored at -20°C.
2.5.5 Ge n o m ic  D N A  stan da rd s
Rat genomic DNA (Novagen) was supplied at a concentration of 285 ng/pL  (equivalent to 1.4 x 
10*^  single stranded copies per pL). This was diluted to 143 ng/pL  (equivalent to 2 x 10  ^ single 
stranded copies per pL). In each analysis 5 pL of this standard was analysed giving a top standard 
of 1 X 10  ^copies. This standard was diluted to give 1 x 10 ,^ 1 x 10'*, 1 x 10  ^and 1 x 10  ^copies by a 
10-fold serial dilution. All standards were prepared using DEPC-treated water.
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2.5.6 Real-t im e  PCR pr o to c o l
To minimise pipetting errors a bulk mix was prepared containing the probe and primers, water and 
TaqMan universal PCR Master Mix (Applied Biosystems). Table 2.17 shows the volumes per 
reaction. 20 pL of the bulk mix was aliquoted into each required well o f a 96 well optical reaction 
plate (ABgene® Thermo-Fast®). 5 pL of each cDNA sample or standard solution was then added 
to the appropriate well on the plate. Two wells per plate contained 5 pL of DEPC-treated water as 
sample blanks. Repeat analysis of samples was not undertaken due to the high reproducibility o f the 
quantitative real-time PCR analysis, typically under 2 % (K. Swales, personal communication); in 
addition, as a minimum of tbree biological repeats were present for each data point this provided a 
more robust measure o f the variation within the biological system.
Table 2.17: Reagent volumes for preparation of TaqMan bulk mix
Component Volume (pL)
Forward primer (10 |LiM ) 1
Reverse primer (10 pM) 1
Probe (5 pJVQ 0.5
DEPC-treated water 5
TaqMan universal PCR Master mix 12.5
Following sample application the plate was sealed with an optical adhesive cover (ABgene®). The 
plate was centrifuged at 1000 rpm for 1 minute. The plate was placed in the ABI Prism® 7000 
sequence detection system (Applied Biosystems). The plate layout was assigned within the SDS 
software and the appropriate detector (FAM/TAMRA) selected. The reaction volume per well was 
25 )liL. The thermal cycling conditions were as Table 2.18.
Table 2.18: Thermal cycling conditions for TaqMan real time PCR
Stage Temperature (°C) Time (minutes) Repetitions Function
1 50 2 1
2 95 10 1 Dénaturation
3a 95 0.25
40 Annealing/Extension
3b 60 1
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Once completed the run was analysed by adjusting the baseline (default setting 0.2) to the mid point 
o f the exponential phase of the amplification plots for all the standards. All samples were then 
checked to fall within the high and low samples of the standard curve to ensure the baseline setting 
was adequate for all samples, and that measurements would fall within the linear range of the 
analysis. The program (ABI Prism 7000 Sequence Detection System version 1.0® AppHed 
Biosystems) automatically converted the Q  values for the samples into target copies using the 
predefined standard curve. The results were exported for analysis that involved calculation of 
mRNA copies per ng total RNA and the mean and standard error calculated for each sample group. 
This was used to calculate fold-change values compared to vehicle-control (DMSO) and basal 
expression values.
2.6 L a c t a t e  D e h y d r o g e n a s e  (LDH) a ssa y
The cytotoxic potential of the compounds used in the study was determined using the Cytotoxicity 
Detection Kit (Roche), a colorimetric assay for quantitation of LDH release firom damaged/dying 
cells. Cells were seeded in 96-well plates and dosed as for transfection experiments (section 2.4.3) 
over a 96 hour period. Growth medium was removed every 24 hours and replaced immediately 
with fresh medium containing compound of interest (prepared as section 2.4.3). As positive control 
for each time-point, untreated cells were subjected to complete lysis as induced by addition of 
Triton X-100 (2%) for 15 minutes. The negative control at each time-point was FaO cells incubated 
alone. AU samples were stored at 4°C in microplates until time of assay.
Prior to assay, microplates were centrifuged at 250 g for 10 minutes to peUet ceUular debris. 
Supernatant was transferred to a fresh 96-weU plate and dUuted 1 in 4 with fresh growth medium. 
Reaction buffer (100 pL) was added to each weU containing sample (100 pL) and incubated at 
room temperature in the absence of Ught for 20 minutes, prior to analysis using a multi-weU ELISA 
reader. Cytotoxicity was calculated as foUows: cytotoxicity (%) = (test value - negative control 
value)/(positive control value - negative control value) x 100.
70
2.7 Statistical  Analysis
Results were analysed for statistical significance using one-way analysis o f variance (ANOVA) with 
Bonferroni all means Post Hoc test (GraphPad Prism Software version 4.0, San Diego, CA).
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3 M ic r o a r r a y  a n a l y sis  o f  g e n e  e x p r e s s io n  i n  r a t  l iv e r
FOLLOWING EXPOSURE TO LIVER GROWTH AGENTS
3.1 In t r o d u c t io n
DNA Microarray analysis can provide information on gene expression on a genome-wide scale. 
Although not fully quantitative, arrays allow rapid identification o f key gene expression changes that 
can then be validated and characterised. This experiment sought to discover genes involved in the 
response to administration of liver growth agents, potentially identifying biomarkers o f liver growth 
that could be useful in candidate-drug toxicity screening. The sample generation, collection and raw 
data production were performed at GlaxoSmithKline (Welwyn, UK) prior to the commencement 
of this project. All subsequent bioinformatic analysis was carried out at University o f Surrey by 
Elizabeth Anderson.
3.2 Ge n e s  a n d  E x pr e ssed  Se q u e n c e  T ags id e n t if ie d  e x h ib it in g  
POTENTIAL CO-ORDINATE REGULATION
Affymetfix gene arrays are composed of 25-mer oligonucleotide probes complementary to a section 
of an mRNA or expressed sequence tag (EST). The sequences of the probes are represented by 
accession numbers and are termed gene fragments. For each potential gene, several probes are used 
spanning the length of the expressed sequence, thus increasing the confidence in any change 
measured in the expression o f a gene. In this experiment, from the initial «20,000 genes represented 
on the array, the expression of approximately 6000 gene fragments were selected as being altered in 
response to the liver growth agents administered (Figure 2.2), based on an arbitrary cut-off of a 
minimum 3-fold change versus control. Next, it was necessary to identify genes showing consistent 
expression profiles in response to aU three liver growth agents. Wy-14,643, dexamethasone and 
CPA display different effects on the liver such as hypertrophy, hyperplasia or a combination of 
both. It was hypothesised that any gene demonstrating similarity in response to all three 
compounds was likely to be a key regulator in the control of liver growth.
From the gene Fragments identified from the multi-compound comparison, several were already 
associated with known genes. For the remaining gene fragments, association with genes was 
achieved by probing the rat genome sequence with the fragment sequence (obtained using the
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NCBI accession number) using the BLAST alignment tool (Altschul et al, 1990) available at NCBI 
(www.ncbi.nlm.nih.org/BLAST). If  this failed to confirm the gene identity, the fragment sequence 
was used to probe the est_others database (www.ncbi.nlm.nih.org/BLAST/blastn) in order to 
obtain a longer sequence. This extended sequence could then be searched against the rat genome 
sequence with increased probability o f identifying the associated gene. In many cases it was not 
possible to identify the gene at the time. The rat genome sequence is currently under constant 
update, and as the sequence nears completion it will become possible to identify the remaining gene 
fragments.
From this multi-compound comparison, 38 gene fragments were identified as showing similar 
expression profiles with time across all three compounds used in the study (Table 3.1).
The 38 genes/ESTs showing potential importance in a co-ordinated response to liver growth 
agents were next clustered manually into groups according to the shape of their expression profile, 
removing the importance of scale of change from the data. This method was used to reveal genes 
that were potentially related to each other in response to the same stimuli. The clustering identified 
many groups of which two were selected for further investigation. The criteria for selection 
included similarity o f expression profile between gene fragments, and any evidence o f a functional 
connection that could be found. This was only possible where a gene was identifiable from the 
fragment sequence.
The manual clustering was verified using the Multi-Variate Statistical Package (MVSP 3.1 © 
Kovach Computing Services) analysing similarity between gene expression profiles by hierarchical 
cluster analysis (HCA) with random input order using an unweighted pair group method with 
arithmetic mean (UPGMA) linkage technique with Pearson Coefficient to score similarities. This 
gives equal weight to all points in each cluster and is therefore a more balanced clustering 
technique, with a Pearson Coefficient of 1 indicating complete similarity, a value o f zero showing 
no similarity, and -1 indicating an inverse relationship.
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Figure 3.1 shows the results of the HCA for all 38 genes or ESTs. It shows two main regions where 
the expression profiles for gene fragments were (i) consistent over all three compounds 
administered and (ii) consistent with the expression profiles of another gene fragment. The Pearson 
Coefficient for expression profiles for the gene fragments corresponding to Malic enzyme 1 (Mel) 
and rat Brain Acyl CoA Hydrolase (rBACI^ is 0.74. This indicates a close similarity in the 
expression profiles for these genes in response to each of the three liver growth agents 
administered. Mel and rBACH share a common involvement in lipid homeostasis and both 
enzymes are cytoplasmic (section 3.3.2).
The second interesting cluster in Figure 3.1 includes seven gene fragments of which six could be 
linked to genes (section 3.3.1). This cluster has a Pearson Coefficient of 0.75 indicating a similarity 
in the expression profiles for these genes. As with Mel and rBACH, all seven gene fragments 
cluster together across all three compounds.
Figure 3.2 shows the clustering of the two groups of genes selected for further investigation. The 
profiles for one of the groups comprising HCaRG, N oblp, Sp3, LRCH4, rCOUPg, OGFRLl and 
an unidentified gene (labelled EST) were clustered against the profiles for Mel and rBACH. This 
highlights the similarities between the expression profiles within each cluster, and also the 
difference between the two clusters (Pearson Coefficient o f -0.3 between groups). Each o f these 
two clusters of genes show potential for co-ordinate regulation and were investigated further.
Table 3.2 shows the changes in expression for the genes selected for further investigation in 
response to each of the three compounds. This highlights both the similarity in expression profile 
between compounds for each gene, and also the similarity between potentially co-regulated genes. 
For HCaRG, N oblp, Sp3, LRCH4, rCOUPg, OGFRLl and the EST there is a consistent initial 
increase in expression at 6 and 12 hours post-initial dose followed by a prolonged decrease in 
expression. It is possible that the initial 12 hours post-dose represents a stress response to the 
addition of xenobiotic and is not the true response. The crucial phase of the response is likely after 
this initial period, as indicated by the period of inhibition being sustained over a much longer 
period (>72 hours).
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Table 3.2: Expression changes for genes selected for further investigation
Gene Drug
Directi
6
on of expre 
12
ssion chang 
24
je at time-p 
48
oint (hr po: 
72
st-dose)
96
WY T T ; : ;
HCaRG Dex T T ; ; .L
CPA T T ; ; :
WY T t : ; :
N oblp Dex T T : ;
CPA T T ; ; : ;
WY T T : ;
Sp3 Dex T T ; :
CPA T T ; :
WY T T : : :
LRCH4 Dex T T ; :
CPA T T ;
WY T T : ;
rCOUPg Dex t T ;
CPA T T : ;
WY T T ; ; i
OGFRLl Dex t t i i
CPA t T ; i
WY - T ; -
EST Dex - t : ; ; -
CPA - T : ; -
WY T T T T T T
rBACH Dex T T T T t T
CPA T T t t T T
WY T T T t T T
Mel Dex - T T T T T
CPA - t t T T T
Fragments are listed in order according to profile characteristics starting from inhibition (green) 
through to induction (yellow) across all time-points. (Dashed fields represent <3-fold change in 
response to hver growth agent administration.) EST represents gene fragment AI044183 that could 
not be associated with a gene at the time of investigation.
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3.3 M ic r o a r r a y  A n a l y s i s  -  E v i d e n c e  o f  p o s i t i v e  c o n t r o l s
The identification of transcripts previously shown to be modulated by liver growth agents in rodent 
liver adds to the confidence in the robustness of the microarray analysis performed at GSK- 
However, the genes selected for further investigation do not include any classical mediators of 
proliferation or apoptosis, the most likely reason for this being the minimum 3-fold change (versus 
control) threshold. This would remove many genes that alter by only a small amount from the 
analysis. Alternatively, selection o f fragments of interest using profile similarity may exclude some 
gene fragments that are associated with cell proliferation/apoptosis, but which do not form part of 
a co-ordinated response.
The arrays included controls to ensure the technique was carried out correctly, however it was 
necessary to identify some compound-specific expression changes as controls to verify that the 
doses of the compounds used were appropriate. Such controls could include drug metabolising 
enzymes such as a specific member of the Cytochrome P450 family that would be induced in 
response to levels of a certain xenobiotic in the body. Similarly, the expression o f genes linked to 
cell cycle control such as the cyclins and Cdks, or genes involved in apoptosis such as member of 
the Bcl-2 family of proteins would be expected to alter in response to administration o f liver 
growth agents. The following describes some examples o f positive controls for each of the 
compounds administered.
3.3.1 Wy-14,643
Wy-14,643 (WY) is known to induce the expression of CYP4A1 (Aldridge et al, 1995) with 20-fold 
induction observed in precision cut rat liver slices dosed for 24 hours with 50 pM WY (Pan et al, 
2002). The Affymetrix array contained several probe sets for CYP4A1 (probe set accession 
numbers M57718, AA924267, X07259) each containing sixteen different 25-mer oligonucleotide 
probes. Table 3.2 shows the results for the expression of CYP4A1 in response to WY (50 
mg/kg/day). The results for the WY-treated samples indicate a similar response to that observed 
previously (29-fold induction at 24 hours post-dose), with similar induction profiles across the three 
probes. Hence the dose o f Wy-14,643 used in this study was sufficient to induce an appropriate 
response by the major liver detoxifying enzyme for this compound.
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Genes associated with cellular proUferation and apoptosis were also altered in response to WY 
administration. The pro-apoptotic protein Bcl-2-related ovarian killer (Bok) was first identified by 
Hsu and colleagues (1997) who found overexpression o f the protein in Chinese hamster ovary 
(CHO) cells resulted in apoptosis. In response to WY administration the expression o f Bok 
(AF027954) was reduced to 30 percent o f control at 24 hours post-dose (Table 3.3). The decreased 
expression of Bok and hence the potential reduction in apoptosis provides possible evidence that 
liver growth had been induced by WY.
The gene CcnA2 encodes the cell cycle-related protein cyclin A2 that binds to Cdk2 allowing G i/S  
and Gz/M cell cycle transitions. Expression of CcnA2 is known to be up-regulated in mouse Ever 
tumours (Haddad et al, 2000), with cyclin A2 expression increasing proportionally to the 
proliferative response of rat liver following induction of transient liver proliferation (Payraudeau et 
al, 1998). Following administration of WY the expression of CcnA2 (AA998516) increased 
between 48 and 96 hours post-dose (Table 3.3) as would be expected during cehular proliferation. 
Taken together the results for CYP4A1, Bok and CcnA2 indicate that the dosing of WY used in the 
experiment was appropriate to induce cellular proliferation and a metabolic response to the 
compound.
Table 3.3: Positive controls from Microarray analysis o f rat liver following WY 
administration
Fragment
Accession
Number
Gene
Gene expression (drug/control) hours post initial dose
12 24 48 72 96
M57718
AA924267
X07259
AF027954
AA998516
CYP4A1
CYP4A1
CYP4A1
Bok
CcnA2
2.5
4.7
3.3
0.9
1.0
6.5 
21.6 
14.9
1.6
0.2
4.2
29.2 
14.8 
0.3
1.6
5.6
38.5
17.5 
1.1
3.6
3.6
19.8
14.5
0.6
4.0
5.7 
61.3 
9.5 
0.5
18.7
Fragment accession number and corresponding gene are shown with expression profile across the 
dme-points analysed. Values represent treated/control with values in bold representing >3-fold 
change versus control, indicating potential biological significance. WY dosing scheme described in 
section 2.2.1.
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3.3.2 D e x a m e t h a so n e
Dexamethasone is a steroidal compound known to induce a range of CYP genes most notably the 
gene CYP3A23 (alias CYP3A1, CYP3A3; 98-percent nucleotide sequence identity). Meredith and 
colleagues (2003) showed a 97-fold increase in CYP3A1 expression by real-time quantitative PCR 
analysis following 50 m g/kg/day dexamethasone over a four day period. In this experiment 
CYP3A1 (L24207) gene expression was induced to a maximum of 12.8-fold 12 hours post initial 
dose (Table 3.3). This indicates that the dose of dexamethasone used was sufficient to induce a 
metabolic response.
Expression of the pro-apoptotic protein Bad (Bcl2-associated death promoter) was down-regulated 
to 30-percent of control following dosing with dexamethasone (Table 3.4). This could indicate a 
proliferative response to administration of the liver growth agent. Cyclin G2 (AI171262) expression 
decreased to 20-percent of control at 24 hours post initial dose (Table 3.3). Cyclin G2 was 
proposed as a negative regulator of cell cycle progression in the gastric adenocarcinoma cell line 
SGC-7901 (Liu et al, 2004), and was found to induce cell cycle arrest via complex formation with 
protein phosphatase 2A (Bennin et al, 2002). The expression of cyclin G1 (AI178559) was 
increased at maximum 3.5-fold in response to dexamethasone administration (Table 3.4). Jensen 
and colleagues (2003) reported reduced tumour incidence in cyclin G1-deficient mice that was 
linked to negative feedback on cellular levels of the tumour suppressor protein p53.
Dexamethasone also induced expression of the tumour-associated protein 1 (TAl) to a maximum 
6.4-fold at 12 hours post initial dose in this study. TA l is not highly expressed in adult rat liver, but 
is abundant in rat hepatoma (Sang et al, 1995), indicating TAl may have a role in tumour 
progression. Hence the induction of TAl by dexamethasone observed herein may be indicative o f a 
biological response leading to tumour initiation.
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Table 3.4: Positive controls from Microarray analysis of rat liver following DEX
administration
Fragment
Accession
Number
Gene
Gene expression (drug/control) hours post initial dose
12 24 48 72 96
L24207_r_at*
L24207_j_at*
AA818072
AI171262
AI178559
AB015432
CYP3A1
CYP3A1
BAD
CcnG2
CcnGl
TAl
1.4 
0.4 
0.3 
0.5
3.5 
1.3
10.6
12.8
0.5
0.5
1.3
6.4
5.6
3.4
1.3
0.2
1.7 
0.3
5.3
3.5
0.9
0.6
1.2
0.4
11.2
5.0 
0.6 
1.5 
1.2
1.1
4.1
2.0
1.7
1.1 
1.2
0.7
Fragment accession number and corresponding gene are shown with expression profile across the 
time-points analysed. Values represent treated/control with values in bold representing >3-fold 
change versus control, indicating potential biological significance. Dexamethasone dosing scheme 
described in section 2.2.1. (*L24207_r_at and L24207_j_at represent two separate probe sets for 
CYP3A1.)
3.3.3 Cy pr o t e r o n e  acetate
CPA is known to induce expression of CYP3A23 (CYP3A1). Schuetz and colleagues (1998) found 
the induction o f CYP3A23 by CPA was via a DR3 element in the gene promoter, and was similar 
to the induction by dexamethasone. The maximal alteration in expression of CYP3A1 (L24207) was 
an induction o f 10.3-fold following CPA administration (Table 3.4) indicating an appropriate 
response by the liver.
Similar to the results following administration of WY (section 3.4.1), the expression o f Bok 
(AF027954) and CcnA2 (AA998516) were altered in response to CPA administration. Bok 
expression was reduced to 30 percent of control at 48 hours post initial dose and to 10-percent of 
control after 96 hours (Table 3.5). CcnA2 expression increased 18-fold over control at 48 hours 
post initial dose of CPA (Table 3.5). These results are similar to the expression changes induced by 
WY administration, indicating that the dosing scheme for CPA was appropriate.
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Table 3.5: Positive controls from Microarray analysis o f rat liver following CPA
administration
Fragment
Accession
Number
Gene
Gene expression (drug/control) hours post initial dose
12 24 48 72 96
L24207_r_at*
L24207_j_at*
AF027954
AA998516
CYP3A1
CYP3A1
Bok
CcnA2
1.5
0.6
0.9
0.6
5.7
6.3
0.5
0.6
10.3
2.7
0.5
2.3
4.5
3.1
0.3
18.0
10.3
4.2
0.5
4.0
3.4
2.2
0.1
6.2
Fragment accession number and corresponding gene are shown with expression profile across the 
time-points analysed. Values represent treated/control with values in bold representing >3-fold 
change versus control, indicating potential biological significance. CPA dosing scheme described in 
section 2.2.1. (*L24207_r_at and L24207_j_at represent two separate probe sets for CYP3A1.)
3.4 D i s c u s s i o n
In this section, microarray analysis was used to identify gene fragments significantly altered in rat 
liver by exposure to one of three liver growth agents, and then groups o f co-ordinated gene 
fragments selected for further analysis. The positive controls highlighted in section 3.3 represent a 
selection of gene expression changes firom the microarray data. They increase confidence that the 
change in expression of the genes of interest were in response to a dose of each compound that 
could be expected to induce liver growth. Many of the gene fragment accession numbers were not 
linked to known genes at the time of analysis, due in part to the incompleteness of the rat genome 
sequence. Although this linkage would be possible for any single gene from an individual fragment 
or its related EST, it would be unfeasible to do so with the large number of ‘unknown’ fragments 
present on the microarray. Hence many interesting positive controls would have been missed 
through lack of gene annotation for the array. Similarly the use of a minimum 3-fold change to 
refine the data, may have missed some mediators of growth that did not alter in their expression to 
this extent. However the positive controls described are sufficient to consider the data suitable for 
the identification of genes involved in liver growth.
The cluster analysis identified several groups demonstrating potential co-ordinate regulation, of 
which two were selected for further investigation. One group of genes were found to be down-
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regulated in response to liver growth agent administration, the second group being up-regulated. 
Current information on these genes is summarised below wherever published work existed.
3.4.1 Ge n e s  su ppr essed  i n  r e sp o n se  t o  liver  grow th  a g e n t
ADMINISTRATION
A group of seven gene fragments were identified as showing potential co-ordinate regulation, 
exhibiting inhibition of gene expression in response to liver growth agent administration. Six of 
these could be linked to genes, with one gene fragment being unidentifiable at present (Figure 3.3). 
From the six genes identified only four have been investigated previously and these are detailed 
below.
Hypertension-related, calcium-regulated gene (HCaRG) is a calcium-regulated nuclear protein first 
identified by Solban et al (2000). The group were attempting to identify gene(s) responsible for the 
negative calcium balance observed in the spontaneously hypertensive rat. Solban and colleagues 
went on to clone both the rat and human orthologues of HCaRG. The gene is expressed in many 
tissues including the liver and its expression is greatly increased in the adult. The expression of 
HCaRG was greatly reduced in tumour cells and cancerous cell lines (Solban etal, 2000).
HCaRG was found to be a potential regulator o f cellular proliferation. Overexpression o f rat 
HCaRG in the HEK293 cell line (human embryonic kidney) resulted in decreased proliferation as 
measured by cell counting and pH] thymidine incorporation as compared to vector only (Solban et 
al, 2000). Cell cycle analysis showed the reduced proliferation was via GzM cell cycle arrest (Devlin 
et al, 2003). HCaRG has since been implicated in cellular repair after injury, with overexpression of 
HCaRG in two renal cell lines leading to increased cellular migration, extracellular matrix adherence 
and expression of genes involved in cellular migration such as T N Fa (Hader et al, 2005). This 
evidence suggests that HCaRG may be part o f a protective mechanism against cellular injury and 
unwanted cellular proliferation.
The nin one binding protein (NobIp) is a nuclear protein first identified in Saccharomyces cerevisiae 
(S.cerevisiae) by Tone and colleagues (2000). It has since been identified in many species including 
most recendy human where it was found to be expressed primarily in the Ever, lung and spleen 
(Zhang et al, 2005). The N0B1  gene in S.cerevisiae that encodes N oblp, a 459 amino acid protein,
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was detectable in growing cells but not in cells in the stationary phase. N oblp  was found in the 
proteasomal band following glycerol gradient centrifugation and was therefore postulated to be 
involved in proteasome function in growing cells (Tone et al, 2000). N oblp  was found to function 
in proteasome assembly, forming a complex with the 19S regulatory particle, facilitating its binding 
to the 20S proteasome in the nucleus (Tone et al, 2002). N oblp  is then internalised and degraded 
by the newly formed 26S proteasome. Overexpression of N O Bl overcame the defects in 
maturation of the 20S proteasome caused by the UmplDelta mutation (Tone et al, 2002), which 
usually results in the formation of functionally impaired proteasomes (Ramos et al, 1998), indicating 
that N oblp  is essential to functional proteasome assembly.
N oblp  was recently found to have a second important role in the cell. N oblp  is essential for the 
processing of 20S pre-rRNA to the mature 18S rRNA in ribosome synthesis (Fatica et al, 2003). 
Eukaryotic ribosome synthesis occurs to a large extent in the nucleolus, with transcription of a 
single transcript that is cleaved forming the mature 18S rRNA (small ribosomal unit), 5.8S and 2S 
rRNAs (large ribosomal unit). The transcription, pre-rRNA cleavage and ribosome assembly events 
occur in the nucleolus, with pre-40S and pre-60S ribosomal subunits being subsequendy 
transported to the cytoplasm. In S.cerevisiae the maturation of these ribosomal subunits includes 
processing of 20S pre-rRNA to form the mature 18S rRNA via cleavage by N oblp. Fatica and 
colleagues (2003) showed that depletion of N oblp  led to accumulation o f 20S pre-rRNA. They 
found N oblp  to be associated with the pre-40S particle, and present in both the nucleus and 
cytoplasm, suggesting that N oblp  accompanies the pre-40S particle during export from the nucleus 
to the cytoplasm.
The Sp (specificity protein) family o f transcription factors are known to bind to GC-rich regions of 
DNA, and are ubiquitously expressed (Kolell and Crawford, 2002). Spl and Sp3 are closely related, 
are thought to have been formed from a gene duplication event from Sp4 (Kolell and Crawford, 
2002), and compete for the same DNA binding sites (Hagen et al, 1994). Expression o f Sp3 is self­
regulated with the human Sp3 promoter containing two binding sites for Spl/Sp3, with binding to 
both sites necessary for full promoter activity (Lou et al, 2005). Self-regulation is achieved through
86
the C-terminal D-domain of Sp3, which decreases transactivation o f the Sp3 promoter (Hammill et 
a/, 2005).
Sp3 is increased in cells undergoing differentiation and is a positive regulator o f a
CDK inhibitor and key negative regulator of the cell cycle (Koutsodontis et al, 2002). The 
proliferative action o f c-Myc in alleviating cell cycle arrest has been linked to sequestration of 
Spl/Sp3, preventing Spl/Sp3 binding and transactivation of the p 2 1 ciPi/WAFi promoter (Gartel et 
al, 2001). Functional cooperation between the tumour suppressor protein p53 and Spl/Sp3 was 
shown to up-regulate transcription of p21^^i/w^^ and the p53-up-regulated mediator of apoptosis 
(PUMA), and hence Spl/Sp3 may be essential to the cellular response to p53 activation 
(Koutsodontis et al, 2005). Hence a reduced level of cellular Sp3 (as observed in the microarray 
data herein) could remove the negative regulation o f growth by p2 1 ciPi/WAFi^  and therefore 
contribute to the proliferative effect of a liver growth agent.
rCOUPy also known as Ear2 or Nr2F6 (subfamily 2, group F, member 6) is an orphan nuclear 
receptor and a member of the chicken ovalbumin upstream promoter family of transcription 
factors (COUP-TFs), which are involved in the transcriptional regulation of a variety o f genes. 
Ear2, the human orthologue of rCOUPy, is highly expressed in human foetal liver and is predicted 
to be similar in primary structure to steroid and thyroid hormone (T3) receptors (Miyajima et al, 
1988). Zhu and colleagues (2000) showed that Ear2 interacts with the T3 receptor TR|3l, a 
mediator of the effects o f T3 in cells. The interaction with Ear2 caused repression o f the binding of 
TR|3l to the T3 response element (TRE) in effector gene promoters. This negative regulation of 
transcriptional activity by Ear2 also extended to the glucocorticoid receptor (GR) and the estrogen 
receptor (ER). Similarly, COUP-TFs have been shown to interact with and negatively regulate 
binding of other receptors to target promoters, including the Vitamin D receptor, the retinoic acid 
receptor, PPARs, RXR and HNF4 (Qiu et al, 1996). Therefore down-regulation o f rCOUPy 
expression in response to a liver growth agent (as observed in the microarray data herein) may 
contribute to liver growth through removal of its negative influence on other receptors.
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Figure 3.3; Summary of known literature on potentially co-regulated genes
Gene
HCaRG
Noblp
Sp3
rCOUPg
LRCH4
0GFRL1
EST
Physiological function
N egative regu la to r of cellu lar proliferation A 
via GglVI cell cycle a rre s t
E ssen tia l for 2 6 8  p ro te a so m e  b io g e n esis  
an d  for p ro cess in g  of 2 0 8  pre-rR NA  to 
th e  m atu re  1 8 8  rRNA
P ositive regu la to r of th e  CDK inhibitor 
p2 icipi/wAFi_ rnay b e  e s se n tia l for th e  
cellu lar re sp o n se  to  p53 activation
P otential n ega tive  regu la to r of 
transcrip tional activation by T R p i,
GR, RAR, PPA R  an d  HNF4
Exposure to 
liver growth agents
No function known a t p re se n t
i E x p ressio n  in 
r e s p o n s e  to  liver 
grow th a g e n ts
I
Removal of 
negative influence 
on liver growth
J
Summary of the literature as described in text indicating potential co-regulation of HCaRG, N oblp, 
Sp3, rCOUPg, LRCH4, OGFRLl and the gene fragment AI044183 (EST in diagram). The 
inhibition of gene expression observed for each of the genes/EST in response to exposure to liver 
growth agents may be causative of liver growth through the removal of a negative influence on 
growth.
3.4.2 Ge n e s  in d u c e d  in  r espo n se  t o  liver  grow th  a g e n t  a d m in is t r a t io n
Rat Brain acyl CoA hydrolase (rBACH) is a cytosolic enzyme that catalyses the hydrolysis of 
paknitoyl CoA to palmitate and coenzyme A (CoASH), and could therefore regulate intracellular 
levels of acyl CoAs, free fatty acids and CoASH (Hunt and Alexson, 2002). Hence rBACH may 
have an important regulatory role by modulating the levels of fatty acyl CoA, which can either be 
ligands for certain transcription factors or substrates for fatty acid metabolising enzymes. rBACH is 
a Type II thioesterase (high molecular mass group) and has a broad specificity with activity towards 
Co to C20 fatty acyl CoAs (Hunt and Alexson, 2002). rBACH expression is constitutively active in 
brain and testis, whereas its expression could be induced in liver using die peroxisome proliferator
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di(2-ethylhexyl)phthalate (DEHP) (Yamada et al, 1997a). The induction of rBACH expression by 
liver growth agent administration observed in the microarray data herein is therefore in agreement 
with published results using peroxisome proliferators, providing increased confidence in the 
analytical approach used herein.
MaHc enzyme 1 (Mel) is a cytosolic, NADP-dependent enzyme that generates NADPH for fatty 
acid biosynthesis through oxidative decarboxylation o f malate to pyruvate. A regulatory 
PPAR/RXR response element (PPRE) was identified in the maHc enzyme promoter, conferring 
responsiveness to peroxisome proliferators (Castelein et al, 1994). It was found that the orphan 
nuclear receptor COUP-TF competes with PPAR/RXR for this PPRE, therefore preventing 
transactivation of the Mel promoter in the absence of exogenously added ligands (Baes et al, 1995). 
Human malic enzyme expression is induced in response to T3 via TR(3 binding to a TRE in the ME 
promoter (Gonzalez-Manchon et al, 1997). The identification of a PPRE in the promoter of M el is 
confirmatory to the results seen herein where Wy-14,643 administration induced Mel expression.
3.4.3 Sum m ary
In this chapter a bioinformatic approach has been used to identify a subset of gene fragments that 
show co-ordinated expression profiles in response to multiple, chemically distinct, liver growth 
agents. The expression of HCaRG, N oblp, Sp3, rCOUPy, LRCH4 and OGFRLl despite showing 
an initial increase in expression that was likely a stress response, showed a prolonged decrease in 
response to liver growth agent administration that was observable between 12 and 24 hours post­
initial dose. This time-point most likely represents a regulatory phase in the response to the 
xenobiotics, since treatment of rats with a single dose o f Wy-14,643 (100 mg/kg) results in 
increased expression o f Cdk genes between 24 and 48 hours post-dose with entry into DNA 
synthesis also observable at this time-point (Rininger etal, 1997). Also, rats treated with Wy-14,643 
only show altered hepatocyte foci following 22 weeks o f treatment, with neoplastic Ever nodules 
observable between 26 and 50 weeks, and hepatoeluEar carcinoma progressing thereafter (Rao and 
Reddy, 1987). Given that Ever tumours are only observable in rats foEowing long-term treatment, it 
is likely that expression changes at 24 hours post-initial dose are not purely a consequence o f a 
pathological state.
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Although little information exists at present on the function of LRCH4 and OGFRLl, the other 
genes identified in this cluster indicate a protective role against deleterious proliferation. HCaRG 
has been identified as a suppressor of growth through GzM cell cycle arrest (Devlin et al, 2003). 
N oblp  is essential for proteasome assembly (Tone et al, 2002), and its suppression could be 
influential on the levels o f proteins that would otherwise be degraded by the 26S proteasome. Sp3 
transcriptionally regulates a wide variety of genes including the up-regulation of anti-prohferative 
genes such as p2 1 ciPi/wAFi (Koutsodontis et al, 2002). rCOUPy may negatively affect other 
receptors that influence proliferation such as PPARs (Qiu et al, 1996), hence its suppression would 
remove this negative control.
The response of rBACH and Mel to liver growth agent administration is in agreement with 
published data where administration of peroxisome proliferators induced their expression (Yamada 
et al, 1997a; Castelein et al, 1994). rBACH and Mel are both involved in Hpid homeostasis, and this 
response to liver growth agents may represent a direct response to the effect of the compounds on 
nuclear receptors such as PPARa, or due to the increased metabolic demand from proliferative 
cells.
Further investigation of the effect of liver growth agent administration on the transcriptional 
activation of all these genes is necessary to prove co-ordination in their regulation, and whether the 
expression changes observed are a cause or an effect o f chemically-induced growth. In the 
following chapters these changes will be confirmed (Chapter 4) and the molecular mechanisms 
underlying such a co-ordinated response examined (Chapter 5).
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4 V a l id a t io n  a n d  c h a r a c t e r iz a t io n  o f
GENE EXPRESSION BY IN  VIVO AND IN  VITRO 
LIVER GROWTH AGENT ADMINISTRATION
4.1 I n t r o d u c t i o n
Validation of the microarray analysis in the preliminary study was required in order to confirm that 
the genes selected in Chapter 3 were suitable for further investigation, as microarray analysis is not 
considered fully quantitative. Two approaches were followed to confirm the changes observed in 
gene expression: First, real-time PCR was used to quantify the changes in gene transcript level in 
response to administration of liver growth agents with a dosing scheme similar to that used in the 
preliminary experiment. Samples were analysed from rat liver, primary rat hepatocytes and from the 
immortalised rat hepatoma FaO cell line. Second, assessment of promoter activity in response to in 
vitro dosing with liver growth agents was undertaken. The upstream promoter sequences from each 
gene of interest were cloned wherever possible into a reporter plasmid upstream of the secretable 
alkaline phosphatase gene (SEAP). The reporter gene assay allows confirmation o f the preliminary 
study data, and is also used in the dissection o f gene promoters, as will be demonstrated in 
Chapter 5.
4.2 V a l i d a t i o n  o f  t h e  m i c r o a r r a y  a n a l y s i s  b y  Q u a n t i t a t i v e  
REAL-TIME PCR
Following analysis of the in vivo microarray data, it was necessary to validate the results from the 
preliminary study using a fully quantitative technique. The expression of the selected genes was 
assessed using quantitative real-time PCR following the method described in section 2.5.
A range of samples were tested including in vivo samples from rat liver (at 24, 48 and 72 hours post­
dose), samples from primary rat hepatocytes in culture (12 to 96 hours post-dose), and from 
cultured FaO cells (12 to 96 hours post-dose). For the samples produced from rat liver, all samples 
and subsequent cDNA synthesis were produced for a previous experiment by D r K. Swales at the 
University of Surrey. For the samples produced from primary rat hepatocytes, all steps from dosing 
through to cDNA synthesis were performed by D r K. Plant at the University o f Surrey. For the 
samples produced from FaO cells, all steps were performed by E. Anderson. FaO cells were dosed
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using the peroxisome proliferator clofibric acid (CFA) instead o f Wy-14,643 due to a lack of 
commercial availability at the time. The dose was chosen based on published in vitro work using 
peroxisome proliferators (Meredith et al, 2003). All analysis using real-time PCR was performed by 
E. Anderson.
In each case, samples were produced with and without Reverse Transcriptase (RT) enzyme in order 
to determine genomic DNA contamination. All RT negative controls were free o f this 
contamination (data not shown), hence all results represented amplification from RNA templates 
only. The results for each gene are shown in the following sections, with any significant changes in 
expression highlighted. All results are normalised to the levels of 18S rRNA in the sample, and 
expressed as fold-change against control (DMSO) values. 18S rRNA was used for normalisation as 
substantial variation had been noted following normalisation to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) levels (data not shown) as has been observed by others (Goidin et al, 
2001, Bas et al, 2004). Due to the abundance of 18S rRNA aU samples required prior dilution with 
nuclease-free water (1 in 1000). For all points the standard error of the mean (SEM) was calculated 
across repeat samples and was less than 10% in each case.
4.2.1 Ge n e s  su ppr essed  in  r e sp o n se  t o  liv er  grow th  a g e n t
ADMINISTRATION
Analysis of the results of the microarray experiment identified a group o f seven fragments showing 
a reduction in expression in response to administration of liver growth agents. O f these seven 
fragments, six could be positively identified, and hence their expression validated using quantitative 
real-time PCR. It should be noted that analysis of the FaO cell Hne and the primary hepatocytes was 
not undertaken for the expression of all six genes due the identification o f some o f the microarray 
fragments after these analyses had been carried out.
Figure 4.1 shows the expression profiles for HCaRG transcript levels analysed by microarray and 
quantitative real-time PCR. The microarray analysis showed an initial increase in gene expression 
followed by a rapid decrease in expression between 12 and 48 hours post initial dose, reaching a 
maximal change at 48 hours. The response to all three compounds was very similar in profile, with 
dexamethasone resulting in the largest decrease to 10-percent o f control. The results o f the real­
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time PCR analysis o f rat Ever (Figure 4.1) show a greatly decreased response to aE three compounds 
compared to the microarray analysis, however the expression profile was maintained, with maximal 
decrease in expression occurring at 48 hours post iiEtial dose. This was true o f the response of 
cultured primary hepatocytes (Figure 4.1) and o f cultured FaO ceUs (Figure 4.1) as measured by 
quantitative real-time PCR. For each sample type the response was greatly reduced compared to the 
microarray analysis, which could be due to the increased specificity and dynamic range afforded by 
real-time quantitative PCR, or due to differences in the probe designs between the analyses. Despite 
this, vaEdation of the decreased expression o f HCaRG was achieved for each compound tested in 
at least one sample type, verifying the inhibition of expression shown in the microarray analysis.
The expression profiles generated for N oblp  by microarray analysis (Figure 4.2) show an initial 
increase in gene expression between 6 and 12 hours post dose, simEar to that observed with 
HCaRG (Figure 4.1). N oblp  expression then decreased graduaUy reaching the peak o f inhibition of 
expression at 72 hours post dose (13-percent of control foEowing CPA administration). This 
inhibition of expression was confirmed by quantitative real-time PCR analysis o f Ever from 
xenobiotic-exposed rats, with dosing regimes as used previously in the microarray experiment 
(Figure 4.2); however, a decreased fold change (2-fold decrease versus control) at 48 hours post 
dose was observed with this analysis. The real-time PCR analysis o f primary hepatocytes also 
confirmed the inhibition of gene expression observed in the microarray analysis, however the 
profEes differed in the time point o f maximal inhibition. Dexamethasone (100 pM) caused N oblp  
expression to decrease to 80-percent of control at 24 hours post dose, Wy-14,643 (100 pM) to 85- 
percent o f control at 48 hours post dose, and CPA (100 pM) to 70-percent of control by 96 hours 
post dose. However the resiEts from the cultured primary hepatocytes reflected different conditions 
and different dosing to the in vivo experiments, with removal of the influence o f non-parenchymal 
ceUs potentiaUy influencing the degree of change of gene expression. Also, since N ob lp  and the 
other genes suppressed by Ever growth agent administration are nuclear proteins, it may be that 
smaU changes in expression level could have drastic effects on the ceUular response.
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Figure 4.1: Expression of HCaRG in response to administration of liver growth agents
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In vivo gene expression of HCaRG as generated by microarray analysis and by quantitative real-time 
PCR analysis of rat liver (n=5) when dosed with liver growth agents (section 2.2.1), and in vitro 
expression of HCaRG in primary hepatocytes (n=5) and FaO cells (n=3) dosed with liver growth 
agents and generated by quantitative real-time PCR analysis. Variation in repeat measurements was 
less than 10-percent in each case. *=p<0.05, **=p<0.01, ***=p<0.001 relative to vehicle control 
using one-way ANOVA with Bonferroni’s multiple comparison post hoc test.
The expression profiles for rCOUPg in response to xenobiotics are shown in Figure 4.3. Microarray 
analysis demonstrates a similar response by rCOUPg to all three compounds, with the response in 
the initial 12 hours post dose also being similar as for HCaRG and N oblp  (Figure 4.3). The 
expression then decreases rapidly to around 50-percent of control by 24 hours, and remains 
inhibited for the following 72 hours. The quantitative real-time PCR analysis of rat Uver confirms 
this inhibition, with rCOUPg expression decreasing to 60-percent of control at 48 hours post initial
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dose. The results showed high similarity between the expression profiles for the three compounds 
tested. The quantitative real-time PCR analysis of cultured FaO cells also confirms the inhibition of 
rCOUPg expression (Figure 4.3), showing high similarity to the microarray results, with a 
prolonged decrease in gene expression from 24 to 96 hours post initial dose. The extent of this 
decrease varied from 40-percent of control in response to dexamethasone (100 pM) to 65-percent 
of control in response to CFA (50 pM) at 24 hours post initial dose.
Figure 4.2: Expression of N oblp in response to administration of liver growth agents
Liver - microarray Liver - quantitative real-time PCR
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h  vivo gene expression of N oblp as generated by microarray analysis and by quantitative real-time 
PCR analysis of rat liver (n=5) when dosed with liver growth agents (section 2.2.1), and in vitro 
expression of N oblp in primary hepatocytes (n=5) and FaO cells (n=3) dosed with hver growth 
agents and generated by quantitative real-time PCR analysis. Variation in repeat measurements was 
less than 10-percent in each case. *=p<0.05, **=p<0.01, ***=p<0.001 relative to vehicle control 
using one-way ANOVA with Bonferroni’s multiple comparison post hoc test.
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Figure 4.3: Expression of rCOUPg in response to administration of liver growth agents
Liver - rracroarray Liver - quantitative real-time PCR
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In vivo gene expression of rCOUPg as generated by microarray analysis and by quantitative real-time 
PCR analysis of rat liver (n=5) when dosed with Uver growth agents (section 2.2.1), and in vitro 
expression of rCOUPg in FaO ceUs (n=3) dosed with Uver growth agents and generated by 
quantitative real-time PCR analysis. Variation in repeat measurements was less than 10-percent in 
each case. *=p<0.05, **=p<0.01, ***=p<0.001 relative to vehicle control using one-way ANOVA 
with Bonferroni’s multiple comparison post hoc test.
The microarray analysis of Sp3 expression in response to Uver growth agent administration (Figure 
4.4) showed high similarity to the results for N oblp (Figure 4.2). Sp3 expression increased initiaUy 
between 6 and 12 hours post initial dose, and then decreased graduaUy to 48 hours. This expression 
then decreased rapidly in the next 24 hours, with a maximal inhibition of gene expression (10- 
percent of control) in response to CPA (60 mg/kg/day) occurring at 72 hours post initial dose. The 
quantitative real-time PCR analysis of primary hepatocytes in culture (Figure 4.4) confirmed the
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inhibition of Sp3 expression observed in the microarray experiment. The response to CPA (100 
pM) and dexamethasone (100 pM) showed a decrease in expression o f Sp3 to 85-percent of control 
at 24 hours post dose, decreasing to 70-percent of control in response to CPA (100 pM) at 48 
hours post dose. The response to CPA by the primary hepatocytes reflects the microarray generated 
expression profile for this compound, with CPA causing the greatest extent of inhibition of Sp3 
expression in both experiments.
Figure 4.5 shows the expression profiles for LRCH4. The microarray analysis of LRCH4 expression 
shows high similarity to that o f rCOUPg (Figure 4.3), with an initial increase in gene expression at 
12 hours, followed by a rapid decrease to 24 hours post initial dose in response to all three 
compounds, with maximum inhibition to 30-percent of control at this time-point in response to 
CPA (60 mg/kg/day). The inhibition LRCH4 expression was then maintained to 96 hours post 
initial dose in response to each of the compounds, with dexamethasone (100 mg/kg/day) causing a 
maximal decrease to 16-percent at 72 hours post initial dose. The quantitative real-time PCR 
analysis o f LRCH4 expression (Figure 4.5) confirmed the microarray profiles, showing a consistent 
inhibition of LRCH4 expression across the time-points analysed, reaching a maximal decrease to 
approximately 55-percent of control for aU three compounds at 96 hours post initial dose.
The microarray analysis o f the expression o f OGFRLl (Figure 4.6) shows similar results to the 
other genes, particularly for rCOUPg (Figure 4.3) and LRCH4 (Figure 4.5) with OGFRLl 
expression increasing initially and then rapidly decreasing between 12 and 24 hours post initial dose. 
The profiles were similar across the three compounds tested, with a consistent decrease in 
OGFRLl expression between 24 and 96 hours, with maximal decrease to 21-percent o f control at 
72 hours post initial dose in response to CPA (60 mg/kg/day). The expression of OGFLRl was 
not validated by quantitative real-time PCR as the gene was identified late on in the project and 
attempts to clone the promoter were unsuccessful due to the high GC content of the sequence and 
hence an inability to produce a clean PCR amplification o f the promoter.
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Figure 4.7 shows tlie microarray results for the gene fragment AI044183. It was not possible to 
identify the gene associated with fragment AI044183 (which was derived from an EST) during the 
period of the project and hence validation could not be undertaken. The results show an initial 
increase in expression between 6 and 12 hours, with a gradual decrease in expression in response to 
dexamethasone (100 mg/kg/day) and CPA (60 mg/kg/day) to 72 hours post initial dose (causing 
maximal inhibition of 5-percent of control). The expression profile in response to WY-14,643 (50 
mg/kg/day) only differed from the other two compounds at 24 hours post initial dose where it 
caused inhibition of expression of the gene associated with AI044183 to 8-percent of control.
Figure 4.4: Expression of Sp3 in response to administration of liver growth agents
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In vivo gene expression of Sp3 as generated by microarray analysis and in vitro expression o f Sp3 in 
FaO cells (n=3) dosed with hver growth agents and generated by quantitative real-time PCR 
analysis. Variation in repeat measurements was less than 10-percent in each case. *=p<0.05, 
**=p<0.01, ***=p<0.001 relative to vehicle control using one-way ANOVA with Bonferroni’s 
multiple comparison post hoc test.
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Figure 4.5: Expression of LRCH4 in response to administration of liver growth agents
Liver - microarray Primary hepatocytes - quantitative real-time PCR
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In vivo gene expression of LRCH4 as generated by microarray analysis and in vitro expression of 
LRCH4 in FaO cells (n=3) dosed with liver growth agents and generated by quantitative real-time 
PCR analysis. Variation in repeat measurements was less than 10-percent in each case. *=p<0.05, 
**=p<0.01, ***=p<0.001 relative to vehicle control using one-way ANOVA with Bonferroni’s 
multiple comparison post hoc test.
Figure 4.6: Expression of OGFRLl and AI044183 in response to administration of liver 
growth agents
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In vivo gene expression of OGFRLl (A) and AI044183 (B) as generated by microarray analysis 
when dosed with liver growth agents (section 2.2.1). Variation in repeat measurements was less than 
10-percent in each case.
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4.2.2 Ge n e s  in d u c e d  in  r e sp o n se  t o  liv er  grow th  a g e n t  a d m in ist r a t io n
The preliminary study identified Mel and rBACH as showing potential co-ordinate regulation, with 
the expression of these genes increasing in response to liver growth agent administration. Figure 4.7 
shows the expression profiles for Mel from the microarray analysis and from the quantitative real­
time PCR analysis o f both in vivo Hver samples and samples from FaO cells. The results o f the 
microarray analysis (Figure 4.7) show a pronounced effect of Wy-14,643 administration at 12 hours 
post initial dose that decreases rapidly, before steadily increasing between 48 and 72 hours with 
maximal expression (15-fold over control) at 72 hours. Administration of CPA resulted in a similar 
pattern of expression with a maximum 9-fold increase over control at 72 hours post initial dose. 
Dexamethasone administration gave similar results but with a greatly reduced fold change over 
control (4-fold maximum at 72 hours post initial dose).
Figure 4.7 also shows the results of the quantitative real-time PCR analysis of rat Hver dosed as in 
the initial microarray experiment. The expression of Mel shows similar pattern of change but at a 
reduced level compared to the microarray analysis. Administration of Wy-14,643 produced a 
gradual increase in expression over control between 24 and 72 hours reaching 5-fold at 72 hours 
post initial dose. However, this may not represent the maximum response since only three time- 
points were taken for analysis during this experiment: It is possible that a longer exposure time (96 
hours) would have seen a greater response. CPA and dexamethasone produced similar results at 24 
and 48 hours post-dose, however the expression never increased above two-fold for the time- 
points measured. Once again, it is possible that a larger response occurring at a later time point that 
was not measured during the in vivo real-time quantitative PCR experiment.
Examination of the response to xenobiotics in cultured FaO ceUs showed gready reduced fold- 
changes in the expression of Mel over control treated ceUs (Figure 4.7). The administration of the 
peroxisome proHferator CFA resulted in a 1.5-fold change in expression at 72 hours. However the 
response of the cultured ceUs was consistendy reduced across aU the genes analysed, indicating that 
the ceUs were not sufficiendy similar to in vivo hepatocytes to aUow measurement o f the effects of 
such compounds. Although the FaO ceU Hne is generaUy regarded to be the most accurate rat 
hepatocyte model, loss/reduction o f genomic activation in response to xenobiotics is a common
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phenomenon for many hepatocyte cell lines, usually as a result of the reduced expression of 
important transcription factors. Indeed, the response of FaO cells to peroxisome proliferators such 
as nafenopin has previously been shown to be reduced when compared to the effect in vivo (Bayly et 
(zX, 1993).
Figure 4.8 shows the expression profiles for rBACH in response to liver growth agents. The 
microarray analysis revealed similar results to the profiles for M el, with a maximal 17-fold increase 
in expression over control in response to Wy-14,643. The profiles for both CPA and 
dexamethasone are again reduced compared to the effect of Wy-14,643, increasing to 6-fold and 8- 
fold respectively at 96 hours post initial dose. The quantitative real-time PCR analysis o f rat liver 
(Figure 4.8) is similar in profile to the microarray data for Wy-14,643 administration, but with a 
diminished response (maximal 6-fold at 72 hours post-dose). This response is similar to that 
observed for M el, indicating that it is either a difference between analysis by microarray and by 
real-time PCR, or that there was some RNA degradation during storage of the samples used in the 
real-time PCR experiment, which could cause a narrowing in the difference between control and 
treated tissue. The results for the FaO cell line (Figure 4.8) show a 2.2-fold change in rBACH 
expression over control following administration of CFA at 72 hours post initial dose. 
Dexamethasone and CPA produced no significant increases in expression o f rBACH in the period 
48 to 96 hour post-dose.
Taken together, the results confirm a similarity between these two genes, although the similarity 
across the three compounds has not been confirmed. The relationship between rBACH and Mel 
could therefore be specific to Wy-14,643 and CFA, and hence to peroxisome proliferators in 
general.
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Figure 4.7: Expression of Mel in response to administration of liver growth agents
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PÎPO gene expression of Mel as generated by microarray analysis and by quantitative real-time 
PCR analysis of rat liver (n=5) when dosed with liver growth agents (section 2.2.1), and in pitro 
expression of HCaRG in FaO cells (n=3) dosed with liver growth agents and generated by 
quantitative real-time PCR analysis. Variation in repeat measurements was less than 10-percent in 
each case. *=p<0.05, **=p<0.01, ***=p<0.001 relative to vehicle control using one-way ANOVA 
with Bonferroni’s multiple comparison post hoc test.
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Figure 4.8: Expression of rBACH in response to administration of liver growth agents
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In vivo gene expression of rBACH as generated by microarray analysis and by quantitative real-time 
PCR analysis of rat liver (n=5) when dosed with liver growth agents (section 2.2.1), and in vitro 
expression of HCaRG in FaO cells (n=3) dosed with liver growth agents and generated by 
quantitative real-time PCR analysis. Variation in repeat measurements was less than 10-percent in 
each case. *=p<0.05, **=^p<0.01, ***=p<0.001 relative to vehicle control using one-way ANOVA 
with Bonferroni’s multiple comparison post hoc test.
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4.3 Re p o r t e r  c o n st r u c t  analysis o f  g e n e  pr o m o t e r  ac tiv ity
An alternate strategy to validate the microarray results was the cloning of the upstream promoter 
sequences for the genes of interest. Examination of the response of these regulatory sequences to 
the test chemicals allows a direct measure o f the effect o f each xenobiotic on the transcriptional 
activity of the gene, further confirming the changes seen in the initial microarray analysis. For each 
gene, the region immediately adjacent to the transcriptional start site was identified and the 
approximately 1 kilobase o f sequence amplified by PCR. The resulting approximate 1 kilobase of 
regulatory region was cloned into a reporter vector upstream of the SEAP gene. Transfection into 
the FaO ceU line aUowed quantitation of the control exerted by the cloned regulatory region, 
through the production of a secretable alkaline phosphatase into the growth medium for easy assay 
using a chemiluminescent method.
4.3.1 Cl o n in g  o f  1 kilobase  upstream  g e n e  pro m o ters
The foUowing section describes the details of the cloning of each promoter and the results of the 
subsequent transfections. Although attempts were made to clone aU of the genes o f interest, I was 
not able to clone the proximal regulatory regions for rCOUPg, OGFRLl and Mel within the time 
constraints of the project. This is most likely due to the high GC content o f these regulatory 
regions, a consequence of the CpG islands often associated with gene regulatory regions. Successful 
cloning o f promoter sequences into pCR®2.1 or pCR®-Blunt (Invitrogen) and subsequently into 
pSEAP was achieved for rBACH, HCaRG, N oblp, Sp3 and LRCH4.
Since rBACH and Mel showed a response specific to both Wy-14,643 and CFA (Figures 4.7 and 
4.8), only the group of genes suppressed in response to Uver growth agents were investigated 
beyond their basal promoter activity.
4.3.1.1 Identification of gene promoters
4.3.1.1.1 HCaRG
The fragment accession number for HCaRG (AA899199) used on the microarray refers to a 543 bp 
sequence. This sequence was used to interrogate the blastn database at NCBI using the BLAST 
aUgnment tool, and aUgned to the 1100 bp RefSeq mRNA (NM_139108). This mRNA sequence
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was then used to interrogate the rat genome, producing a single hit with the chromosome 8 contig 
(accession number NW_047780). The gene was found to run parallel with the contig, with the 
initial kilobase of proximal promoter sequence located at positions 9551251 to 9552200 on the
contig. PCR primers were designed encompassing this region and part of the first exon to ensure 
that all potential regulatory elements around the transcription start site were included (Figure 4.9).
Figure 4.9: Chromosomal contig references for the cloned region of the HCaRG promoter
9551251
1 exon 1 i exon 2
955:2200 9552273
9552257
Region cloned
N W _047780 
(chrom osom e 8  contig)
Chromosomal mapping of the rat HCaRG mRNA (NM_139108) to the rat genomic contig 
NW_047780 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
4.3.1.1.2 N oblp
The fragment accession number for N oblp  (AA956531) from the microarray was used to 
interrogate the BLAST tool against the blastn database at NCBI, and aligned to the 1547 bp RefSeq 
mRNA (NM_199086). The mRNA sequence was searched against the rat genome and produced a 
single hit with the chromosome 19 contig (accession number NW_047535). The gene was found to 
run opposite with the contig, and hence the 1 kilobase upstream promoter was located at positions 
8856871 to 8857932 on the contig. PCR primers were designed encompassing this region and part 
of the first exon (Figure 4.10).
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Figure 4.10: Chromosomal contig references for the cloned region of the Noblp promoter
exon 2 exon 1
8856800
8856745
8856871
Region cloned
8857932
N W _ 0 4 7 5 3 5  
(ch rom osom e 19 contig)
Chromosomal mapping of the rat N oblp mRNA (NM_199086) to the rat genomic contig 
NW_047535 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
4.3.1.1.3 LRCH4
The fragment accession number for LRCH4 (AI045165) was searched using the BLAST tool 
against the blastn database at NCBI, and aligned to the 2581 bp mRNA (XM_001068283). The 
mRNA sequence was searched against the rat genome and produced a single hit with the 
chromosome 12 contig (accession number NW_047369). The gene was found to run parallel with 
the contig, and hence the 1 küobase upstream promoter was located at positions 7675201 to 
7676187 on the contig. PGR primers were designed encompassing this region and part of the first 
exon (Figure 4.11).
Figure 4.11: Chromosomal contig references for the cloned region of the LRCH4 promoter
exon 1 exon 2
767E5187 7676489
7675201 7676339
- y —
Region cloned
N W _047369  
(chrom osom e 12 contig)
Chromosomal mapping of the rat LRCH4 mRNA (XM_001068283) to the rat genomic contig 
NW_047369 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
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4.3.1.1.4 Sp3
The fragment accession number for Sp3 (AI008907) was searched using the BLAST tool against 
the blastn database at NCBI, and aligned to the 2661 bp mRNA (NM_001029905). The mRNA 
sequence was searched against the rat genome and produced multiple hits, the most identical falling 
within a chromosome 3 contig (accession number NW_047656). The gene was found to run 
opposite to the contig, and hence the 1 kilobase upstream promoter was located at positions 
1871491 to 1872479 on the contig. PCR primers were designed encompassing this region and part 
of the first exon (Figure 4.12).
Figure 4.12: Chromosomal contig references for the cloned region of the Sp3 promoter
exon exon 1
1870962 1871491
1871430 1872479
Region cloned N W _ 0 4 7 6 5 6  
(c h ro m o s o m e  3  con tig )
Chromosomal mapping of the rat Sp3 mRNA (NM_001029905) to the rat genomic contig 
NW_047656 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
4.3.1.1.5 rCOUPg
The fragment accession number for rCOUPg (AA009019) was searched using the BLAST tool 
against the blastn database at NCBI, and aligned to the 1775 bp mRNA (NM_139113). The mRNA 
sequence was searched against the rat genome and produced a single hit with the chromosome 16 
contig (accession number NW_047470). The gene was found to run opposite to the contig, and 
hence the 1 kilobase upstream promoter was located at positions 881259 to 882253 on the contig. 
PCR primers were designed encompassing this region and part of the first exon (Figure 4.13).
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Figure 4.13: Chromosomal contig references for the cloned region of the rCOUPg promoter
j  exon 2 | exon 1
880765 881259
881222 882253
Region for cloning N W _ 0 4 7 4 7 0  
(c h ro m o s o m e  16 contig)
Chromosomal mapping of the rat rCOUPg mRNA (NM_139113) to the rat genomic contig 
NW_047470 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
4.3.1.1.6 OGFRLl
The fragment accession number for OGFRLl (AI045104) was searched using the BLAST tool 
against the blastn database at NCBI, and aligned to the 1728 bp mRNA (NM_001025708). The 
mRNA sequence was searched against the rat genome and produced a single hit with the 
chromosome 9 contig (accession number NW_047813). The gene was found to run opposite to the 
contig, and hence the 1 kilobase upstream promoter was located at positions 22247453 to 22248425 
on the contig. PCR primers were designed encompassing this region and part of the first exon 
(Figure 4.14).
Figure 4.14: Chromosomal contig references for the cloned region of the OGFRLl promoter
exon 2 exon 1
22247094 22247453
22247332 22248425
Region for cloning N W _ 0 4 7 8 1 3  
(c h ro m o s o m e  9  con tig )
Chromosomal mapping of the rat OGFRLl mRNA (NM_001025708) to the rat genomic contig 
NW_047813 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
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4.3.1.17 rBACH
The fragment accession number for rBACH (D88890) was searched using the BLAST tool against 
the blasm database at NCBI, and aligned completely to the 1523 bp mRNA (NM_013214). The 
mRNA sequence was searched against the rat genome and produced three hits. From these three 
hits, one was identified as an active gene, aligning to the chromosome 5 contig (accession number 
NW_047727). The other two hits were confirmed as inactive pseudo-genes by searching against the 
EST_others database at NCBI, whereby no alignments were found. The gene was found to run 
parallel with the contig, and hence the 1 küobase upstream promoter was located at positions 
9228940 to 9229834 on the contig. PCR primers were designed encompassing this region and part 
of the first exon (Figure 4.15).
Figure 4.15: Chromosomal contig references for the cloned region of the rBACH promoter
exon 1 exon 2
922Î1834 9229^79
9228940 9230007
Y
Region cloned
NVV_047727 
(c h ro m o s o m e  5  con tig )
Chromosomal mapping of the rat rBACH mRNA (NM_013214) to the rat genomic contig 
NW_047727 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
4.3.11.8 M el
The fragment accession number for Mel (AI171506) was searched using the BLAST tool against 
the blastn database at NCBI, and aligned to exon 14 of the 1761 bp mRNA (NM_012600). The 
mRNA sequence was searched against the rat genome and produced a single hit with the 
chromosome 8 contig (accession number NW_044800). The gene was found to run opposite with 
relation to the contig, and hence the 1 küobase upstream promoter was located at positions 
8233072 to 8234080 on the contig. PCR primers were designed encompassing this region and part 
of the first exon (Figure 4.16).
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Figure 4.16: Chromosomal contig references for the cloned region of the M el promoter
exon 2 exon 1
8232994 8233072
8232994
Region for cloning
8234080
N W _ 047800  
(c h ro m o s o m e  8  contig)
Chromosomal mapping of the rat N oblp mRNA (NM_012600) to the rat genomic contig 
NW_044800 showing the position of exon 1, the promoter region cloned and the genomic 
references for the region (blue).
4.3.1.2 Cloning of promoters into vector
Following PCR amplification of the proximal promoters of the genes of interest, the products were 
cleaned by gel extraction (section 2.3.6.1), and cloned into an initial vector pCR®2.1 (Invitrogen) 
that allowed blue/white screening of colonies. Following confirmation of the presence of the 
correct insert by diagnostic digest and direct sequencing (section 2.3.6.S) the inserts were cloned 
into the expression vector pSEAP. Figures 4.17 to 4.21 show the diagnostic digests for each o f the 
promoter constructs that was cloned. Digests were designed to cut at one point within the cloned 
region using a specific restriction enzyme cutting site, with the other site falling outside the cloned 
region, allowing confirmation of both the identity of the cloned region and its orientation. In each 
case the appropriate sized fragments have been produced as compared to either a 10 kb or a 100 bp 
step ladder. Therefore from the nine genes that had been selected for further investigation, four of 
the genes whose expression was suppressed and one of the genes whose expression was induced in 
response to liver growth agent administration were successfully cloned into pSEAP. These were 
rBACH (induced) and HCaRG, Noblp, LRCH4 and Sp3 (suppressed).
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Figure 4.17: Diagnostic digests of pHCaRG-SEAP using Bgl I I 20ià N ot I
1.5 kb
500 bp
Diagnostic digest of pHCaRG-SEAP using two separate enzymes for confirmation of cloned 
region. Lane 1 contains the construct digested with Bgl II producing two bands of size 805 bp and 
4940 bp. Lane 2 contains the construct digested with Not I  producing two bands of size 1261 bp 
and 4484 bp.
Figure 4.18: Diagnostic digests of pNoblp-SEAP using B g ll l  and N o t I
3 kb 
2 kb
1 kb
? 1.5 kb 
1 kb
500 bp
Diagnostic digest of pNoblp-SEAP using two separate enzymes for confirmation o f cloned region. 
Lane 1 contains the construct digested with Bg/ II producing two bands of size 739 bp and 5087 bp. 
Lane 2 contains the construct digested with Not I  producing two bands of size 1342 bp and 4484 
bp.
I l l
Figure 4.19: Diagnostic digests of pSp3-SEAP using Spe /  and N ot I
3 kb 
2 kb
1 kb
1.5 kb 
1 kb
500 bp
Diagnostic digest of pSp3-SEAP using two separate enzymes for confirmation o f cloned region. 
Lane 1 contains the construct digested with Spe I  producing two bands of size 703 bp and 5085 bp. 
Lane 2 contains the construct digested with Not I  producing two bands of size 1304 bp and 4484 
bp.
Figure 4.20: Diagnostic digests of pLRCH4-SEAP using Spe /  and N o t I
1.5 kb
500 bp
3 kb 
2 kb
1 kb
Diagnostic digest of pSp3-SEAP using two separate enzymes for confirmation o f cloned region. 
Lane 1 contains the construct digested with Spe I  producing two bands of size 933 bp and 4842 bp. 
Lane 2 contains the construct digested with Not I  producing two bands of size 1291 bp and 4484 
bp.
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Figure 4.21: Diagnostic digests of pRBACH-SEAP using Pst I
3 kb 
2 kb 
1 kb
Diagnostic digest of pRBACH-SEAP using the enzyme Pst I  for confirmation of cloned region 
(lane 1) producing two bands of size 870 bp and 4665 bp.
4.3.2 Basal e x pr essio n  of 1 kilobase  r epo r t er  g e n e  c o n str u c ts
Figure 4.22 shows the levels of basal expression of SEAP following transfection o f each of the 
promoter constructs generated. O f the four promoter constructs generated from the suppressed 
group of genes, only the HCaRG and N oblp  promoters caused significant SEAP expression over 
control (pSEAP). Sp3 and LRCH4 promoter constructs failed to show significant basal activity, 
hence it would be impossible to investigate inhibition of SEAP expression using these constructs. It 
is possible that the key regulatory element(s) for these genes are not contained within the proximal 
1 kb of promoter sequence, but further upstream, or that an enhancer sequence not present in the 
reporter constructs, is required for maximal expression of Sp3 and LRCH4. Hence only HCaRG 
and N oblp  were investigated further, with the hypothesis that they would form a model for the rest 
of the group of seven co-regulated genes. rBACH proved to be a strong promoter inducing SEAP 
expression at a higher level than the SV40 promoter, however the suppression of gene expression 
observed for the group of seven genes represented a more interesting group to investigate further 
due to the similarity across aU three compounds tested. Therefore the potential co-ordinate 
regulation of rBACH and Mel was not investigated further.
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Figure 4.22: Basal expression of SEAP under control of cloned gene promoters of interest
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Basal levels of SEAP activity in growth medium were measured 48 hours post-transfection into 
FaO cells for each promoter construct. ***=p<0.001, ns = not significant relative to control 
(empty pSEAP vector) using one-way ANOVA with Bonferroni’s multiple comparison post hoc 
test. pSEAP under the control of the SV40 promoter was included as a positive control. Basal level 
for rBACH promoter construct is included but was not investigated further (see section 4.2.2).
4.3.3 E ffec t  of liver  grow th  a g e n t s  o n  r epo r t e r  g e n e  c o n str u c t s
Following assessment of the basal activity of the gene promoters it was necessary to investigate the 
effect of liver growth agent administration on FaO cells transfected with the 1 kb promoter 
constructs. Due to the low basal activity of the Sp3 and LRCH4 promoter constructs it was 
impossible to investigate the inhibitory effects of liver growth agents on these genes. Hence only 
the constructs containing the promoters of HCaRG and N oblp  were investigated further.
4.3.3.1 Assessment of compound toxicity by the lactate dehydrogenase release
assay
To confirm that any inhibition of gene expression observed was not due to cellular toxicity, FaO 
cells were first dosed with Hver growth agents according to the dosing scheme for the reporter gene 
assay and assayed for LDH release, to examine for toxicity.
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Figure 4.23 shows the results o f the LDH assay. In untreated cells a small degree o f cell death is 
seen over the culture time, with the percentage of LDH release increasing from 9-percent at 24 
hours to 13-percent at 96 hours post initial dose. The DMSO (vehicle) control shows no significant 
effect on LDH release compared to untreated cells across all the time-points measured, 
demonstrating that it has no effect on cell viability.
AU the drugs caused only minor, if any ceU death, with the maximal effect being a 4-percent 
increase in the level of LDH release in response to CPA (100 pM) at 48 hours post initial dose. The 
peroxisome proliferators CFA and Wy-14,643 showed a protective effect by causing a smaU but 
significant decrease in LDH release at 48 and 72 hours post initial dose (CFA) and 96 hours post 
initial dose (Wy-14,643). No increase in LDH release was observed for any of the compounds at 24 
hours post initial dose. At this time-point a measurable decrease in the expression o f the genes of 
interest had occurred as shown by microarray and quantitative real-time PCR, indicating that the 
decreases observed for these genes were not due to xenobiotic toxicity.
The physiological relevance of these doses is difficult to determine due to the differences between 
in vivo and in vitro test systems. A quaUtative similarity has been noted between primary cultures of 
rat hepatocytes and in vivo liver (de LongueviUe et al, 2003, Jessen et al, 2003). In a microarray 
experiment to assess gene expression between the two systems, the response o f primary 
hepatocytes dosed with Wy-14,643 (500 pM) was 80-percent of in vivo liver dosed at 100 m g/kg 
(Jessen et al, 2003). At this dose, Wy-14,643 is known to cause hepatocardnogenesis in rodents in 
long-term studies (Motoki etal, 1997).
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Figure 4.23: Effect o f exposure of test compounds on cultured FaO cell viability by 
LDH assay
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Toxicity of all the compounds used in transfection assays was assessed by assay of LDH release. 
Cells were incubated with compound in growth medium at the maximum dose used in transfection 
assays for the appropriate time. Medium was removed for assay and fresh medium containing 
control or compound replaced. Values expressed are percentage of total LDH release as induced by 
incubation of cells with 2% Triton X-100 in growth medium for 10 minutes. *=p<0.05, 
***=p<0.001 relative to vehicle control (DMSO) at each time-point using one-way ANOVA with 
Bonferroni’s multiple comparison post hoc test.
4.3.3.2 Dose response analysis
Following transfection with the promoter constructs to confirm basal activity for the gene 
promoter sequences, the constructs were transfected into FaO cells and exposed to drug or control 
for 48 hours prior to assessment of SEAP expression. In this way it was possible to determine the 
effect of the compounds on the 1 kb proximal promoter sequences and their effect on gene 
expression, as inferred from their ability to drive expression of SEAP. The 48 hour time-point was 
chosen since all the genes suppressed in response to liver growth agent exposure showed evidence 
of suppression by this time-point, particularly in the microarray results. Since the pHCaRG-SEAP 
and pNoblp-SEAP were the only constructs to show significant basal activity for assessment of
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inhibition, it was most important that this time-point would be relevant for them, as is the case for 
both genes following quantitative real-time PCR assessment of rat liver (Figures 4.1 and 4.2).
The compounds tested were the peroxisome proliferators CFA and Wy-14,643, CPA and 
dexamethasone as used in the previous experiments. A range of doses from 1 pM to 100 pM were 
selected to analyse the dose response of each construct, allowing assessment of the optimal dose 
for future experiments. In each case the vehicle control was DMSO, with results representing 
repeat samples (n=5) expressed as mean ± SEM. Dose response analysis allowed validation o f the 
response observed in the microarray data, with the ability to define the most appropriate dose and 
hence the maximal response by each promoter, which was not the case for the in vitro quantitative 
real-time PCR analysis.
Figure 4.24 shows the dose response results for the two constructs in response to dexamethasone. 
In both cases a highly significant response was observed, reaching a maximal 2.5-fold decrease in 
SEAP expression for HCaRG at 100 pM, and maximal 3.5-fold decrease for N oblp  at 100 pM. 
The HCaRG promoter (Figure 4.24a) caused consistent suppression of SEAP expression across the 
range of doses, indicating that the dose required for maximal suppression was potentially in the nM 
range. In comparison, the N oblp  promoter (Figure 4.24b) exhibited increasing inhibition o f SEAP 
expression with increasing dose, and the dose causing maximal suppression may have been in 
excess of 100 pM. Hence the HCaRG promoter appears to have reached the maximal suppression 
using a concentration o f  1 pM, whereas the maximal suppression o f N oblp  may be at a 
concentration higher than 100 pM. Therefore the HCaRG promoter may be more sensitive to the 
presence o f dexamethasone than the N oblp  promoter, but the N oblp  promoter is capable o f 
suppressing SEAP expression to a greater degree than the HCaRG promoter (3.5-fold decrease for 
N oblp  versus 2.5-fold for HCaRG). From the range of doses tested the dose of 100 pM was 
chosen for future experiments since this dose did not produce toxic effects in the FaO cells at 24 
and 48 hours post dose (Figure 4.23) and produced a significant degree of suppression by both 
promoter constructs.
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Figure 4.24: Dose response of HCaRG and Noblp promoter constructs to dexamethasone
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Promoter constructs for HCaRG (A) and N oblp (B) were transfected into FaO cells (n=5) and 
following a 24 hour incubation were dosed with compound at the appropriate dose or DMSO 
(control). Growth medium was removed following 48 hour incubation and assayed for SEAP using 
the chemiluminescent method described in section 2.4.5. ***=p<0.001 relative to vehicle control 
(DMSO) using one-way ANOVA with Bonferroni’s multiple comparison post hoc test.
Figure 4.25 shows the dose response curves for administration of CPA. The HCaRG promoter 
significantiy suppressed SEAP expression at 1 pM but failed to in response to 10 or 25 pM CPA 
(Figure 4.25a). However, at 50 pM CPA the expression of SEAP was suppressed to a similar extent
as the 1 pM dose, and at 100 pM it was reduced to 25-percent of control. Therefore, for HCaRG
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there is a biphasic response to CPA that could be due to the involvement of different nuclear 
receptors at low and high doses. An example is in the expression of glutathione T-trans feras se A2 
that is suppressed in response to low doses of dexamethasone in a GR-dependent manner, and 
induced by high doses via PXR activation producing a biphasic expression profile (Falkner et al, 
2001). For the N oblp  promoter all the doses resulted in significant suppression o f SEAP 
expression, however there was a notable increase in suppression at 10 pM that decreased at 25 pM, 
prior to increasing at 50 and 100 pM (Figure 4.25b). For both constructs 100 pM CPA produced 
the greatest degree of suppression of SEAP expression, with administration of this dose resulting in 
a ~5-fold decrease in the expression of SEAP for both promoter constructs. For pHCaRG-SEAP 
the difference in expression of SEAP between 50 and 100 pM CPA was ~2-fold versus 5.5-fold, 
and for pNoblp-SEAP this difference was ~3-fold versus 5-fold. This difference cannot be 
accounted for by the 17-percent increase in LDH release at 48 hours post dose with 100 pM CPA 
versus control treated cells (Figure 4.23), and hence it was decided to dose with 100 pM CPA in 
future experiments, despite the increase in LDH release observed at this dose.
Figure 4.26 shows the dose response results for administration of CFA. For both the HCaRG 
construct (Figure 4.26a) and the N oblp  construct (Figure 4.26b) there was a correlation between 
dose and suppression of SEAP expression. In both cases 100 pM CFA produced the greatest 
degree of suppression, reaching a 2-fold decrease for each construct. It is likely that this dose 
produced near to the maximal suppression since the results for 25 and 50 pM were very similar to 
that for 100 pM CFA. However, since there was no significant increase in LDH release in response 
to 100 pM CFA, and in fact a reduction in LDH release was observed at 48 and 72 hours post 
initial dose, this dose was used for future experiments.
Figure 4.27 shows the dose response results for administration of Wy-14,643. For the pHCaRG- 
SEAP construct a maximal suppression of SEAP expression of 2.6-fold versus DMSO control was 
observed using 50 pM Wy-14,643 (Figure 4.27a). For the Noblp-SEAP construct this compound 
produced the least suppression of SEAP expression compared to the other liver growth agents 
administered, reaching a maximal suppression of 1.7-fold at 100 pM Wy-14,643 (Figure 4.27b).
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Since Wy-14,643 (100 pM) caused the maximal effect on the N oblp promoter, and a statistically 
significant effect on the HCaRG promoter (~2-fold decrease versus DMSO control), but did not 
cause any detrimental effects on LDH release at any of the time-points assessed (Figure 4.23), this 
dose was used in future experiments.
Figure 4.25: Dose response of HCaRG and N oblp promoter constructs to CPA
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Promoter constmcts for HCaRG (A) and N oblp  (B) were transfected into FaO cells (n=5) and 
following a 24 hour incubation were dosed with compound at the appropriate dose or DMSO 
(control). Growth medium was removed following 48 hour incubation and assayed for SEAP using 
the chemiluminescent method described in section 2.4.5. ***=p<0.001 relative to vehicle control 
(DMSO) using one-way ANOVA with Bonferroni’s multiple comparison post hoc test.
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Figure 4.26: Dose response of HCaRG and Noblp promoter constructs to CFA
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Promoter constructs for HCaRG (A) and N oblp (B) were transfected into FaO cells (n=5) and 
following a 24 hour incubation were dosed with compound at the appropriate dose or DMSO 
(control). Growth medium was removed following 48 hour incubation and assayed for SEAP using 
the chemiluminescent method described in section 2.4.5. *=p<0.05, **=p<0.01, ***=p<0.001 
relative to vehicle control (DMSO) using one-way ANOVA with Bonferroni’s multiple comparison 
post hoc test.
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Figure 4.27: Dose response of HCaRG and Noblp promoter constructs to Wy-14,643
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Promoter constructs for HCaRG (A) and N oblp (B) were transfected into FaO cells (n=5) and 
following a 24 hour incubation were dosed with compound at the appropriate dose or DMSO 
(control). Growth medium was removed following 48 hour incubation and assayed for SEAP using 
the chemiluminescent method described in section 2.4.5. **=p<0.01, ***=p<0.001 relative to 
vehicle control (DMSO) using one-way ANOVA with Bonferroni’s multiple comparison post hoc 
test.
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4.3.3.3 Time response analysis at optimum dose
After the dose response experiments it was necessary to analyse the time response to administration 
of the compounds. The constructs were transfected into FaO cells and following 24 hours 
incubation were dosed with each compound at the appropriate dose. Medium was removed for 
assay every 24 hours for a 72 hour period, and fresh medium containing the compound was 
subsequently replaced and incubated for the next 24 hours.
Figure 4.28 shows the results of the time response experiment. The results for the HCaRG 
promoter construct (Figure 4.28a) show a significant suppression of SEAP expression (~2-fold 
versus DMSO control) across the entire 72 hour period measured, with similar results between the 
four liver growth agents tested. This was not attributable to drug toxicity since measurement of 
LDH release of cells under the same conditions showed no toxicity at 24 hours, and only a marginal 
effect at 48 hours post-dose (section 4.3.3.1).
Figure 4.28b shows the results for the N oblp  promoter construct. The effect of the compounds 
was less consistent than for HCaRG but produced the same magnitude of suppression, indicating 
that the two promoters may be under the same control in response to liver growth stimuli. The 
main differences between the two constructs were that at 24 hours post-dose Wy-14,643 (100 jiM) 
failed to significantly suppress SEAP expression and that at 72 hours dexamethasone (100 pM) 
produced a 20-percent decrease in SEAP expression compared to 50-percent for HCaRG at the 
same time point. However, the suppression of SEAP expression exhibited at 48 hours for both 
promoter constructs across all four compounds is similar to that from the real-time PCR analysis in 
rat liver (Figure 4.1b and 4.2b), and indicates that the promoters are potentially co-regulated in 
response to liver growth stimuli.
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Figure 4.28: Effect o f liver growth agents on HCaRG and N oblp promoter constructs with 
time
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Promoter constructs for HCaRG (A) and N oblp (B) were transfected into FaO cells and following 
24 hour incubation were dosed with either compound or DMSO (control). Growth medium was 
removed every subsequent 24 hours for a 72 hour period and assayed for SEAP using the 
chemiluminescent method described in section 2.4.5. *=p<0.05, **=p<0.01, ***=p<0.001 relative 
to vehicle control (DMSO) at each time-point using one-way ANOVA with Bonferroni’s multiple 
comparison post hoc test.
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4.4 D iscussion
The genes identified from the bioinformatic analysis as showing co-ordinate regulation by liver 
growth agents in Chapter 3 have been validated in this chapter. In addition, the response has been 
characterised using a range o f liver growth agents, exposure periods and doses, using both 
quantitative real-time PCR and reporter gene assay. For rBACH and Mel the response was found 
to be specific to the peroxisome proliferators Wy-14,643 and CFA. Although the two genes may 
represent an important part o f the response to peroxisome proliferator exposure, the changes in 
their expression do not represent a central event in the cellular response to varied liver growth 
stimuli, and hence were not investigated further herein.
For the genes originally identified as being suppressed in response to liver growth agent 
administration there was a high similarity in expression profile across aU seven genes. Despite the 
range of sample types and dosing schemes examined within this chapter the suppression observed 
in vivo by microarray analysis was confirmed throughout the quantitative real-time PCR validation 
experiments, although to a varying extent as might be expected from comparison between in vivo, 
primary and immortalised cells. The FaO cell line is a well differentiated hepatoma cell line (Moore 
and Weiss, 1982) that has previously been used to assess the effect o f both Wy-14,643 and 
dexamethasone on PPARa expression (Sterchele et al, 1996). The cell line also displays inhibition 
of apoptosis as induced by the peroxisome proliferator nafenopin (50 pM) as is observable in vivo 
(Bayly et al, 1994). However, the transcription profile of the cell line is known to decrease with 
increasing passage number (M. Weiss, personal communication) and this may have contributed to 
the reduced response compared to samples from liver and primary hepatocytes.
The microarray data suggested the presence o f two sub-groups within the group of seven genes 
whose expression was suppressed by liver growth agents; HCaRG, rCOUPg, LRCH4, OGFRLl 
and A1044183 showing maximal inhibition of gene expression at 48 hours, and Sp3 and N ob lp  at 
72 hours post initial dose. However the quantitative real-time PCR data from rat hver administered 
the same dosing regime showed a highly similar response between HCaRG, rCOUPg and N oblp , 
indicating that the response of the seven genes may be more similar than the microarray data 
initially su^ested.
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Throughout the dosing experiments for HCaRG and N oblp  a consistent suppressive effect has 
been observed. This was true whether by microarray, quantitative real-time PCR or reporter gene 
assay analysis o f the suppression o f gene expression. The magnitude of suppression was >2-fold 
versus control in the majority o f the results, with similar profiles o f suppression in response to the 
variety of liver growth agents used. Since a wide variety of sample types and techniques were used 
in the validation of this suppression, there is a high certainty that it represents a genuine response to 
liver growth stimuH, since it is not due to toxic insult from such compounds as proved by the 
assessment o f cellular LDH release.
The successful cloning of the HCaRG and N oblp  promoters and the validation o f their inhibitory 
response to liver growth stimuli by reporter gene assay confirms the potential co-ordinate 
regulation of these two genes in the response to liver growth stimuli. Despite the difficulties in 
cloning the rCOUPg and OGFRLl promoters, and the lack o f basal activity o f the Sp3 and LRCH4 
1 kb proximal promoter constructs, validation of the co-regulation of all seven genes would be 
possible following identification o f the key regulatory transcription factor(s) governing the response 
o f HCaRG and N oblp  to liver growth agents (Chapter 5).
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5 T a r g e t  e x a m in a t io n  a n d  M u t a g e n e s is
5.1 I n t r o d u c t i o n
The response of HCaRG and N oblp  to liver growth agent administration in vitro (Chapter 4), 
confirmed the similarity in the expression of these two genes in response to these agents first 
observed with the in vivo microarray experiment (Chapter 3). Therefore, further analysis is required 
to explore the regulation of HCaRG and N oblp  with the view to understanding the molecular 
mechanism controlling the response to agents causing liver growth. Little is known about the 
regulation o f either HCaRG or N oblp  since both genes were identified recently (Solban et al, 2000; 
Tone et al, 2000) and the majority of the research on these genes has centred on their downstream 
effects. Similarly, no previous link has been suggested between these two genes and the other five 
genes identified as exhibiting potential co-ordinate regulation from the in vivo microarray study 
(Chapter 3).
HCaRG is a potential regulator of cellular growth and differentiation as shown by its 
overexpression in the human embryonic kidney cell line HEK-93, resulting in reduced proliferation 
of the cells (Solban et al, 2000), which was later shown to be via cell cycle arrest (Devlin et al, 
2003). In contrast, no dkect link between N oblp  and cellular growth has previously been 
suggested, with the major role o f N oblp  being as an essential component for the formation o f the 
26S proteasome (Tone et aL, 2000) and for pre-rRNA synthesis (Fatica et al, 2003). The effect of 
decreasing expression o f these genes could be detrimental to the cell, since the 26S proteasome is 
important in the breakdown of ubiquitinylated proteins and decreased removal of ubiquitinylated 
proteins could result in the maintenance of intracellular signals that should have been removed, 
potentially impacting upon cell growth. Similarly, removal of a protein such as HCaRG that acts to 
prevent cellular division through the promotion of differentiation and the ability to induce cell cycle 
arrest would be detrimental to the cell with regard to transformation.
The following chapter presents the results of dissection of the promoters o f HCaRG and N ob lp  
including identification of the important regions controlling the response to liver growth agents. It 
describes the in silico analysis performed on the relevant sections of the gene promoters as identified 
by deletion construct analysis, and outlines the approach taken to reduce the number o f potential
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response elements implicated in the response of HCaRG and Noblp. This in turn allows 
presentation of a model on the role o f upstream transcription factors in the regulation o f the two 
genes and their response to liver growth agents (Chapter 6).
5.2 C l o n i n g  a n d  A n a l y s i s  o f  d e l e t i o n  m u t a n t  c o n s t r u c t s
Following analysis o f the 1 kilobase upstream promoter regions of HCaRG and N oblp, the 
promoter constructs were each used as templates for generation of three smaller daughter 
constructs. The generation o f these deletion constructs was accomplished using PCR amplification 
from primers containing existing restriction enzyme cutting sites, or where not possible point 
mutations that were created to produce cutting sites (Figure 5.1). The PCR products were then 
digested with the appropriate enzyme(s) and sub-cloned in to pSEAP. Table 5.1 shows the PCR 
primers and the enzymes for each deletion construct generated.
Figure 5.1: Strategy for generation of deletion constructs
Stage 1 PCR using nested primers containing RE cutting sites with 
999 bp (HCaRG) and 1066 bp (Noblp) promoter constructs 
as template. Generation of smaller promoter fragments:
HCaRG 
701 bp 
474 bp 
93 bp
Noblp 
725 bp 
312 bp 
71 bp
Stage 2 Gel purification of PCR products followed by 
digestion with appropriate enzyme(s)
Stage 3 Ligation into pSEAP
The stages in the generation of deletion constructs for HCaRG and N oblp. Firstly PCR 
amplification is performed using nested primers containing a restriction enzyme (RE) cutting site 
unique to the region o f interest, producing daughter fragments. Secondly the PCR products are 
purified by gel extraction to remove any interfering non-specific bands, and the product is digested 
with the appropriate enzyme(s). Thirdly the digested product is ligated into pSEAP that has been 
digested with the same enzyme(s) and purified by gel extraction. The ligation mixture can then be 
transformed into E.Co//DH5a for generation of large quantities of the construct.
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Table 5.1: PCR primers and restriction enzymes used to generate deletion constructs
Gene n am e / 
Fragm ent 
length (bp)
Forward prim er Reverse prim er
HCaRG - 701
gaactcacagagatctgtctgcct
t
gcttacttagatcgcagatctcgag
t
HCaRG - 474
taaggcaggtaccacacaaatttacgaccc
T
tgtacc Jicc651
atctcgagcggccgccagtg
t
HCaRG - 93
gcgctcggtaccg^aaccac
t
ggttcc —> Avû6S I
atctcgagc^ccgccagtg
T
N oblp  - 725
tagctcggtaccccattttttaata^
t
tgtacc —> Acc651
gcttacttagatcgcagatctcgag
T
N oblp  - 312
atcgaaggtaccttactgatttatatgatag
t
çgçacc Acc651
gcttacttagatcgcagatctcgag
t
% /E
N oblp - 71
gttcctctcgagtccgggaggagtg
T
ctccag —> Xho I
atctcgagcggccgccagtg
T
PCR primers for generation of deletion constructs from 1 kb promoter sequences. Restriction 
enzyme cutting sites are shown in bold with relevant enzyme, mutated bases are underlined where 
relevant. Forward primers were designed within the promoter region to produce smaller promoter 
constructs, in combination with a reverse primer located 3’ to the promoter i.e. within the pSEAP 
vector sequence.
Figure 5.2 illustrates the design of the deletion constructs for the HCaRG (Figure 5.2a) and N oblp  
(Figure 5.2c) promoters. Each daughter fragment is contained within the larger fragment, allowing 
removal of a portion of the sequence in each case, and assessment of the intervening sequence for 
its input into regulation of gene expression. It should be noted that the format o f the labelling of 
constructs, for example Noblp-71 bp, indicates the promoter in question and the size of the 
promoter region cloned into pSEAP, and does not reflect the total number of base-pairs of 
promoter cloned. The choice of such a nomenclamre is because along with the regulatory regions, a 
portion of exon 1 was amplified in the initial PCR. For the HCaRG constructs this represented 57 
bp of the 73 bp in exon 1, and for the N oblp constructs this was the entire 72 bp in exon 1. The 
position of the Not I  site used in the diagnostic digest is shown in each case, with the second N ot I  
cutting site being located elsewhere within the pSEAP construct sequence. The diagnostic digests
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for the HCaRG (Figure 5.2b) and N oblp  (Figure 5.2d) deletion constructs indicate the presence of 
the correct insert in each case.
Figure 5.2: Generation of deletion constructs and diagnostic analysis using N o t I
A
999 bp
- 701 bp
- 474 bp
Not 1 - 4  bp
-93  bp
exon 1
exon 1
—  exon 1
HCaRG- 999 bp 
HCaRG- 701 bp
HCaRG- 474 bp 
HCaRG-93 bp
+57 bp
B
1.5 kb 
1 kb
500 bp
y  y  y  y  
y  y  y  y
4 kb 
3kb 
2kb
1 kb
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-1066 bp
- 725 bp
-312 bp
Not  /  - 4 bp
71 bp
Nob1p-1066 bpHexoni - —
-| ewn 1 - — Nob1p-725bp
-| exon 1 ■ —
exon 1 |-|— Nob1p-312bp 
Nob1p- 71 bp
+72 bp
D
f-» "  y  /
y  y / y
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500 bp
4 kb 
3 kb 
2 kb
1 kb
A Cloned region of HCaRG promoter and deletion constructs showing Not I  cutting sites as used 
in diagnostic digest for all constructs. A second Not I  site was located within the vector sequence. 
Region cloned included promoter upstream of TSS and 57 bp of the 73 bp exon 1. B HCaRG 
deletion mutants and 1 kb promoter construct digested with Not I  to give 4484 bp in each case and 
355 bp (HCaRG-93), 736 bp (HCaRG-474), 998 bp (HCaRG-701), and 1261 bp (HCaRG-999). C 
Cloned region of N oblp promoter and deletion constructs showing Not I  cutting sites as used in 
diagnostic digest for all constructs. Region cloned included promoter upstream of TSS and the 
entire 72 bp of exon 1. D N oblp deletion mutants and 1 kb promoter construct digested with Not I  
to give 4484 bp in each case and 378 bp (Noblp-71) 588 bp (Noblp-312), 1001 bp (Noblp-725), 
and 1342 bp (NobIp-1066).
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5.2.1 B asal e x pr e ssio n  fro m  d e l e t io n  m u t a n t  co n str uc ts
Prior to investigating the drug-induced response for each of the deletion constructs it was necessary 
to analyse the basal function o f each region o f the HCaRG and N oblp  promoters. Constructs were 
transfected as previous into FaO cells (Section 2.4.4) and SEAP expression assayed after 48 hours 
incubation at 37°C in 5% CO2. The results for the HCaRG deletion constructs (Figure 5.3a) 
showed a significant increase in SEAP expression compared to pSEAP empty vector for the initial 
93 bp of proximal promoter, increasing the relative luminescence units over 1000-fold. This 
indicates not only the presence o f one or more regulatory elements within the entire cloned region 
(as previously demonstrated in Chapter 4), but that the proximal 93 bp of the HCaRG proximal 
promoter contains sufficient regulatory elements to support a reasonable level o f basal expression.
The HCaRG-474 bp construct showed a slight increase in SEAP expression over the HCaRG-93 
bp construct indicating that the intervening 381 bp o f promoter contains one or more regulatory 
elements exerting a further positive effect on HCaRG gene expression, but to a lesser extent than 
the element(s) within the initial 93 bp of promoter sequence. The HCaRG-701 bp construct 
induced a lesser increase in SEAP expression than the previous constructs, inducing 72-percent of 
the level o f the previous construct. This suggests the presence of a negative regulatory element(s) 
within this additional 227 bp region of the HCaRG promoter as indicated in Figure 5.3a. The 
region between 701 and 999 bp upstream of the transcription start site induced a lower increase in 
SEAP expression compared to the previous construct, again indicating the presence o f one or more 
negative elements within this region.
Overall the basal analysis o f HCaRG promoter functionality indicates that the response element(s) 
located within the initial 474 bp of proximal promoter sequence are influential on positive 
regulation of SEAP expression, whereas the region 474 to 999 bp has a net negative effect on gene 
expression.
132
Figure 5.3: Basal expression of SEAP from HCaRG and Noblp deletion constructs
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Deletion constructs for HCaRG (A) and N oblp (B) were transfected into FaO cells as described in 
section 2.4.4. Following incubation for 24 hours the growth medium was removed and assayed for 
SEAP as described in section 2.4.5. Deletion analysis of the HCaRG and N oblp  promoters 
indicated the presence of positive (+) and negative (-) response elements important for the basal 
regulation of gene expression as compared to the previous construct in each case. One-way 
ANOVA with Bonferroni’s post-hoc test was used to assess statistical significance relative to 
previous construct (n=5) * p<0.05, ** p<0.01, ***p<0.001.
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The results for the N oblp  deletion constructs are shown in Figure 5.3b. As observed in Chapter 4 
the N oblp  promoter produced approximately 10-fold lower activation o f SEAP expression 
compared to the HCaRG regulatory region (Section 4.3.2). Inclusion of the initial 71 bp of 
proximal promoter produced an 8-fold increase in SEAP expression over the empty pSEAP 
plasmid alone, indicating the presence o f one or more positive regulatory elements within this 
region. However, the region with the greatest positive influence on basal expression contained the 
first 725 bp of the proximal promoter, this region inducing a maximum 26-fold over pSEAP alone. 
The Noblp-1066 bp construct induced SEAP expression to 60-percent o f the Noblp-725 bp 
construct indicating the presence of one or more negative regulatory elements within this 341 bp 
region. Overall the basal analysis of N oblp  promoter functionality indicates that the response 
element(s) located within the initial 725 bp o f proximal promoter sequence are influential on 
positive regulation of SEAP expression, whereas the region 725 to 1066 bp has a net negative effect 
on gene expression.
5.2.2 E ffe c t  o f  liver  grow th  a g e n t s  o n  d e l e t io n  m u t a n t  c o n str u c t s
Following analysis of the basal expression of SEAP induced by each of the promoter constructs it 
was necessary to investigate the effect of dosing with liver growth agents as this would allow 
identification of the region(s) of the HCaRG and N oblp  promoters that were responsible for the 
inhibition observed in response to dosing with liver growth agents: It is not necessarily the case that 
the same regulatory element(s) responsible for basal control of gene expression would also be 
involved in the response to xenobiotics.
The deletion constructs were transfected into FaO cells and then dosed on the following day with 
one o f several liver growth agents for a 48 hour period. This had previously been shown to 
represent a period of maximal inhibition of gene expression (Section 4.3.3). The results for the 
dosing experiment are shown in Figure 5.4. The HCaRG-93 bp construct (Figure 5.4a) showed a 
significant decrease in SEAP expression in response to all three compounds. Dosing this construct 
with dexamethasone and CPA (both at 100 pM) resulted in 30-percent SEAP expression compared 
to DMSO control. SEAP expression was reduced similarly for the HCaRG-474, -701 and -999 bp 
constructs in response to dexamethasone and CPA versus control. The response to CFA (100 |jM)
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was reduced compared to dexamethasone and CPA, only achieving approximately 60-percent of 
control for the HCaRG-93 bp construct. Only the HCaRG-999 bp construct maintained the level 
of inhibition of SEAP expression observed for the -93 bp construct.
Figure 5.4a includes the level o f significance calculated between constructs above the graph. For 
dexamethasone and CPA treatment there was no significant difference between each o f the 
promoter constructs, indicating that the response element(s) responsible for the inhibition of SEAP 
expression are located within the initial 93 bp of proximal promoter. CFA treatment produced 
significant differences between the -474 bp and -93 bp constructs, and between the -999 bp and - 
701 bp constructs. However, there was no significant difference in SEAP expression between the - 
93 bp and -999 bp constructs, indicating that the response was again located to the initial 93 bp of 
the HCaRG promoter. Overall, as all liver growth agents caused a decrease in gene expression for 
all of the reporter gene constructs, including the construct containing the shortest regulatory region, 
then this is su^estive that the response elements responsible for their action are located within the 
first 93 bp of the HCaRG proximal promoter.
The N oblp  deletion constructs (Figure 5.4b) demonstrated a similar response to the HCaRG 
constructs. The Noblp-71 bp construct showed the greatest degree of inhibition o f SEAP 
expression for dexamethasone and CPA, resulting in 20-percent of the control level. There was no 
significant difference between the -71 bp, -312 bp, -725 bp and 1066 bp constructs for these two 
compounds, indicating that the initial 71 bp o f the N oblp  promoter were important in the 
inhibition of gene expression observed. The N oblp  constructs demonstrated greater similarity 
between the three compounds than the HCaRG constructs. However, there was a significant 
difference in the level of inhibition of gene expression between the -71 bp and -312 bp constructs 
in response to CFA. The suppression of SEAP expression was at 70-percent o f control for the -71 
bp construct compared to 40-percent of control for the -312 bp construct.
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This indicates that although the initial 71 bp of promoter contains one or more regulatory elements 
important for the response to xenobiotics, there is a further element(s) within the following 241 bp 
of promoter sequence that is required for the fuU extent of inhibition observed. This may be related 
to the basal activities of these two constructs (Figure 5.3b) where the -312 bp construct obviously 
contained one or more elements essential for the basal functioning of the promoter that were not 
contained within the initial 71 bp o f promoter sequence. Overall a similar situation was seen for 
N oblp  as for the HCaRG reporter constructs, with all liver growth agents causing a decrease in 
gene expression across all of the N oblp  reporter gene constructs. This is therefore suggestive that 
the response elements responsible for their action are located within the first 71 bp o f the N oblp  
proximal promoter.
5.2.3 D isc ussio n
The results of the basal and drug-induced analysis of promoter functionality indicate that the initial 
93 bp of proximal promoter sequence for HCaRG, and the initial 71 bp of the N oblp  promoter are 
largely responsible for the inhibition of gene expression observed. The response of the Noblp-312 
bp construct to CFA (Figure 5.4b) indicates the presence of other element(s) within the proximal 
promoter that are important for the full extent o f inhibition. Further analysis of the proximal 
promoter regions of these two genes is now required to identify potential response elements 
located within them that are responsible for the inhibitory effects of the liver growth agents on 
gene expression.
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5.3 I n v e s t i g a t i o n  o f  t h e  k e y  r e s p o n s e  e l e m e n t s  i n  t h e  
CONTROL OF HCaRG AN D N O B IP  GENE EXPRESSION
5.3.1 I n SIU CO ANALYSIS OF IMPORTANT REGULATORY REGIONS
Following identification of the regions of the HCaRG and N oblp  promoter sequences responsive 
to liver growth agents, it was necessary to identify the transcription factor(s) responsible for this 
response. In silico analysis allows regions of DNA sequence to be probed for potential response 
elements based on published consensus sequences for a variety of transcription factors. Several 
search facilities are available to probe the TRANSFAC database (Wingender et al, 1996) that lists 
these consensus sequences based on published information. Matlnspector (www.genomatix.de) 
(Quandt et al, 1995) and Match™ (www.gene-regulation.com) are two such tools, and interrogation 
using both tools allows a greater confidence that identified response elements are likely to be 
biologically relevant. However, experimental verification is always necessary to ensure that potential 
binding sites do exist, including techniques such as electromobility shift assay (EMSA) to prove the 
transcription factor binds to the response element, and site-directed mutagenesis to ablate the 
binding of the transcription factor and investigate its influence on gene expression.
Matrix searching was first proposed by Quandt and colleagues (1995) whereby the sequence is 
compared to a known consensus sequence for a transcription factor, and scored based on the 
matrix similarity and the core similarity to that consensus sequence. The matrix describes the 
individual binding profile for an individual or group o f transcription factors (Wingender et al, 
1996). The matrix similarity describes the similarity between a matrix and a part o f the input 
sequence, with the core similarity representing the similarity between the five most conserved 
nucleotides in the matrix and the input sequence. The search initially identifies regions with core 
similarities above a pre-defined threshold that can be set to minimise false positives or false 
negatives. The matrix similarity is calculated only for the regions with sufficiently high core 
similarity. For the analysis of the HCaRG and N oblp  promoters, relatively stringent values for core 
similarity (>0.70) and matrix similarity (>0.70) were used since the regions to be analysed were 
sufficiently small (93 and 71 bp respectively) to allow for the minimisation of false negatives. 
Despite this, approximately four hundred sites were identified using this method for each gene.
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with the vast majority of these likely to be false positives, often due to identification of binding sites 
for transcription factors that are poorly expressed in the liver.
Initially, sites for transcription factors that were not expressed in the liver were removed as these 
would be unlikely to be responsible for a liver-specific effect. The remaining sites were further 
reduced by comparison between the HCaRG and N oblp  promoters: Since co-regulation has been 
observed, this would require the presence of the same response element(s) in both promoters. O f 
the remaining sites several interesting transcription factors were selected as being possible 
candidates in the regulation of HCaRG and N oblp  gene expression (Table 5.2). These included 
numerous response elements for members of the family of signal transducer and activator of 
transcription (STAT), for the retinoic acid receptor (RAR)-related orphan receptor alpha (RORa), 
the estrogen receptor (ER) and for NF-kB. However there were still in excess o f ten potential 
transcription factors of interest and numerous potential response elements for each within the 
initial ~100 bp of proximal promoter of either gene. Due to the impossibility of mutating each site 
in a trial and error approach it was decided to utilise simple dosing experiments using the promoter 
constructs already generated in order to reduce the number of potential response elements 
implicated in the response under investigation.
Table 5.2: Potential transcription factor binding sites common to HCaRG and N ob lp  
proximal promoter regions
Transcription factor HCaRG N oblp
AhR -74, -68, -16 -65, +10
Nrf2 -28 +32
STATl -50, -29 -65
STAT6 -27 -4
NF-kB -87, -55, -33, -23 -39
ER -62 -5
RORa -36, -24 -7
The 93 bp and exon 1 of the HCaRG proximal promoter, and 71 bp and exon 1 were searched 
against the TRANSFAC database using both Matlnspector and the Match tool. A selection of the 
potential binding sites common to both promoters is shown. AhR: aryl hydrocarbon receptor, 
Nrf2: NF-E2-related factor 2, STAT: signal transducer and activator o f transcription, NF-kB: 
nuclear factor kappa B, ER: estrogen receptor, RORa: RAR-related orphan receptor alpha.
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5.3.2 D o sin g  WITH p-NAPHTHOFLAVONE
P-naphthoflavone (P-NF) is a synthetic flavone compound and an inducer o f phase I detoxifying 
enzymes such as CY PlA l/2. P-NF is known to both increase the expression of the NFE2-related 
factor 2 (Nrf2) (Huang et al, 2000) and to be an agonist of the aryl hydrocarbon receptor (AhR) 
(Sinai et al, 1999). Activation o f Nrf2 and AhR have been implicated in the control of the response 
to xenobiotics, activating a gene battery with particular affect on expression of phase I and phase II 
detoxifying enzymes (Kohle and Bock, 2006). Several potential Nrf2 and AhR response elements 
were identified as being present in both the HCaRG and N oblp  proximal promoter regions, hence 
a dosing experiment was performed to examine the involvement of these transcription factors. 
Cells were dosed following transfection of the HCaRG-93 bp and Noblp-71 bp deletion 
constructs, along with the full 1 kb constructs to compare and allow confirmation that the effect 
was localised to the first ~100 bp o f proximal promoter. P-NF was dosed in the range 1 to 100 pM 
and the results were compared to the dosing experiments using liver growth agents. Similar results 
for dosing with P-NF and with the liver growth agents would indicate that the AhR and/or Nrf2 
were involved in the mechanism leading to reduced expression of HCaRG and N oblp  during drug- 
induced liver growth.
Figure 5.5 shows the results o f the P-NF dosing experiment. The results for HCaRG (Figure 5.5a) 
show that there was a significant inhibition of gene expression in response to 10 |uM P-NF that 
increased with the maximal inhibition of SEAP expression occurring in response to the 100 pM 
dose, where a reduction in SEAP expression to 44-percent o f control was observed. The similarity 
in inhibition elicited by P-NF for both the -93 bp and -999 bp promoter constructs indicates that 
the response is occurring in the initial 93 bp of promoter proximal. In agreement with this were the 
results for the N oblp  reporter gene constructs (Figure 5.5b) where a dose response was observed 
across the range tested, with inhibition o f SEAP expression occurring to the greatest extent (36- 
percent of control) following dosing with 100 pM P-NF. In addition, similarity between the -71 bp 
and -1066 bp constructs’ response indicates that the response to p-NF is mediated via the initial 71 
bp o f promoter proximal to the TSS, and adds to the evidence that the HCaRG and N ob lp
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promoters are controlled by the same transcription factor(s) and are co-regulated in response to 
Hver growth stimuli.
The dosing experiment using P-NF highlighted the similarity in the response of the two promoters 
and more importantly, resulted in inhibition of SEAP expression to a similar extent to that resulting 
from liver growth agent administration. Therefore it is likely that this response is mediated through 
the action of the AhR, Nrf2, or a combination of both transcription factors.
Figure 5.5: Effect o f P-naphthoflavone on SEAP expression controlled by HCaRG and 
N oblp  proximal promoter regions
55OOO1 
50000 
45000-1 
40000 
35000 
3  30000- 
K 25000- 
20000 -  
15000- 
10000-  
5000 
0 I
HCaRG-93 HCaRG-999
Deletion Construct
nzziD M S O  
IZZ lpN F IgM 
C = ]  pNF lOgM 
[ZZ3 PNF 25gM 
pNF 50|xM 
M N p N F  lOOgM
B
9000-1 
8000- 
7000 
60004 
3  5000 
 ^ 4000 
3000 
2000 
1000 
0
DMSO 
pNF IgM 
pNF lOgM 
pNF 25 [M 
PNF 50pM 
^ p N F  lOOgM
N oblp-71 N oblp-1066
Deletion Construct
HCaRG (A) and N oblp (B) constructs containing the smallest and largest regions of the promoter 
were transfected into FaO cells as described in section 2.4.4. Cells were treated with P-NF in the 
range 1 to 100 pM for 48 hours prior to assay for SEAP. One-way ANOVA with Bonferroni’s 
post-hoc test was used to assess statistical significance relative to DMSO control for each construct 
(n=5) * p<0.05, ** p<0.01, ***p<0.001.
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5.3.3 T r a n sc r ip t io n  factors e x h ib it in g  in f l u e n c e  o n  H C aR G  a n d  N o b Ip
The identification of the involvement o f Nrf2 and/or AhR in the response of HCaRG and N oblp  
to liver growth agent administration greatly reduced the number o f potential response elements 
requiring further investigation; Figure 5.6 illustrates the positions of the AhR and Nrf2 sites within 
the HCaRG and N oblp  promoters as identified using Matlnspector and verified using the Match™ 
tool. Using both Matlnpector and Match™ increased the likelihood of selecting genuine binding 
sites, especially as Matlnspector can automate the selection o f promoter regions, verifying the 
sequence obtained manually (as in section 4.3.1.1). Figure 5.6 also shows the core and matrix 
similarity scores (section 2.2.2.3) for each potential response element.
The region of interest for the HCaRG promoter contains a single Nrf2 site located 28 bp upstream 
of the TSS. This site shows a high core similarity (0.884) indicating that the most conserved 
nucleotides for the NrfZ consensus sequence are present in the HCaRG promoter at this point. 
Three potential AhR response elements (termed dioxin-response elements) were identified at 16, 68 
and 74 bp upstream of the TSS. All three show a core similarity of 0.747 indicating that the five 
most conserved nucleotides of the AhR consensus sequence are not necessarily present at these 
sites. However, this does not discount the possibility that these AhR sites are functional since there 
can be a degree of flexibility with regard to the exact consensus sequence. Often some of the core 
nucleotides are more crucial for transcription factor binding than others, or a change from one 
purine or pyrimidine to the other can sometimes occur without any detrimental effect.
The only Nr£2 site identified within the region of interest for the N oblp  promoter is located within 
the sequence of exon one. This region was cloned into the construct purely to improve 
optimisation of the initial PCR amplification. This potential Nrf2 site shows a core similarity o f 
1.000 indicating a perfect match to all five of the most conserved nucleotides o f the Nr£2 
consensus sequence. Figure 5.7 shows the positioning o f the exons of the N ob lp  mRNA 
(NM_199086), plus those exons that code for the untranslated regions (UTRs) and coding sequence 
(CDS) of the gene. The rat N oblp  gene possesses a short 5’ UTR of nine base pairs (Figure 5.7), 
hence the potential NrfZ site is located 23 bp within the coding region i.e. the region o f the mRNA 
that is translated into protein; such a location would suggest that is not necessarily biologically
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active, as response elements are traditionally associated with regulatory and, not coding regions. 
However, recent evidence has demonstrated that response elements can occur located upstream 
and downstream of the transcription start site. Downstream regulatory elements for genes 
transcribed by RNA polymerase II have been identified within proximal and distal exons for 
example within exon 1 of the elastin gene (Pierce et al, 2006) and exon 6 of the keratin 18 gene 
(Neznanov et al, 1997), and within introns for example intron 2 of the mouse thymidine kinase 
gene (Rotheneder et al, 1991).
Figure 5.6: Location of potential NrfZ and AhR response elements for HCaRG and N oblp
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Promoter and exon (dark grey) regions are shown for HCaRG and N oblp. Potential sites of 
interest shown are NrfZ and AhR with the corresponding core similarity (CS) and matrix similarity 
(MS) scores (section 2.2.23) obtained by interrogation of each sequence using Matlnspector 
(www.genomatix.com) to probe the TRANSFAC database of consensus sequences. Sites are 
positioned relative to the transcription start site /TSS) for each gene.
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The N oblp  promoter also contains two potential AhR response elements, the first just within the 
first exon and the second located within the promoter, 65 bp from the TSS. O f the two sites 
identified it is the second that possesses the higher core similarity score (0.820 versus 0.747) 
indicating that this region of the DNA is potentially more suited to binding of the AhR/ARNT 
complex. Figure 5.6 also shows the position o f a second potential NrfZ response element in the 
N oblp  promoter region located 272 bp from the TSS. This region was included in the search due 
to the finding that the Noblp-312 bp construct exhibited close to a 3-fold increase in SEAP 
expression versus the Noblp-71 bp construct under basal conditions (Figure 5.3b). Therefore this 
second NrfZ site may potentially be involved in achieving complete transactivation of the N oblp  
gene.
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5.3.4 D o sin g  w it h  b e n z o (a) p y r e n e  a n d  3-m e t h y l c h o l a n t h r e n e
Dosing with P-NF indicated the involvement o f NrfZ and/or AhR in signal propagation, but 
cannot distinguish between the activation of these two transcription factors. It was necessary to 
identify which of the two transcription factors was responsible for the inhibition o f gene expression 
observed for HCaRG and N oblp  in response to liver growth agent administration. In order to 
attempt to distinguish this a dosing experiment was performed using the known AhR agonists 3- 
methylcholanthrene (3-MC) and benzo(a)pyrene: If  the response to agonists of the AhR was similar 
to that elicited by liver growth agent and P-NF administration this would be indicative o f AhR 
involvement in the control o f HCaRG and N oblp  expression. A failure to respond to the AhR 
agonists would indicate that NrfZ was more likely to control expression of these genes.
The HCaRG and N oblp  promoter constructs were initially dosed with the AhR agonist 3-MC. 
Dosing with 3-MC resulted in decreased SEAP expression to 70-percent o f control at 25 pM for 
the HCaRG-93 construct and at 0.1 pM for the HCaRG-999 construct (Figure 5.8a) indicating the 
possible involvement of AhR in the regulation of this gene. The results for N oblp  show a more 
pronounced effect with expression of SEAP decreasing to 61-percent of control for the Noblp-71 
construct following dosing with 3-MC at 25 pM. This was similar for the Noblp-1066 construct 
with a significant inhibition of SEAP expression across the range 5 pM to 100 pM.
The inhibition observed was not of the same magnitude as that seen using either P-NF or the liver 
growth agents, despite the fact that 3-MC is a potent AhR activator. This may be merely a dose- 
dependent effect, a ligand-specific effect or be suggestive that that the inhibition o f HCaRG and 
N oblp  gene expression observed in response to liver growth agent administration is unlikely to be 
controlled solely by the AhR.
The results observed for 3-MC administration were confirmed using a second AhR agonist. 
Administration of benzo(a)pyrene failed to produce a significant inhibition of SEAP expression 
except at 500 pM for the HCaRG-999 construct (Figure 5.9a). The effect on the Noblp-71 
construct was to inhibit SEAP expression to 80-percent o f control at 25 pM B(a)P (Figure 5.9b). A 
similar response occurred for the Noblp-1066 construct between 10 pM to 250 pM  B(a)P,
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mirroring the difference observed between the 71 bp and 1066 bp constructs in response to dosing 
with 3-MC (Figure 5.8b). This difference in the sensitivity of the two constructs could indicate the 
presence of an influential AhR response element located between 71 and 1066 bp upstream of the 
transcription start site.
Figure 5.8: Dose response curve for 3-methylcholanthrene administration to FaO cells 
transfected with HCaRG and N oblp promoter constructs
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The effect of 3-methylcholanthrene on the HCaRG promoter constructs (A) and N oblp  promoter 
constructs (B) are shown. For each dose both constructs were transfected for comparison with the 
response by the initial ~100 bp of proximal promoter. One-way ANOVA with Bonferroni’s post- 
hoc test was used to assess statistical significance relative to DMSO control for each construct 
(n=5) * p<0.05, ** p<0.01, ***p<0.001.
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Figure 5.9: Dose response curve for benzo(a)pyrene administration to FaO cells transfected 
with HCaRG and N oblp  promoter constructs
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The effect of ben2 o(a)pyrene on the HCaRG promoter constructs (A) and N oblp  promoter 
constructs (B) are shown. For each dose both constructs were transfected for comparison with the 
response by the initial ~100 bp of proximal promoter. One-way ANOVA with Bonferroni’s post- 
hoc test was used to assess statistical significance relative to DMSO control for each construct 
(n=5) * p<0.05, ** p<0.01, ***p<0.001.
To estimate whether a difference in potency between P-NF, 3-MC and benzo(a)pyrene was the 
cause of the differing response between the compounds their EC50 values were compared. The 
EC50 value of a compound relates to the molar concentration producing 50-percent o f the maximal 
effect for that compound. Example EC50 values are shown in Table 5.3 for P-NF, 3-MC and
148
benzo (a)pyrene to allow comparison between the three compounds with respect to their ability to 
cause activation and nuclear translocation of the AhR. This is commonly measured by the 
activation of expression o f the AhR target gene CYPIAI. The EC50 values shown in Table 5.3 were 
not produced in the FaO cell line, but using a yeast reporter assay co-expressing human or mouse 
AhR/ARNT (Kawanishi et al, 2003) or using the rat hepatoma cell line H-4-II E  (Piskorska- 
Pliszczynska et al, 1986). As can be seen from Table 5.3, P-NF is the most potent activator of the 
AhR having the lowest EC50 value. 3-methylcholanthrene has an EC50 value approximately double 
that of P-NF (Kawanishi et al, 2003), with benzo(a)pyrene being the weakest activator of the AhR, 
with an EC50 value ranging from 20-fold to 45-fold greater than that o f 3-methylcholanthrene 
(Kawanishi et al, 2003). Hence it would be expected that double the concentration of 3- 
methylcholanthrene, and up to 150-fold higher the concentration of benzo(a)pyrene would be 
required to produce the same result as dosing with P-NF.
Table 5.3: E C 5 0  values for P-NF, 3-methylcholanthfene and benzo(a)pyrene
O rganism E C ^ (n M )
P-NF 3-methylcholanthrene Benzo(a)pyrene
Mouse ^ 14 30 600
Mouse 1 8 14 700
Human ^ 6 20 900
Human ^ 5 20 600
Rat2 28
^From experiments using yeast containing reporter constructs co-expressing mouse AhR and 
ARNT (l&wanishi et al, 2003).  ^Measured in rat hepatoma H-4-II E  cells (Piskorska-Pliszczynska 
et al, 1986).
Given that B(a)P, like 3-MC, is a potent activator of AhR, albeit with an EC50 10-fold greater than 
that of 3-MC (Kawanishi et al, 2003), this adds weight to the prediction that the AhR is not the sole 
transcription factor controlling HCaRG and N oblp  expression. This data is therefore consistent 
with a second factor, possibly NrfZ, being involved.
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5.3.5 A ssessm en t  o f  t h e  in v o l v e m e n t  o f  N rf2 a n d  Ah R  in  t h e  c o n t r o l  o f  
H C aR G  a n d  N o b Ip
As experiments using P-NF and the AhR agonists 3-MC and benzo(a)pyrene implicated the 
involved o f NrfZ and AhR in the inhibition of HCaRG and N oblp  gene expression by liver growth 
agents, but failed to distinguish which receptor was more important, alternate strategies were 
required. First, the influence o f NrfZ was removed using treatment with the protein synthesis 
inhibitor cycloheximide, and second, a series of mutagenesis experiments were performed to 
remove the potential transcription factor binding sites identified in the previous section.
5 .3 .5 .1  D o sin g  w ith  cyclohexim ide
Cycloheximide (CHX) is a protein synthesis inhibitor that can be dosed for short periods to reduce 
the levels o f labile transcriptions factors: NrfZ is one such factor with a half-Hfe of less than 20 
minutes (Itoh et al, 2003). Therefore a dosing experiment was performed using CHX at an 
appropriate concentration with or without dexamethasone (100 filVQ or p-NF (100 pM), to study 
the effect on reporter gene expression when NrfZ levels had been reduced. If  NrfZ mediates the 
inhibitory effect of these chemicals on HCaRG and N oblp  gene expression then dosing with CHX 
should remove or lessen this inhibition in response to dexamethasone or P-NF. This technique has 
been used previously by Ma et al (2004) where CHX was dosed and the levels o f Nrf2 and the 
downstream enzyme under investigation were assessed after 5 hours incubation using Northern 
Blotting. This experiment has two potential flaws in that CHX dosing for 24 hours is toxic to FaO 
cells, as visible by light microscopy, and that the reporter gene SEAP needs to be translated to be 
detected. To mitigate these potential issues dosing with CHX was limited to the first 5 hours post­
dose, as performed in the experiments by Ma et al (2004).
However, as can be seen from Figure 5.10, CHX exposure did have a significant effect on basal 
SEAP expression. Dosing with CHX (10 pg/mL) for 5 hours caused decreased SEAP expression 
for both HCaRG-93 (Figure 5.10a) and Noblp-71 (Figure 5.10b) constructs, reducing it to 25- 
percent for HCaRG and 30-percent for N oblp. The effect o f CHX on the expression o f SEAP for 
HCaRG-93 and Noblp-71 promoter constructs suggests that treatment with CHX has caused 
inhibition o f SEAP expression and therefore prevented accurate determination of the effect of
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Nrf2 depletion on HCaRG and N oblp expression using this method. Dosing with CHX inhibits 
protein synthesis and hence only long-lived proteins synthesised prior to the time of dosing would 
remain active within the cell.
Figure 5.10: Effect of CHX dosing on SEAP expression from HCaRG-93 and Noblp-71 
constructs
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The effect of dosing for 5 hours with CHX (10 pg/mL) on SEAP expression from HCaRG-93 (A) 
and Noblp-71 (B) constructs is shown. Dexamethasone (100 pM) or (3-NF (100 pM) was dosed 
with or without CHX to determine the effect of labile transcription factors on the inhibition of 
SEAP expression in response to liver growth agents observed previously. Data was analysed using 
one-way ANOVA with Bonferroni’s post-hoc test for both liver growth agent versus control, and 
for CHX alone versus CHX in combination with Hver growth agent (*** p <0.001).
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To attempt to overcome this difficulty the experiment was repeated, but quantitative real-time PCR 
was used to measure genomic expression o f N oblp  and HCaRG. Figure 5.11a shows the effect of 
exposure to CHX with and without liver growth agents on the genomic expression of HCaRG. 
Dosing with CHX alone produced a 9-fold decrease in HCaRG expression compared to untreated 
cells that were exposed to DMSO only, which could indicate that a labile protein is responsible at 
least in part for the basal level of expression of HCaRG. Dosing with CHX plus either 
dexamethasone, CPA or CFA resulted in a significant decrease in HCaRG expression compared to 
the respective liver growth agent alone. This could indicate that a labile factor is also involved in the 
response to liver growth agents, and that removal of this factor may limit the response. Treatment 
with CHX in combination with CPA was not sufficient to completely ablate the response to CPA, 
as shown by the significant difference versus CHX alone. This could indicate that a labile factor 
alone is not sufficient to cause the response to CPA.
Figure 5.11b shows the results for N oblp  expression that are similar to those for HCaRG. The 
effect of CHX in combination with dexamethasone, CPA or CFA versus CHX alone was less 
pronounced for N oblp, decreasing expression approximately two-fold in each case. These results 
could indicate a similar situation as for HCaRG, with a labile factor being required for the response 
to Hver growth agents, and the need for one or more factors unaffected by the incubation with 
CFIX particularly in the response to CPA. However this experiment suffered two major drawbacks 
in that the suppression of HCaRG and N oblp  expression caused by CHX alone is potentially so 
large as to obscure the effects in combination with the Hver growth agents. Also, due to the 
cytotoxic effect of prolonged CHX exposure on FaO cells it was not possible to continue to 
monitor the effect of CHX into the period of inhibition o f gene expression i.e. 24 to 96 hours post­
dose. Hence it would be necessary to use a more specific technique such as site-directed 
mutagenesis or gene silencing by RNA interference to assess the involvement o f NrfZ in the 
regulation of HCaRG and Noblp.
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Figure 5.11: Effect of CHX dosing on HCaRG and N oblp expression in FaO cells by 
quantitative RT-PCR
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HCaRG (A) and N oblp (B) expression in FaO cells was determined by quantitative RT-PCR 
following a 5-hour incubation with CHX (10 pg/mL) with or without Hver growth agent. CeUs 
were seeded into 6-weU plates at a density of 5 x 10  ^cells/mL and incubated overnight at 37°C (5% 
CO2) prior to dosing. CeUs were exposed to CHX + /-  dexamethasone, CPA or CFA (100 pM). 
Following dosing ceUs were lysed, RNA was extracted and cDNA synthesised as described in 
section 2.5. One-way ANOVA with Bonferroni’s post-hoc test was used firstly to assess statistical 
significance between ceUs exposed to Hver growth agent with and without CHX, and secondly 
between Hver growth agent with CHX and CHX alone (n=3) * p<0.05, ** p<0.01, ***p<0.001.
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5.3.5.2 Site-directed mutagenesis of AhR and Nrf2 regulatory elements
SDM is a technique that allows the introduction of point mutations into a DNA sequence. This is 
accomplished using PCR amplification with primers containing the mutated sequence. In this way 
several bases can either be changed/deleted to alter/remove a transcription factor response 
element. It is often useful when altering the sequence to change the base in question from a purine 
to a pyrimidine residue as this is most likely to impact upon transcription factor recognition of, and 
binding to, the response element. The steps involved in the generation of mutants are shown in 
Figure 5.12 and described in section 23.6.1.
Figure 5.12: Strategy for generation of mutant constructs by site-directed mutagenesis
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A unique restriction enzyme cutting site for Acc III was introduced within the Nrf2 response 
element causing mutation of several nucleotides important for the binding o f NrfZ to the response 
element. PCR amplification from the HCaRG-93 bp construct using the sense 1 and antisense 1 
primers produced the upstream fragment, with sense primer 2 and antisense primer 2 producing the 
downstream fragment. The two fragments were subsequently digested with Acc III and ligated 
together. The HCaRG-93 bp primers (Table 2.11) were then used to amplify the ligated fragment 
prior to digestion with Acc6S I  and Xho I  and ligation into pSEAP. This procedure was repeated for 
generation of the other mutant constructs using the primers shown in Table 2.13.
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The in silico analysis of the HCaRG-93 and Noblp-71 promoter regions identified the presence of 
both NrfZ and AhR potential response elements in both cases. To attempt to address the 
hypothesis that one or both transcription factors were involved in the control of HCaRG and 
N oblp, constructs containing mutated response elements for each of the potential binding sites 
were produced. Since the potential NrfZ site identified in the Noblp-71 bp construct was found 
within the exon 1 sequence, a second potential NrfZ site located within the 241 bp between the 
Noblp-71 bp and -312 bp constructs was also mutated. As both the response o f the N oblp  
deletion mutants under basal conditions (Figure 5.3b) and in response to CFA (Figure 5.4b) 
indicated that this 241 bp region was important it was also useful to mutate this potential Nrf2 site 
to assess its role in the response to the peroxisome proliferator. For each response element of 
interest, one mutation per construct was produced; hence the involvement of each binding site was 
determined separately. Wild-type and mutated constructs were transfected into FaO cells and the 
basal activities and the effect of dosing with liver growth agents determined. Unfortunately due to 
time constraints and difficulties with the initial PCR optimisation of the downstream fragments, the 
potential NrfZ site in the Noblp-71 bp and one of the potential AhR sites in the same construct 
could not be successfully mutated. The potential NrfZ site in the HCaRG-93 bp was successfully 
mutated, along with the potential NrfZ site in the Noblp-312 bp construct and the second potential 
AhR site in the Noblp-71 bp construct that had produced the higher core similarity score of the 
two AhR sites identified (Figure 5.6).
The basal expression o f the wild-type and mutated constructs is shown in Figure 5.13. The 
expression of SEAP from the wild-type constructs observed in Figure 5.13 is in agreement with the 
previous basal analysis of these deletion constructs (Figure 5.3), with the Noblp-312 bp construct 
showing greater than two-fold SEAP expression over the Noblp-71 bp construct. With regard to 
the mutant constructs, o f the three potential response elements mutated only the NrfZ site in the 
HCaRG-93 bp construct appears to have any effect on basal expression, with its ablation eliciting a 
1.7-fold increase in SEAP expression versus the wild-type construct; this suggests that the NrfZ 
response element in the HCaRG-93 bp construct is a functional binding site, and under basal 
conditions it may act in a inhibitory fashion on HCaRG gene expression.
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Figure 5.13: Basal expression of SEAP from HCaRG and Noblp wild-type and mutant
constructs
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Constructs containing wild-type HCaRG and N oblp promoter sequences were transfected into 
FaO cells (section 2.4.4) in parallel with constructs containing mutated sites for Nrf2 and AhR. 
One-way ANOVA with Bonferroni’s post-hoc test was used to assess statistical significance of each 
mutation relative to the wild-type sequence (n=5) ***p<0.001.
Following analysis of response element ablation on basal expression, the effect of liver growth 
agent administration for a 48 hour period was examined. Figures 5.14 to 5.16 show the effect of 
mutagenesis on the inhibition of SEAP expression by dexamethasone, CPA, Wy-14,643 and P-NF. 
For all three cases, no consistent effect was seen upon mutation of the individual response 
elements, which in general had no effect on the inhibition of reporter gene expression by the three 
xenobiotics. However, some small, statistically significant effects were seen with Wy-14,643. 
Mutation of the potential Nrf2 response element in the HCaRG-93 bp construct influenced the 
response to Wy-14,643, with the Nrf2 mutant decreasing SEAP expression to 64-percent o f the 
wild-type construct, indicating that removal of the influence of this potential Nrf2 element would 
cause further inhibition of HCaRG expression. Mutation of the potential AhR element in the 
Noblp-71 bp construct also affected the response to dosing with Wy-14,643, resulting in an 
increase in SEAP expression to 130-percent of the wild-type construct. The significance of this
156
result is difficult to determine since dosing with this compound failed to significantly change SEAP 
expression for either the wild-type or mutated construct versus DMSO control.
Figure 5.14: Effect o f mutation of the potential Nrf2 response element in the HCaRG-93 bp 
construct
3
a:
50000
40000-
30000-
20000 -
10000-
1
C = 1 D M S 0  
C n  Dex (100 pM) 
C = 3 C P A (1 0 0  pM) 
■ ■ W y -1 4 ,6 4 3 ( 1 0 0  pM) 
■ ■ P - N F  (100 pM)
H C aR G -93 (Nrf2) wt H C aR G -93 (Nrf2) mut
The construct containing the wild-type promoter sequence were transfected into FaO cells (Section
2.4.4) in parallel with the construct containing the mutated site for Nrf2. One-way ANOVA with 
Bonferroni’s post-hoc test was used to assess statistical significance of the effect of each compound 
versus DMSO control, and also the effect of the mutation relative to the wild-type for each 
compound (n=5) *p<0.05, **p<0.01, ***p<0.001.
Figure 5.15: Effect of mutation of the potential AhR response element in the Noblp-71 bp 
construct
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The construct containing the wild-type promoter sequence were transfected into FaO cells (Section
2.4.4) in parallel with the construct containing the mutated site for the AhR. One-way ANOVA 
with Bonferroni’s post-hoc test was used to assess statistical significance of the effect of each 
compound versus DMSO control, and also the effect of the mutation relative to the wild-type for 
each compound (n=5) *p<0.05, **p<0.01, ***p<0.001.
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Figure 5.16: Effect of mutation of the potential Nr£2 response element in the Noblp-312 bp 
construct
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The construct containing the wild-type promoter sequence were transfected into FaO ceUs (Section
2.4.4) in parallel with the construct containing the mutated site for Nrf2. One-way ANOVA with 
Bonferroni’s post-hoc test was used to assess statistical significance of the effect of each compound 
versus DMSO control, and also the effect of the mutation relative to the wild-type for each 
compound (n=5) *p<0.05, **p<0.01, ***p<0.001.
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5.4 D iscussion  o n  co-o r d in a te  regulation  of HCaRG a n d
N o bIp
A consistent finding throughout this study was the similarity in the response of HCaRG and 
N oblp  to the various compounds administered. This similarity in the response o f the genes to liver 
growth agents that had been shown in Chapter 4 at the mRNA and promoter level was continued 
throughout the deletion analysis, the exposure to P-NF and the AhR agonists 3-MC and B(a)P, and 
the use of cycloheximide to remove the effect of Nrf2. This indicates a strong possibility that 
HCaRG and N oblp  are co-regulated and that the transcription factor(s) influencing their co­
ordinated regulation are key to the response to compounds causing liver growth. The data 
presented in this chapter shows that the regulation is likely to be mediated through one o f two 
factors, AhR and Nr£2, although we could not fully discriminate which is the central factor in the 
response.
In the analysis of gene promoters and the upstream factors governing their regulation the major 
difficulty is determining the key response elements from the thousands o f potential sites located 
within the sequence. In the case of the two genes of interest in this study there was no information 
to assist in the selection of candidate transcription factors since the majority of the experiments 
performed to date have been interested in the downstream effects of the two genes. The analysis of 
deletion constructs performed in Section 5.2 successfully reduced the region of each promoter for 
further analysis to 93 bp for HCaRG and 71 bp for Noblp.
In silico analysis of the potential binding sites revealed approximately 400 potential response 
elements within either region. Even following removal of sites that were not common to both 
sequences, and sites for transcription factors not expressed in liver, there were in excess o f 20 
potential sites for each gene. Dosing experiments were utilised to reduce the number o f potential 
sites for further analysis. P-NF was selected since it was a known inducer of the expression o f genes 
under the control of Nrf2 and AhR. Dosing with P-NF is known to induce expression o f the phase 
2 detoxifying enzyme NAD(P)H:quinone oxidoreductase 1 (NQOl) in mouse hepatoma cells via 
increased Nr£2 that can be blocked using the protein synthesis inhibitor cycloheximide (Ma et al, 
2004). p-NF also induced expression of the gamma-glutamylcysteine synthetase subunit genes in
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HepG2 cells where a concomitant increase in the binding of Nrf2 to the ARE in the gene 
promoters was observed (Wild et al, 1999). Similarly P-NF was found to induce expression of 
CYPlAl in rodent white adipose tissue via the AhR, at the same time as inducing expression of the 
Nrf2 downstream target genes N Q O l, glutathione S-transferase Ya (GST-Ya) and heme 
oxygenase-1 (HO-1) (Yoshinari et al, 2006). Exposure of the HCaRG and N oblp  constructs to P- 
NF resulted in reduced expression o f SEAP that was dose-dependent with a maximal two-fold 
decrease observed in response to 100 pM in both cases (Figure 5.5). This was similar to the 
response observed for the same constructs following exposure to dexamethasone, CPA and to a 
lesser extent CFA (Figure 5.4). This indicated that the response of the HCaRG and N oblp  
promoters to liver growth agents was mediated by Nrf2, AhR or a combination o f both 
transcription factors.
The AhR agonists 3-MC and B(a)P were used to attempt to differentiate between the influence of 
Nrf2 and AhR in the control of expression of HCaRG and N oblp. The two agonists are known to 
have different potencies with 3-MC being approximately 10 times more potent than B(a)P as 
evidenced by the ability of each compound to induce expression from a reporter construct 
containing multiple xenobiotic response elements upstream of the P-galactosidase gene (Kawanishi 
et al, 2003). The response of the HCaRG and N oblp  constructs to the AhR agonists failed to 
discriminate between the AhR and Nr£2 since a partial response was observed for both gene 
promoters in response to both compounds (Figures 5.8 and 5.9). Therefore it is possible that the 
AhR is either co-operating with Nr£2 as suggested by Ma and colleagues (2004) in the control of 
N Q O l, or that the AhR is capable of compensating for Nrf2, or possibly the AhR is involved 
upstream of Nrf2 as observed by Miao and colleagues (2005) who identified xenobiotic-response 
element (XRE)-like sequences in the Nr£2 promoter. In this last scenario, activation of AhR and 
nuclear translocation of the receptor would occur prior to transactivation of the Nrf2 gene via the 
XREs in the Nrf2 promoter, and Nr£2 would then directly affect the transactivation o f the HCaRG 
and N oblp  genes. This may explain why the response to the AhR agonists was less pronounced, 
with activation of both the AhR and liberation of pre-existing Nr£2 from Keapl being required 
initially, followed by increased expression of Nrf2 in response to the AhR. Without co-induction of
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Nrf2 initially the response may be stunted, relying solely on AhR-induced up-regulation of Nrf2 
expression to exert the effect on HCaRG and N oblp  expression.
Figure 5.11 appears to implicate a labile factor, such as Nrf2, in the control o f HCaRG and N oblp  
under basal conditions as shown by the decrease in expression o f these two genes in the presence 
of CHX. Co-administration of liver growth agents with CHX decreased expression of HCaRG and 
N oblp  compared to liver growth agent administration alone. Therefore it is possible that a labile 
factor is also involved in altering the expression o f both genes in response to liver growth agents. 
This appears to be the case at 5 hours post-dosing, but to allow monitoring o f the effect o f removal 
of Nrf2 beyond this point another technique such as gene silencing would be required in order to 
maintain the cells beyond the initial 24 hour dosing period whilst removing the effect of Nrf2. 
However since the basal levels of Nrf2 are very low (data not shown), dosing with a suitable agonist 
such as P-NF a few hours after transfection with the siRNA may improve the ability to optimise 
the gene silencing o f Nr£2. Dosing with P-NF could be continued during the 48 hour period prior 
to basal analysis, thus increasing the expression of Nrf2 in the unsilenced cells to a level that would 
allow comparison with the silenced cells. If  silencing of Nr£2 resulted in the continued reduction of 
the response to liver growth agents as observed during the first 5 hours during the period of 
elevation of HCaRG and N oblp  expression, this would indicate that increased transactivation by 
Nrf2 was responsible for the inhibition o f expression observed.
The mutagenesis experiments (section 5.3.5.2) failed to discriminate between Nrf2 and AhR as the 
central mediator behind the Ever growth agent effects. This can be explained by one o f three 
possible scenarios: First, as not all the response elements were ablated it is possible that one o f the 
other sites is responsible for the effects observed. Second, if more than one site acts in unison to 
propagate the effect then ablation of one site may not have a noticeable effect. Third, it is possible 
that ablation o f a single site is compensated for by the activation o f a second response element to 
propagate any signal. To discover which of these scenarios is true it will be necessary to undertake 
further investigation, ablating more sites and ablating multiple sites in a single construct.
161
6 GENERAL DISCUSSION
6.1 D iscussion
Many compounds are known to cause liver enlargement (hepatomegaly) in rodents, including a 
variety o f compounds frequently exposed to humans. This exposure can be from the environment 
such as herbicides, occupational, such as industrial solvents, or fcom pharmaceutical compounds 
such as the hypolipidaemic agent clofibrate. The finding that a potential therapeutic compound 
causes Ever growth in pre-clinical testing results in the requirement for in-depth studies to 
understand the risk to humans, and indeed the potential for compound attrition at this point is 
high. Therefore it is advantageous to identify such compounds as early in development as possible, 
which can be made possible using in vitro screening for gene expression changes known to correlate 
with hepatomegaly. Sirmlarly, it is important to further understand the species differences between 
humans and rodents, so that potentiaEy useful drugs are not discarded based on irrelevant 
information. The major advantages of in vitro screening in this way are that human ceE lines can be 
used aEowing more relevant information about potential undesirable effects on humans, and that 
the analysis is more suited to high throughput than using in vivo experiments. Therefore reEable 
biomarkers of Ever growth are necessary to identify compounds causing Ever growth and the 
relevance to humans.
Hepatomegaly is caused by either an increase in the number of hepatocytes (hyperplasia) as caused 
by compounds such as the peroxisome proEferators and CPA, or an increase in the size o f the 
hepatocytes (hypertrophy) as induced by dexamethasone. However these physiological processes 
are not mutuaUy exclusive and it is common that a compound wiE cause hepatomegaly through a 
combination o f hyperplasia and hypertrophy. Since the mechanisms controlling hyperplasia and 
hypertrophy within the Ever are not weE understood at present it can be difficult to assess the risk 
of potential novel therapeutic compounds that exhibit this effect in pre-clinical species.
This project aimed to examine the molecular mechanisms underlying xenobiotic-induced Ever 
enlargement, and thus ultimately to address the difficulties in risk assessment o f therapeutic 
compounds exhibiting this effect in pre-clinical species. The compounds chosen are known to 
cause hepatomegaly in rodents through different routes, hyperplasia, hypertrophy or both, aEowing
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us to examine general liver responses’ to liver growth stimuli as opposed to a specific response to 
either hyperplasia or hypertrophy. The trans crip tome profiles of the three structurally diverse 
compounds were compared with a view to identifying genes central to the process of liver 
enlargement. It is hoped that in the future such genes could then be used as biomarkers o f liver 
enlargement directly, and that identification o f the upstream factors responsible for the gene 
expression changes would allow greater understanding of the mechanism controlling liver 
enlargement.
The project identified several groups of genes exhibiting potential co-ordination in their expression 
profiles in response to the three compounds, and one of these groups was selected for further 
study: The details of this examination are summarised in Figure 6.1. In depth analysis suggested that 
rBACH and Mel actuaUy form a distinct group as they showed high similarity in the response to 
Wy-14,643, but failed to show similar changes in response to CPA and dexamethasone (Figures 4.7 
and 4.8). These two genes were hence not investigated further as they appeared to be subject to a 
peroxisome-proliferator specific response. The resultant group of six known genes, plus one EST 
sequence that could not be linked to any known gene were hence examined in more detail.
Deletion analysis o f the promoters of two of the group members, HCaRG and N oblp, confirmed 
the high similarity in the response to peroxisome proHferators, CPA and dexamethasone observed 
previously (Figure 5.4). The region of the proximal promoter central to mediating this effect was 
localised to within the initial ~100 bp immediately upstream of the transcription start site in both 
cases, and in silico analysis combined with dosing experiments using inducers known to activate 
specific transcription factors allowed identification of two potential regulators. The polyaromatic 
hydrocarbon p-NF produced a similar dose response to that of dexamethasone and CPA (Figure 
5.5), and is known to act through activation of the Ahr and Nr£2, suggesting a role for these 
transcription factors in mediating the response to liver growth agents. P-NF induces expression of 
the cytochrome P450 isoenzyme CYPlAl via activation o f the AhR in a variety o f rat tissues (Sinai 
et al, 1999), and in numerous species (Martignoni et al, 2006, Pesonen et al, 1992). In addition P- 
NF affects other pathways involved in detoxification such as drug transport out o f ceUs. For 
example, induction of mRNA expression of the Multidrug Resistance-Associated Proteins (Mrps)
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has been reported in the mouse via activation of the AhR (Maher et al, 2005). Mrp proteins are 
important for the efflux of conjugated and unconjugated compounds from ceUs, and the same Mrp 
family members were found to regulated by Nrf2 as by AhR (Maher et al, 2005), indicating that 
these two factors were predominant in the regulation of drug efflux from hepatocytes. p-NF 
activation of Nrf2 occurs via release of the transcription factor from its inhibitory protein Keapl 
(Itoh et al, 1999) leading to activation of downstream genes such as N Q O l, a gene that is under 
dual control of both the AhR and Nrf2 (Ma et al, 2004).
Figure 6.1: Summary of findings for co-ordinate regulation in response to liver growth 
agents
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A summary of the findings are illustrated including the initial gene expression changes analysed by 
DNA Microarray and confirmed by real-time quantitative PGR. Reporter gene assay results are 
shown for the HCaRG, Noblp, Sp3 and LRCH4 promoters, and the subsequent findings for 
HCaRG and N oblp with respect to their upstream regulation.
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Nrf2 is a protective gene against toxic insult and oxidative stress, and hence would be unlikely to 
inhibit genes that were protective against cellular transformation. It is possible that the crucial effect 
o f administration of liver growth agents is interference with Nrf2 at the protein level either with the 
mechanism of release of Nrf2 from its inhibitory protein Keapl, or with the rate o f degradation of 
Nrf2 that is free to translocate to the nucleus. Similarly the AhR. is important in the response to 
xenobiotics, increasing expression of Phase I and Phase II detoxifying enzymes such as CYPlAl 
and N Q O l, as well as increasing its own expression simultaneously (Brauze et al, 2006). AhR 
agonists such as benzo(a)pyrene, a polycyclic aromatic hydrocarbon, are genotoxins that can initiate 
and promote carcinogenesis, which is known to occur via activation of the AhR as evidenced from 
studies using AhR knockout mice (Shimizu et al, 2000). Since the liver growth agents used in this 
study are known to cause carcinogenesis through both non-genotoxic (Wy-14,643 and 
dexamethasone) and genotoxic (CPA) routes, it may be that differing extents of co-operation 
between the Nrf2 and AhR pathways is the fundamental mechanistic difference between non- 
genotoxic and genotoxic hepatocarcinogenesis.
Regulation of gene expression by Nrf2 is under intense investigation at present, with the increasing 
finding that this transcription factor co-operates with the AhR to complete its actions (Ma et al, 
2004, Nioi and Hayes, 2004, Maher et al, 2005). This co-operation is rarely straightforward, with a 
number of scenarios being postulated such as (i) direct co-operation between Nr£2 and another 
factor via the formation of a composite element from the separate response elements in a gene 
promoter, (ii) induction of Nrf2 as a result of prior activation of the co-operating factor, or (iii) 
effects on the phosphorylation status of Nrf2 as a result of the action of the co-operating factor 
such as the generation o f reactive oxygen species. A compound null mutant for Nrf2 and AhR has 
been described recently by Noda and colleagues (2003), which was generated due to the increasing 
number o f genes regulated by Nr£2 and AhR where the exact mechanism is not understood. This 
could prove a useful model for the investigation o f Nrf2/AhR interactions.
There is a link between agonists of AhR (and Nrf2) and increased cell proliferation. The role of 
AhR in proliferation appears to be complex with variation between cell types and the AhR agonist 
used. For example, Zatioukalova and colleagues (2007) used the agonists P-NF and 3 -methoxy-4-
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nitroflavone (3M4NF) in an in vitro model of liver “stem-like” and found increased AhR-dependent 
proliferation with down-regulation of proteins involved in cell-to-cell contact. Vondracek and 
colleagues (2005) tested a range of polychlorinated biphenyls (PCBs) in a rat liver epithelial cell line 
and found a correlation between increased cell proliferation and the ability of the PCBs to activate 
the AhR. However, in contrast to these findings sustained activation of the AhR has been shown to 
attenuate Ever regeneration foUowing 70-percent PH, whereby administration of AhR agonists such 
as TCDD disrupted progression through the Gi phase of the ceE cycle (MitcheE etal, 2006).
The response of the HCaRG and N oblp  promoter constructs to P-NF (Figure 5.5) indicates that 
the inhibition observed in response to Ever growth agent administration is regulated by either the 
AhR, Nrf2, or a combination of both transcription factors. Such a co-ordinated response has been 
observed previously in the regulation of N Q O l in hepatoma ceEs (Ma et al, 2004) whereby the 
presence of AhR/ARNT was required for induction of N Q O l, but functional Nrf2 was necessary 
for basal and inducible expression of the gene in response to the AhR ligands tetrachlorodibenzo-^ 
dioxin (TCDD) and tert-butylhydroquinone (tBHQ). The use of an Nrf2/AhR compound nuE 
mutant mouse (Noda et al, 2003) confirmed that Nrf2 is essential for the induction of N Q O l 
expression observed in response to the AhR agonist 3-MC. Significantly it has been shown using 
electromobiEty shift assays that the AhR is part of an ARE-binding complex isolated from the 
nuclei of mouse Hepa-1 ceEs (VasiEou et al, 1995) and hence the AHR could participate in both a 
TCDD-induced XRE response and an oxidative stress-induced response via the ARE. This effect 
may also occur in extrahepatic tissue such as white adipose tissue, where the Ahr and Nrf2 
pathways have been shown to be active, hence EpophiEc compounds accumulating in this tissue 
could induce detoxification via these pathways (Yoshinari et al, 2006). Whether the AhR and Nrf2 
require a functional interaction is not known, and further analysis is required with regard to the 
importance of spacing between XRE and ARE elements in the cross-talk between the two 
transcription factors.
To attempt to differentiate the influence of the AhR and Nrf2 on HCaRG and N ob lp  gene 
expression, FaO ceEs transfected with the HCaRG and N oblp  promoter constructs were exposed 
to the AhR agonists 3-MC (Figure 5.8) and benzo(a)pyrene (Figure 5.9). The response to these
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compounds was reduced compared to dosing with either P-NF (Figure 5.5) or the liver growth 
agents (Figure 4.28), with benzo(a)pyrene only producing only a modest inhibition o f SEAP 
expression for both promoter constructs. The response to 3-MC was similar to that observed with 
P-NF although the same extent of inhibition was not achieved. In explanation of this observation, 
benzo(a)pyrene is an AhR agonist and as such a monofunctional inducer, whereas 3-MC is known 
to be a bifunctional inducer of drug metabolism in that it can induce both Phase I and Phase II 
genes (Prochaska and Talalay, 1988). Kwak and Kensler (2006) showed that 3-MC induces 
expression of the proteasomal gene PsmbS predominantly via activation o f the ARE and not the 
XRE in the gene promoter. Hence, the dhninished inhibition of the reporter gene constructs in 
response to the AhR agonists benzo(a)pyrene and 3-MC observed herein is indicative that whereas 
AhR does play a role in the inhibitory action, activation o f the AhR alone is not sufficient to inhibit 
expression from the HCaRG and Noblp genes.
A highly relevant finding by Miao and colleagues (2005) places the Nrf2/ARE pathway 
downstream of the AhR/XRE pathway. Analysis of the mouse Nrf2 upstream promoter region 
identified three potential AhR binding motifs that were each found to respond to treatment with 
the AHR ligand TCDD using a luciferase reporter assay. Furthermore binding o f the AhR was 
shown for each of the XREs using chromatin immunoprécipitation (ChIP), and sEencing o f AhR 
expression ablated the induction of Nrf2 expression in response to TCDD. The implication of 
these findings is that activation of AhR leads to increased expression of phase I and phase II 
enzymes both through direct interaction with regulatory elements for these genes, but also via Nrf2 
signalling, forming an integrated system for the detoxification o f xenobiotics. This finding that 
signalling by the AhR/XRE pathway may be upstream of the Nr£2/ARE pathway may explain why 
dosing of the HCaRG and N oblp  promoter constructs with the AhR agonist benzo(a)pyrene faEed 
to produce the fiEl extent o f response observed for (3NF. Dosing with an AhR agonist may lead to 
decreased expression of downstream genes such as HCaRG and N oblp  via induction o f the 
Nrf2/ARE pathway, however the direct activation of Nrf2 using a compound such as P-NF may 
increase this effect on HCaRG and N oblp expression or cause an earlier response. SimEarly the co­
operation between Nr£2 and the AhR observed for many other genes may be required for the fiEl
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response of the HCaRG and N oblp  promoters to P-NF, with AhR agonists alone not being 
sufficient to produce the fuU extent of inhibition observed.
Another possible theory for the response of HCaRG and N oblp  to Ever growth agent 
administration is alteration of the méthylation pattern of the gene promoters (Section 1.3.3.1). It is 
possible that transactivation o f these genes is repressed foEowing exposure to Ever growth agents 
due to hypermethylation of CpG islands in the HCaRG and N oblp  promoters. There is no current 
Eterature regarding the extent of méthylation of these genes specificaEy, however there is evidence 
that binding of the AhR to the XRE can be inhibited by hypermethylation within the core sequence 
of the XRE (Takahashi et aL, 1998). Mulero-Navarro and coEeagues (2006) have recently identified 
the AhR promoter as being hypermethylated in tumour ceEs from a number o f leukaemia patients, 
which resulted in very low level expression of the AhR in these ceEs. It was also shown that the 
mechanism for this down-regulation o f AhR expression was impaired binding o f Spl to the AhR 
promoter due to hypermethylation.
The data presented herein suggests, as discussed above that Nrf2 and AhR co-operate to produce 
the inhibition of gene expression observed by microarray analysis; one potential way of further 
dissecting this interaction was through the ablation of specific protein:DNA interaction sites within 
the proximal promoters of the HCaRG and N oblp  genes. The HCaRG-93 bp construct contained 
only one potential Nrf2 site and mutation of the central nucleotides for Nr£2 transactivation faEed 
to remove the inhibition of SEAP expression observed in response to the compounds tested 
(Figure 5.14). It is possible that the mutation was not sufficient to prevent Nrf2 binding, and 
subsequent deletion of the region would be useful in determining whether the site was functional. 
However it could be possible that the multiple AhR sites in this region o f the HCaRG promoter 
were able to compensate for the removal of the influence o f Nrf2. Unfortunately it was not 
possible to determine the extent of involvement of the potential Nrf2 site located within the exon 1 
sequence of Noblp. Mutation of one of the two potential AhR response elements in the Noblp-71 
bp construct (Figure 5.15), and the potential Nrf2 site in the Noblp-312 bp construct (Figure 5.16) 
sinElarly faEed to ablate the response to Ever growth agent administration. Further work would
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include a more comprehensive series of mutagenesis experiments to examine the effect o f multiple 
ablations within the proximal promoters o f these genes.
For the majority of the dosing experiments performed using the HCaRG and N oblp  promoter 
constructs, the peroxisome proHferators clofibric acid and Wy-14,643 failed to produce the same 
extent of response as that of dexamethasone and CPA. This was most notable during dosing o f the 
HCaRG-93 bp and Noblp-71 bp deletion constructs (Figure 5.4) where treatment with clofibric 
acid (100 |LiM) produced <50-percent of the inhibition of SEAP expression observed for 
dexamethasone and CPA treatment. A possible explanation for this jEnding is that the peroxisome 
proHferators used in this study could act on HCaRG and N oblp  predominandy through induction 
of the AhR/XRE pathway as opposed to the Nrf2/ARE pathway. In support o f this is the finding 
o f Fallone and colleagues (2005) where the Caco-2 cell line was used to evaluate the effect o f Wy- 
14,643 and 3-MC on induction of CYPlAl expression, an enzyme largely under the control o f the 
AhR. Exposure to Wy-14,643 (200 juM) alone caused a two-fold increase in the expression of 
CYPlAl over control. Co-administration of Wy-14,643 and 3-MC produced an additive effect on 
CYPlAl expression at low doses of the peroxisome proHferators (30 pM), and a synergistic effect 
was observed using a higher dose (200 pM). This suggests that activation of PPARa by Wy-14,643 
led to both direct induction of the expression o f CYPlAl via the PPREs in the CYPlAl promoter, 
but also enhanced the promoter’s inducibiHty by AhR agonists via increasing AhR expression. The 
mechanism for the induction of AhR by PPARa agonists is not knovm at present, but could be 
relevant to the response of HCaRG and N oblp  to peroxisome proHferators. Unlike the peroxisome 
proHferators used in this study, there is currently no evidence Hnking either dexamethasone or 
cyproterone acetate to activation of the AhR.
Based on the results obtained from the dosing experiments using AhR and Nrf2 agonists and from 
Hterature sources, the following model can be proposed (Figure 6.2). The predicted model for the 
regulation of HCaRG and N oblp  impHcates a degree of cooperation between Nrf2 and AhR, as 
has been identified previously (Ma et al, 2004), in the response to the Ever growth agents 
dexamethasone, CPA and WY-14,643. It should be noted that basal expression o f HCaRG and 
N oblp  could be under the principal control o f another system, although the CHX experiments are
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suggestive that this is a labile factor, which would be consistent with a role for Nrf2. However, 
following exposure to mitogenic stimuli, we propose that the release of Nrf2 from Keapl coupled 
with activation and nuclear translocation of the AhR would combine to inhibit expression of the 
HCaRG and N oblp  genes.
Since N oblp  is essential for 268 proteasome synthesis (Tone et al, 2002), decreased cellular levels 
o f N oblp  could reduce the degradation of proteins such as cell cycle regulators and oxidatively- 
damaged proteins that are known to accumulate in various degenerative diseases (Davies and 
Shringarpure, 2006), and o f Nrf2 itself, all of which rely on degradation by the 268 proteasome to 
regulate their cellular levels. Once activated and released from Keapl, Nrf2 translocates to the 
nucleus to activate various downstream genes via binding to ARE sequences in gene promoters 
(Itoh et al, 1999). However, Keapl can shuttle in and out o f the nucleus to promote ubiquitylation 
of Nr£2 and target it for degradation by the 268 proteasome (Nguyen et al, 2005). Reduced levels of 
N oblp  may impact on this ability to reduce cellular levels o f activated Nrf2 through proteasomal 
degradation. This could lead to a circular amplification of the effect, through the removal o f the 
degradation pathway, which may lead to further decreases in the expression of protective genes 
such as HCaRG that have been shown to cause GzM cell cycle arrest and promote cellular 
differentiation (Devlin et al, 2003). This in combination with potential effects on the other genes 
within this group (LRCH4 and 8p3) that may also act as transcription factors could lead to ceUular 
transformation events that could ultimately result in hepatocarcinogenesis.
The inhibition of expression of N oblp  in response to liver growth agents observed herein suggests 
that the formation of fuUy functional 268 pro teas omes may be impaired in hepatocytes exposed to 
such compounds. This in turn would potentially affect the degradation rates o f numerous proteins 
including that o f the Nrf2 protein itself. Contrary to this hypothesis was the finding by Kwak and 
Kensler (2006) that peptidase activities of the 268 proteasome and the expression o f the catalytic 
core subunit P8MB5 were induced by 3-MC, and that this was controlled exclusively by the 
Nrf2/ARE pathway. Although this supports the idea that Nrf2 expression is a self-regulated 
system, it is not indicative of the reduced degradation o f Nrf2 in response to compounds such as 3- 
MC and p-NF. 8imilarly, Meiners et al (2002) showed that proteasome inhibition caused an increase
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in the expression of many mammalian 26S proteasomal genes, suggesting that this inhibition could 
be averted by increased de novo synthesis of proteasomes. However this analysis was performed 
prior to the cloning of the human N O Bl gene (Zhang et al, 2005) and hence the effect on this 
essential protein could not be assessed.
Figure 6.2: Proposed model for the pathway from liver growth agent administration to liver 
growth
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Liver growth agents entering the cell may bind to the cytoplasmic Nrf2/K eapl complex causing 
release of Nrf2 that can translocated to the nucleus. Similarly AhR may translocated to the nucleus 
in combination with its nuclear translocator protein ARNT. The combination of Nrf2 binding to 
the antioxidant response element (ARE) and AhR binding to the xenobiotic response element 
(XRE) in gene promoters may cause decreased expression of genes such as HCaRG and N oblp. 
HCaRG can suppress the cell cycle via GzM arrest (Devlin et al, 2003) and inhibition of its 
expression may remove a protective influence against cellular transformation. N oblp  is essential for 
26S proteasome synthesis (Tone et al, 2002), hence decreased expression of N oblp  would affect 
proteasomal degradation of proteins. This could include the degradation of Nrf2 following 
promotion of its ubiquitylation by Keapl that is thought to enter the nucleus to modulate Nrf2 
levels (Nguyen et al, 2005). This could result in positive feedback on Nrf2 levels that would amplify 
the situation. These effects in combination with those on other co-regulated genes could ultimately 
lead to carcinogenesis.
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The work presented herein suggests that exposure of cells to compounds such as 3-MC could lead 
to decreased N oblp  expression and reduced levels of functional 26S proteasomes. In support of 
this hypothesis is the finding that treatment of thymocytes with dexamethasone reduces 20S and 
26S proteasomal activity in cell extracts (Beyette et al, 1998). Western Blotting using an antibody to 
the C2 subunit that is present in 20S and 26S proteasomes showed that this effect was not due to a 
change in the number of proteasomes in response to dexamethasone, hence it could be an 
alteration in the functional capacity o f the proteasomes. Since N oblp  is thought to be a chaperone 
for joining o f the 19S regulatory particle with the 208 catalytic core of the proteasome (Tone et al, 
2002), decreased N oblp  may cause disruption of this process and decreased activity o f the resultant 
proteasomes.
A link between the coupling of the AhR and Nr£2 pathways and chemoprevention has been 
postulated previously, with disruption of the pathways leading to increased carcinogenesis. 
Cooperation between the AhR and Nrf2 was reviewed recently with respect to the role o f dietary 
phytochemicals in chemoprevention (Kohle and Bock, 2006). In particular this indicated flavonoids 
(sourced from green tea) and dithiolthiones (from cruciferous vegetables) to be activators o f both 
the AhR and Nr£2 pathways. Nrf2-deficient mice have been shown to display a reduced hepatic and 
gastric complement o f the phase II detoxifying enzymes N Q O l and GST, and that the effect o f the 
chemopreventative compound oltipraz (a dithiolthione) on increasing the expression of these 
enzymes was abrogated in these animals (Ramos-Gomez et al, 2001). As such the incidence of 
gastric neoplasia in the Nrf2-deficient animals in response to treatment with benzo(a)pyrene was 
significantly greater than in controls (Ramos-Gomez et al, 2001).
The role of Nrf2 and AhR in the regulation of HCaRG and N oblp is stiU to be determined. 
Following characterisation of this regulation it would be possible to determine the extent o f co­
regulation between HCaRG, N oblp  and the other five genes identified as exhibiting potential co­
ordinate regulation in Chapter 3. If  it is the case that increased Nrf2/AhR binding to the promoters 
of HCaRG and N oblp  results in inhibition o f these protective genes then it would be interesting to 
understand the reason for this inhibition, since the majority of pathologies result from an 
underlying physiological mechanism responding inappropriately to a new stimulus.
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In summary, we have identified a group o f genes exhibiting potential co-ordinate regulation in their 
expression, which has been confirmed for two of these genes. We are the first to postulate a link 
between these two genes, HCaRG and N oblp, for which little information is currently available 
particularly with regard to their upstream regulation. Similarly neither gene has previously been 
implicated in the response to compounds causing liver growth. We have examined the promoter 
functionality of the proximal 1 kb gene promoters, and are the first to identify a role for the 
transcription factors Nrf2 and AhR in the regulation of HCaRG and N oblp, both individually, and 
regarding their co-regulation. This work has also contributed to the increasing finding that Nrf2 
and the AhR co-operate in the regulation of genes in response to xenobiotic stimuli.
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6.2 F u t u r e  d ir e c t io n s
The results obtained during the course of this project have highlighted an interesting group of 
genes with high similarity in their response to growth stimuli and which exhibit co-ordination in 
their regulation at the level of transcription. However, biological function is generated at the protein 
level and hence assessment at the transcript level alone is not sufficient to assume that the changes 
observed are biologically relevant. To address this it would be necessary to characterise the 
response at the protein level for example using Western blotting. Currently antibodies are 
commercially available for rCOUPg and Sp3 in the rat, and antibodies have been developed against 
human HCaRG (Solban etal, 2000) and N oblp  in yeast (Tone et al, 2000).
To characterise the regulation of HCaRG and N oblp  it would be useful to silence Nrf2 and AhR 
individually and jointly to assess the impact on the inhibition in response to liver growth agent 
administration, and at the same time to assess the effect on cellular proliferation (e.g. BrdU 
incorporation) and apoptosis (e.g. caspase activation). Initial optimisation using an siRNA for Nrf2 
has been undertaken (data not shown) using PNF to increase the cellular levels of Nrf2. Following 
completion o f the optimisation it would be possible to directly assess mRNA levels of HCaRG and 
N oblp  using real-time quantitative PCR. Alternatively, to produce a clearer signal the relevant 
promoter constructs could be transfected on the day following silencing of Nrf2, and subsequently 
the effect of dosing with liver growth agents could be assessed relative to a negative control siRNA.
Since mutation of individual Nrf2 and AhR response elements failed to identify the influence of 
either transcription factor, it would be useful to produce a compound mutant through repeated 
rounds of SDM. Similarly, it would be interesting to overexpress Nrf2 and AhR in FaO cells. This, 
in comparison to the silencing experiment, would identify whether it was increased or decreased 
transactivation of the HCaRG and N oblp  gene promoters by Nrf2 and/or AhR that was resulting 
in inhibition o f gene expression. Ablation o f the response to liver growth agents would indicate 
which possibility was true. Following silencing and overexpression of Nrf2 and/or AhR it would be 
possible to assess the potential co-ordinate regulation between HCaRG, N oblp  and the other genes 
namely Sp3, LRCH4, rCOUPg and OGFRLl, using real-time quantitative PCR to measure the 
effect on the transcript levels of all six genes. Binding studies using either an EMSA, supershift
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assay or ChIP (subject to antibody availability) would prove whether Nr£2 and AhR do bind to the 
HCaRG and N oblp  promoters under basal and drug-induced conditions. This would increase the 
understanding of the regulation of these genes both physiologically and during drug-induced liver 
growth. Immunocytochemical staining o f Nrf2 and AhR would also be useful in determining 
whether nuclear localisation o f the transcription factors occurs in response to liver growth agent 
administration.
It would be interesting to pursue some of the other genes highlighted during the microarray analysis 
(Chapter 3) with a view to identifying further potential markers of liver growth. Finally it would be 
necessary to compare the response o f the rat genes identified to that of the human orthologues to 
assess (i) the degree o f evolutionary conservation for the pathway, (ii) whether the genes were 
involved in hepatomegaly in humans, and (iü) to what extent the genes would be useful as markers 
of liver growth for use in the pharmaceutical industry.
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8.1 V e c t o r  M aps
Figure 8.1: pSEAP plasmid
8 A p p e n d ix
MCS
Notl
(4511)'
(1-72) BamHI
I (2 8 9 )
ori
SEAP
Amp^
Asei
(3185)
SV40 
poly A Xbal
( 1 602 )
- B a m H I
pUC
ori
SailTB = T ran sc rip tio n  b locker
(1870)
R e s tr ic t io n  e n z y m e  s i t e s  in  M C S :
1 10 20 60
GGTACCGAGCTCTTAC6CGTGCTAGCCCGGGCTCGAGATCTGCGATCTAAGTAAGTAA6CTTCGAATCGCGAATTCGCCCACCATGCTG 
Asp718l
Kpiil
Mill! Nhel SrfI Xliol Bglll HhiillM BstBI Nrul EcoRI
MCS: Multiple cloning site, SEAP: secreted alkaline phosphatase, SV40 poly A: SV40 polyadenylation. 
Amp"": lactamase conferring resistance to ampicillin
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Figure 8.2: TOPO® pCR®2.1 plasmid (Invitrogen)
Ml 3 Reverse Pnmer
facZa.ATG
s r . :  e r r  r s T  cc-a :A :  l Æ
Kpn\ Sac I B a# -I  S ee  I 
A3C T o s 'G A r  c : a * c : a
Hini II!
I I
A T : ACS CCA A S : TIC- GIA CCC- 
lAA CSC 3GT IC S  AAC CAT 3GC IC S  ASC CIA S S I  GAI
Ss?X I EcoR I 
I
3TA AC'S SC I GCC AST GIG C IS  C-AA I I I  S-CC C I l l  
CAI IGC CSS CC-G ICA CAC SAC C I I  AAS CGC- 'S A #
EcoR I
B a g  s s c  g a a  i i c  i g c  I n c  CCS C I I  AAS AC'S
EcaR’ 3s8< I Atof I XiKi Ssi I Xba 1 Apal
ASA lA I  CCA ICA CAC IGG CSS CC'S CIC SAG CAI SCA I C I  AGA 'S'SS CSC AAI ICG CCC TAI 
I C I  ATA 3 3 1  AGI S IS  ACC SCC GGC 'SAS S IC  GIA CGI ASA I C I  CCC SSG I I A  ASC G'SS ATA
T7 Promoter M13 Forward (-20) Priner
C IS GCC SI' I IA  % A CGI c:
;t i
lacZa: lacZ gene, fl ori: origin o f replication o f the filamentous phage f l , Kanamycin: 
Kanamycin resistance gene, Ampicillin: lactamase conferring resistance to ampicillin, 
pUC ori: pUC origin o f rephcation
Figure 8.3: pCR®-Blunt plasm id (Invitrogen)
2Ci  CACStCAGSAA ACAGCTAISA CtCAIG. 
GIG-js iC C I I  IGIC.SAIACI g|sTAC
I AIIAC SCCAAGCTAI IIASGIGACS CGIIAGAAIA 
l AAI S CGSTICSAIA AAICCACIGC 9CAAICIIAT
« ' I  ,11 K !o i ea.-'im
AI 3CAICAAGCI I3GIACCSAS CICG3AICCA C:CICAASCI IASTAACGS CCSCCA3I3I 
GAGIICGAIA CGIA3IICSA ACCAIGSCIC -SASCCIAGSI GAICAIISCC SGCGSICACA
rSclAACIGCI G AI C AGS 
CSACCIIAA3 ICC B lu n t  P C R  P r o d u c t
EcoR I FK I e ::R V
CCIGAAIICI GCASAIA 
SSACIIAA'SA CSTCTAI
IGSclc-CCSC TCICCAICACAC 3C3G 3 ICGAGCAIGC AICIAGAG3G CCCAAIIC'SC CCIAIA3ISA 
A3GIASI3IG ACCGCCSGCG A3CIC3IACS IA3AICICC
Blunt
Comments for pCR--Blunt 
3512 nucleotides
lacZa: lacZ gene, ccdB: ccdB cytotoxic gene, Kanamycin: Kanamycin resistance gene, 
Zeocin: Zeocin resistance gene, pUC ori; pUC origin o f replication
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8.2 O r a l  p r e s e n t a t i o n s  o f  t h i s  r e s e a r c h
British Toxicology Society (BTS) Annual Congress, University of Warwick, March 2006 - highly 
commended.
Drug Metabolism Discussion Group (DMDG), Heriot-Watt University, September 2006.
8.3 P o s t e r  p r e s e n t a t i o n s  o f  t h i s  r e s e a r c h
British Toxicology Society (BTS) Annual Congress, Heriot-Watt University, March 2004.
British Toxicology Society (BTS) Autumn Meeting, University of Liverpool, September 2004.
Pfizer Drug Discovery, Sandwich, Kent, September 2004.
13* North American Meeting of the International Society for the Study o f Xenobiotics (ISS5Q, 
Maui, Hawaii, October 2005 (see following page).
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